# Patent

## Title
Polynucleotide encoding osmotin modified for apoplast targeting

## Abstract

This application is a continuation-in-part application of U.S. application Ser. No. 08/258,287, filed Jun. 10, 1994, which is a continuation-in-part application of U.S. application Ser. No. 08/080,850, filed Jun. 24, 1993, now abandoned.

## Background
1. Field of the Invention

The invention is in the field of molecular biology as related to the control of programmed cell death.

2. Description of the Background Art

Cell death occurs as a normal aspect of animal development as well as in tissue homeostasis and aging (Glucksmann, A., Biol. Rev. Cambridge Philos. Soc. 26:59-86 (1950); Ellis et al., Dev. 112:591-603 (1991); Vaux et al., Cell 76:777-779 (1994)). Naturally occurring cell death acts to regulate cell number, to facilitate morphogenesis, to remove harmful or otherwise abnormal cells and to eliminate cells that have already performed their function. Such regulated cell death is achieved through an endogenous cellular mechanism of suicide, termed programmed cell death or apoptosis (Wyllie, A. H., in Cell Death in Biology and Pathology, Bowen and Lockshin, eds., Chapman and Hall (1981), pp. 9-34). Programmed cell death or apoptosis occurs when a cell activates this internally encoded suicide program as a result of either internal or external signals. The morphological characteristics of apoptosis include plasma membrane blebbing, condensation of nucleoplasm and cytoplasm and degradation of chromosomal DNA at inter-nucleosomal intervals. (Wyllie, A. H., in Cell Death in Biology and Pathology, Bowen and Lockshin, eds., Chapman and Hall (1981), pp. 9-34). In many cases, gene expression appears to be required for programmed cell death, since death can be prevented by inhibitors of RNA or protein synthesis (Cohen et al., J. Immunol. 32:38-42 (1984); Stanisic et al., Invest. Urol. 16:19-22 (1978); Martin et al., J. Cell Biol. 106:829-844 (1988)).

The genetic control of programmed cell death has been well-elucidated by the work on programmed cell death in the nematode C. elegans. Programmed cell death is characteristic and widespread during C. elegans development. Of the 1090 somatic cells formed during the development of the hermaphrodite, 131 undergo programmed cell death. When observed with Nomarski microscopy, the morphological changes of these dying cells follow a characteristic sequence. (Sulston et al., Dev. Biol. 82:110-156 (1977); Sulston et al., Dev. Biol. 100:64-119 (1983)).

Fourteen genes have been identified that function in different steps of the genetic pathway of programmed cell death in C. elegans (Hedgecock et al., Science 220:1277-1280 (1983); Ellis et al., Cell 44:817-829 (1986); Ellis et al., Dev. 112:591-603 (1991); Ellis et al., Genetics 112:591-603 (1991b); Hengartner et al., Nature 356:494-499 (1992); Ellis et al., Dev. 112:591-603 (1991)). Two of these genes, ced-3 and ced-4, play essential roles in either the initiation or execution of the cell death program. Recessive mutations in these genes prevent almost all of the cell deaths that normally occur during C. elegans development.

The ced-4 gene encodes a novel protein that is expressed primarily during embryogenesis, the period uring which most programmed cell deaths occur (Yuan et al., Dev. 116:309-320 (1992)). The 549 amino acid sequence of ced-4, deduced from cDNA and genomic clones, contain two regions that are similar to the calcium-binding domain known as the EF-hand (Kretsinger, 1987); however, it is still not clear at present whether calcium plays a role in regulating ced-4 or programmed cell death in C. elegans.

A gain-of-function mutation in ced-9 prevents normal programmed cell death, while mutations that inactivate ced-9 are lethal. This suggest that ced-9 acts by suppressing programmed cell death genes in cells that normally do not undergo programmed cell death (Hengartner, M., et al., Nature 356:494-499 (1992)). The ced-9 gene encodes a protein product that shares sequence similarity with the mammalian prot-oncogene and cell death suppressor bcl-2 (Hengartner, M., et al., Cell 76:665-676 (1994)). The lethality of ced-9 loss-of-function mutations can be suppresed by mutations in ced-3 and ced-4, indicating that ced-9 acts by suppressing the acitivity of ced-3 and ced-4.

Genetic mosaic analyses indicated that ced-3 and ced-4 likely act in a cell-autonomous fahsion within dying cells, suggesting that they might be cytotoxic proteins and/or control certain cytotoxic proteins in the process of programmed cell death (Yuan, J., et al., Dev. Bio. 138:33-41 (1190)).

Cell death also occurs in mammals. nedd2 is a mouse gene which is preferentially expressed during early embryonic brain development (Kumar et al., Biochem. Biophys. Res. Commun. 185:1155-1161 (1992)). Since many neurons die during early embryonic brain development, it is possible that nedd-2 is a cell death gene. Nedd-2 mRNA is down-regulated in the adult brain (Kumar et al., Biochem. & Biophys. Res. Comm. 185:1155-1161 (1992); Yuan, J., et al., Cell 75:641-752 (1993)).

bcl-2 is an oncogene known to inhibit programmed cell death and to be overexpressed in many follicular and B cell lymphomas. Overexpression of bcl-2 as a result of chromosomal translocation occurs in 85% of follicular and 20% of diffuse B cell lymphomas, Fukuhara et al., Cancer Res. 39:3119 (1979); Levine et al., Blood 66:1414 (1985); Yunis et al., N. Engl. J. Med. 316:79-84 (1987).

Overexpression of bcl-2 protects or delays the onset of apoptotic cell death in a variety of vertebrate cell types as well as in C. elegans (Vaux et al., Science 258:1955-1957 (1992); Nunez et al., J. Immun. 144:3602-3610 (1990); Vaux et al., Science 258:1955-1957 (1992); Sentman et al., Cell 67:879-888 (1992); Strasser et al., Cell 67:889-899 (1991)). Expression of bcl-2 in the nematode C. elegans has been shown to partially prevent programmed cell death. Thus, bcl-2 is functionally similar to the C. elegans ced-9 gene (Vaux et al., Science 258:1955-1957 (1992); Hengartner et al., nature 356:494-499 (1992)).

Interleukin-1.beta. converting enzyme (ICE) is a substrate-specific cysteine protease that cleaves the inactive 31 KD prointerleukin-1.beta. at Asp.sup.116 -Ala.sup.117, releasing a carboxy-terminal 153 amino-acid peptide to produce the mature 17.5 kD interleukin-1.beta. (IL-1.beta.) (Kostura et al., Proc. Natl. Acad. Sci., USA 86:5227-5231 (1989); Black et al., FEBS Lett. 247:386-390 (1989); Cerretti et al., Science 256:97-100 (1992); Thornberry et al., Nature 356:768-774 (1992)). IL-1.beta. is a cytokine involved in mediating a wide range of biological responses including inflammation, septic shock, wound healing, hematopoiesis and growth of certain leukemias (Dinarello, C. A., Blood 77:1627-1652 (1991); diGiovine et al., Today 11:13 (1990)). A specific inhibitor of ICE, the crmA gene product of cowpox virus, prevents the proteolytic activation of IL-1.beta.(Ray et al., Cell 69:597-604 (1992)) and inhibits host inflammatory response (Ray et al., Cell 69:597-604 (1992)). Cowpox virus carrying a deleted crmA gene is unable to suppress the inflammatory response of chick embryos, resulting in a reduction in the number of virus-infected cells and less damage to the host (Palumbo et al., Virology 171:262-273 (1989)). This observation indicates the importance of ICE in bringing about the inflammatory response.

Tumor necrosis factor-.alpha. (TNF-.alpha.) is a pleiotropic tumoricidal cytokine (Tracey, K. J. et al., Ann. Rev. Cell. Biol. 9:317-343 (1993)). One of the striking functions of TNF-.alpha. is to induce apoptosis of transformed cells. In the case of non-transformed cells, TNF.alpha. can also induce apoptosis in the presence of metabolic inhibitors (Tracey, K. J., et al., Ann. Rev. Cell. Biol. 9:317-343 (1993). Apoptosis induced by TNF-.alpha. is also suppressed by bcl-2.

One of the most extensively studied functions of TNF-.alpha. is its cytotoxicity on a wide variety of tumor cell lines in vitro (Laster, S. M. et al., J. Immunol. 141:2629-2634 (1988)). However, the mechanism of cell death induced by TNF has been largely unknown. HeLa cells express predominantly p55 TNF receptor which is thought to be responsible for cell death signaling (Englemann, H. et al., J. Biol. Chem. 265:14497-14504 (1990); Thoma, B. et al., J. Exp. Med. 172:1019-1023 (1990)).

HeLa cells are readily killed by TNF-.alpha. in the presence of the metabolic inhibitor cycloheximide (CHX). The cell death induced by TNF-.alpha./CHX shows DNA fragmentation and cytolysis, which are typical features of apoptosis (White, E. et al., Mol. Cell. Biol. 12:2570-2580 (1992)). Expression of adenovirus E1B 19K protein, which is functionally similar to bcl-2, inhibits apoptosis induced by TNF in HeLa cells (White, E. et al., Mol. Cell. Biol. 12:2570-2580 (1992)).

In the present invention, the ced-3 gene (SEQ ID NO: 1) has been cloned and sequenced and the amino acid sequence (SEQ ID NO: 2) of the protein encoded by this gene is disclosed. Structural analysis of the ced-3 gene revealed that it is similar to the enzyme interleukin-1.beta. converting enzyme ("ICE") and that overexpression of the murine interleukin-1.beta. converting enzyme ("mICE") causes programmed cell death in vertebrate cells. Based upon these results, a novel method for controlling programmed cell death in vertebrates by regulating the activity of ICE is claimed. "Caspase" is the official designation for all members of the ICE family. Therefore, the most recent designation for: ICE is "caspase-1," Ich-3 is "caspase-11" and Ich-1 is "caspase-2."

The amino acid sequence of ced-3 was also found to be similar to another murine protein, nedd-2, which is detected during early embryonic brain development, a period when many cells die. The results suggest that ced-3, ICE and nedd-2 are members of a gene family which function to cause programmed cell death.

A new cell death gene, mIch-2 (murine ICE-ced-3 homolog), has been discovered which appears to be in the same family as ced-3, ICE, and nedd-2. mIch-2 is distinguished from other previously identified cell death genes in that it is preferentially expressed in the thymus and placenta of vertebrates. Thus, the invention is also directed to a newly discovered gene, mIch-2, which is preferentially expressed in thymus and placenta and which encodes a protein causing programmed cell death. Thus, the present invention is directed to both the mIch-2 gene sequence (SEQ ID NO: 41) and the protein (SEQ ID NO: 42) encoded by mIch-2. Also encompassed are vectors expressing mIch-2 and host cells transformed with such vectors. The invention also encompasses methods of regulating cell death by expressing mIch-2.

A comparison of the nucleotide sequences of ced-3, mICE, human ICE ("hICE"), nedd-2 and mIch-2 indicates that they are members of a gene family that promotes programmed cell death. The identification of this family facilitated the isolation of the newly discovered cell death gene Ice-ced 3 homolog-1 (Ich-1).

Ich-1 is homologous to the other cell death genes described above and particularly to nedd2. Based upon its structure and the presence of DNA encoding the QACRG sequence characteristic of the active center of cell death genes, Ich-1 was identified as a new member of the ced-3/ICE family. Thus, the present invention is directed to both the Ich-1 gene sequence and the protein encoded by Ich-1. Also encompassed are vectors expressing Ich-1 and host cells transformed with such vectors. Alternative splicing results in two distinct Ich-1 mRNA species. Thus, the invention also encompasses these species, proteins produced from them, vectors containing and expressing the genes, and the uses described herein.

The inventors have also identified a further member of the ICE/ced-3 family, Ich-3(SEQ ID NO: 54). Ich-3 has at least two alternative splicing products. A full length cDNA of one of them from a mouse thymus cDNA library has been identified. It encodes a protein of 418 amino acids that is 38% identical with mICE, 42% identical with mIch-2, 25% with Ich-1, and 24% identical with C. elegans ced-3.

The invention is thus directed to genomic or cDNA nucleic acids having genetic sequences which encode ced-3, mIch-2, Ich-1, and Ich-3. The invention also provides for vectors and expression vectors containing such genetic sequences, the host cells transformed with such vectors and expression vectors, the recombinant nucleic acid or proteins made in such host/vectors systems and the functional derivatives of these recombinant nucleic acids or proteins. The use of the isolated genes or proteins for the purpose of regulating, and especially promoting cell death is also part of the invention.

The invention is also directed to methods for controlling the programmed death of vertebrate cells by regulating the activity of interleukin-1.beta. converting enzyme. Such regulation may take the form of inhibiting the enzymatic activity, e.g. through the use of specific antiproteases such as crmA, in order to prevent cell death. In this way, it may be possible to develop cell lines which remain viable in culture for an extended period of time or indefinitely. Certain cells can only be maintained in culture if they are grown in the presence of growth factors. By blocking cell death, it may be possible to make such cells growth factor independent. Alternatively, ICE activity may be increased in order to promote cell death. Such increased activity may be used in cancer cells to antagonize the effect of oncogenes such as bcl-2.

The present invention is also based on the discovery that TNF-.alpha. activates endogenous ICE activity in HeLa cells and that TNF-.alpha.-induced apoptosis is suppressed by crmA, which can specifically inhibit ICE-mediated cell death. Thus, certain embodiments of the invention are based on the activation of the ICE/ced-3-mediated cell death pathway by TNF-.alpha..

FIGS. 1 and 1A: Genetic and Physical Maps of the ced-3 Region on Chromosome IV

FIG. 1 shows the genetic map of C. elegans in the region near ced-3 with the cosmid clones representing this region depicted below the map. nP33, nP34, nP35, nP36, and nP37 are restriction fragment length polymorphisms (RFLP) between Bristol and Bergerac wild type C. elegans strains. C43C9, W07H6 and C48D1 are three cosmid clones tested for rescue of the ced phenotype of ced-3(n717) animals. The ability of each cosmid clone to rescue ced-3 mutants and the fraction of independently obtained transgenic lines that were rescued are indicated on the right of the figure (+, rescue; -, no rescue; see text for data). The results indicate that ced-3 is contained in the cosmid C48D1.

FIG. 1A is a restriction map of C48D1 subclones. C48D1 was digested with BamHI and self-ligated to generate subclone C48D1-28. C48D1-43, pJ40 and pJ107 were generated by partial digesting C48D1-28 with BglII. pJ7.5 and pJ7.4 were generated by ExoIII deletion of pJ107. These subclones were assayed for rescue of the ced phenotype of ced-3(n717) animals (+, rescue; -, no rescue, -/+, weak rescue). The numbers in parentheses indicate the fraction of independently obtained transgenic lines that were rescued. The smallest fragment that fully rescued the ced-3 mutant phenotype was the 7.5 kb pJ7.5 subclone.

FIGS. 2A-2P Genomic Organization, Nucleotide Sequence, and Deduced Amino Acid Sequence of ced-3

FIGS. 2A-2F shows the genomic sequence of the ced-3 region (SEQ ID NO: 1), as obtained from plasmid pJ107. The deduced amino acid sequence of ced-3 (SEQ ID NO: 2) is based on the DNA sequence of ced-3 cDNA pJ87 and upon other experiments described in the text and in Experimental Procedures. The 5' end of pJ87 contains 25 bp of poly-A/T sequence (not shown), which is probably a cloning artifact since it is not present in the genomic sequence. The likely start site of translation is marked with an arrowhead. The SL1 splice acceptor site of the ced-3 transcript is boxed. The positions of 12 ced-3 mutations are indicated. Repetitive elements are indicated as arrows above the relevant sequences. Numbers on the left indicate nucleotide positions, beginning with the start of pJ107. Numbers below the amino acid sequence indicate codon positions. Five types of imperfect repeats were found: repeat 1, also found in fem-1 (Spence et al., Cell 60:981-990 (1990)) and hlh-I (Krause et al., Cell 63:907-919 (1990)); repeat 2, novel; repeat 3, also found in lin-12 and fem-1; repeat 4, also found in lin-12; and repeat 5, novel. Numbers on the sides of the figure indicate nucleotide positions, beginning with the start of pJ107. Numbers under the amino acid sequence indicate codon positions.

FIG. 2G-FIG. 2K contain comparisons of the repetitive elements in ced-3 with the repetitive elements in the genes ced-3, fem-1, hlh-1, lin-12, glp-1, and the cosmids B0303 and ZK643 (see text for references). In the case of inverted repeats, each arm of a repeat ("for" or "rev" for "forward" or "reverse", respectively) was compared to both its partner and to individual arms of the other repeats. 2G: Repeat 1 (SEQ ID NOS: 3-11); 2A: Repeat 2 (SEQ ID NOS: 12-14); 2I: Repeat 3 (SEQ ID NOS: 15-27); 2J: Repeat 4 (SEQ ID NOS: 28-30); and 2K; Repeat 5 (SEQ ID NOS: 31-33). The different ced-3 sequences which appear in the comparisons are different repeats of the same repetitive element. The numbers "1a", "1b" etc. are different repeats of the same class of repetitive element.

FIG. 2L shows the locations of the introns (lines) and exons (open boxes) of the ced-3 gene as well as the positions of 12 ced-3 mutations analyzed. The serine-rich region, the trans-spliced leader (SL1), the possible start of translation (ATG) and polyadenlyation (AAA) site are also indicated.

FIGS. 2M-2P shows the cDNA sequence (SEQ ID NO: 34) and deduced amino acid sequence (SEQ ID NO: 35) of ced-3 as obtained from plasmid pJ87.

FIGS. 3 and 3A-3B: Comparison of the Structure of the ced-3 Protein and hICE Protein

FIG. 3 shows a comparison of structural features of ced-3 with those of the hICE gene. The predicted proteins corresponding to the hICE proenzyme and ced-3 are represented. The active site in hICE and the predicted active site in ced-3 are indicated by the black rectangles. The four known cleavage sites in hICE flanking the processed hICE subunits (p24, which was detected in low quantities when hICE was purified (Thornberry et al. (1992), p20, and p10) and two conserved presumptive cleavage sites in ced-3 are indicated with solid lines and linked with dotted lines. Five other potential cleavage sites in ced-3 are indicated with dashed lines. The positions of the aspartate (D) residues at potential cleavage sites are indicated below each diagram.

FIGS. 3A-3B contains a comparison of the amino acid sequences of ced-3 from C. elegans (SEQ ID NO: 35), C. briggsae (SEQ ID NO: 36) and C. vulgaris (SEQ ID NO: 37) with hICE (SEQ ID NO: 38), mICE (SEQ ID NO: 39), and mouse nedd-2 (SEQ ID NO: 40). Amino acids are numbered to the right of each protein. Dashes indicate gaps in the sequence made to allow optimal alignment. Residues that are conserved among more than half of the proteins are boxed. Missense ced-3 mutations are indicated above the comparison blocks showing the residue in the mutant ced-3 and the allele name. Asterisks indicate potential aspartate self-cleavage sites in ced-3. Circles indicate known aspartate self-cleavage sites in hICE. Residues indicated in boldface correspond to the highly conserved pentapeptide containing the active cysteine.

FIG. 4: Construction of Expression Cassettes of mICE-lacZ and ced-3-lacZ Fusion Genes

FIG. 4 shows several expression cassettes used in studying the cellular effects of ICE and ced-3 expression. The cassettes are as follows: p.beta.actM10Z contains intact mICE fused to the E. coli lacZ gene (mICE-lacZ). p.beta.actM11Z contains the P20 and P10 subunits of mICE fused to the E. coli lacZ gene (P20/P10-lacZ). p.beta.actM19Z contains the P20 subunit of mICE fused to the E. coli lacZ gene (P20-lacZ). p.beta.actM12Z contains the P10 subunit of mICE fused to the E. coli lacZ gene (P10-lacZ). p.beta.actced38Z contains the C. elegans ced-3 gene fused to the lacZ gene (ced-3-lacZ). pJ485 and p.beta.actced37Z contain a Gly to Ser mutation at the active domain pentapeptide "QACRG" in mICE and ced-3 respectively. p.beta.actM17Z contains a Cys to Gly mutation at the active domain pentapeptide "QACRG" in mICE. pact.beta.gal' is a control plasmid (Maekawa et al., Oncogene 6:627-632 (1991)). All plasmids use the .beta.-actin promoter.

FIG. 5: Genetic Pathways of Programmed Cell Death in the Nematode C. elegans and in Vertebrates

In vertebrates, bcl-2 blocks the activity of ICE thereby preventing programmed cell death. Enzymatically active ICE causes vertebrate cell death. In C. elegans, ced-9 blocks the action of ced-3/ced-4. Active ced-3 together with active ced-4 causes cell death.

FIGS. 6A-6C: mIch-2 cDNA Sequence and Deduced Amino Acid Sequence

FIGS. 6A-6C shows the nucleotide sequence of the mIch-2 cDNA sequence (SEQ ID NO: 41) and the amino acid sequence (SEQ ID NO: 42) deduced therefrom.

FIGS. 7 and 7A: mIch-2 Amino Acid Sequence

FIGS. 7 and 7A contain a comparison of the amino acid sequences of mICE, hICE, mIch-2 and ced-3.

FIG. 8: Potential QACRG Coding Region in the Mouse nedd2 cDNA

The reading frame proposed by Kumar et al. (Biochem. & Biophys. Res. Comm. 185:1155-1161 (1992)) is b. In reading frame a, a potential QACRG coding region (SEQ ID NOS: 44-49) is underlined.

FIGS. 9 and 9A: Comparison of the Amino Acid Sequences of ced-3, hICE and Ich-1

FIG. 9 contains a comparison of the amino acid sequences of ced-3 (SEQ ID NO: 35) and Ich-1 (SEQ ID NO: 43). There is a 52% similarity between the sequences and a 28% identity.

FIG. 9A contains a comparison of the amino acid sequences of hICE (SEQ ID NO: 39) and Ich-1 (SEQ ID NO: 43). There is a 52% similarity between the sequences and a 27% identity.

FIGS. 10A-10B: The cDNA Sequence of Ich-1.sub.L (SEQ ID NO: 50) and the Deduced Amino Acid Sequence of Ich-1.sub.L (SEQ ID NO: 51) Protein Product

The putative active domain is underlined.

FIGS. 10C-10E: The cDNA Sequence of Ich-1.sub.S (SEQ ID NO: 52) and the Deduced Amino Acid Sequence of (SEQ ID NO: 53) Ich-1.sub.S Protein Product

The intron sequence is underlined.

FIG. 11A: The Alternative Splicing of Ich-1 mRNA

The exons are shown in bars. The intron is shown in a line. Nucleotides at the exon-intron borders are indicated.

FIG. 11B: The Schematic Diagram of the Two Alternatively Spliced Ich-1 Transcripts and Ich-1.sub.L and Ich-1.sub.S Proteins

The peptide marked with X may not be translated in vivo. The open reading frames and proteins are shown in bars. Untranslated regions and introns are shown in lines. The positions of Ich-1.sub.S and Ich-1.sub.L stop codons are indicated on the transcript diagram as "stop". Amino acid sequences in Ich-1.sub.S that are different from Ich-1.sub.L are shaded.

FIGS. 12A-12B: A Comparison of the Ich-1 Protein Sequence with the Mouse nedd-2 Protein, the hICE Protein, the mICE Protein, and C. elegans ced-3 Protein

Amino acids are numbered to the right of each sequence. Any residues in nedd-2 (SEQ ID NO: 40), hICE (SEQ ID NO: 39), mICE (SEQ ID NO: 38), and ced-3 (SEQ ID NO: 35) that are identical with Ich-1 (SEQ ID NOS: 51,53) are highlighted. The two point mutations made by site-directed mutagenesis are marked on the top of the sequence.

FIG. 12C: A Schematic Comparison of Structural Features of Ich-1.sub.L and hICE

The active site of hICE and predicted active site of Ich-1.sub.L are indicated. The four known cleavage sites of hICE and potential cleavage sites of Ich-1.sub.L are marked.

FIG. 13: Stable Expression of Ich-1.sub.S Prevents Cell Death of Rat-1 Cells Induced by Serum Removal

Stable transfectants of Rat-1 cells expressing bcl-2, crmA or Ich-1.sub.S were prepared as described in Experimental Procedures. Independent Ich-1.sub.S -positive and Ich-1.sub.S -negative clones were used. At time 0, exponentially growing cells were washed with serum-free DMEM and dead cells were counted over time by trypan blue staining.

FIGS. 14-14A: The cDNA Sequence (SEQ ID NO: 54) and Putative Ich-3 Protein Sequence (SEQ ID NO: 55)

The putative first Met is marked with a dot.

FIGS. 15-15A: Companson of Amino Acid Sequences of Ich-3 (SEQ ID NO: 56) with hICE (SEQ ID NO: 38), mIch-2 (SEQ ID NO: 42), Ich-1 (SEQ ID NO: 43) and ced-3 (SEQ ID NO: 35)

Several amino acid sequences are compared.

FIG. 16: Suppression of TNF-lnduced Cytotoxicity by Overexpression of CrmA

The results are from three separate experiments with each condition done in duplicate.

In the description that follows, a number of terms used in recombinant DNA (rDNA) technology or in the research area of programmed cell death are extensively utilized. In order to provide a clear and consistent understanding of the specification and claims, including the scope to be given such terms, the following definitions are provided.

Gene

A DNA sequence containing a template for a RNA polymerase. The RNA transcribed from a gene may or may not code for a protein. RNA that codes for a protein is termed messenger RNA (mRNA). It is understood, however, that a gene also encompasses non-transcribed regulatory sequences including, but not limited to, such sequences as enhancers, promoters, and poly-A addition sequences.

A "complementary DNA" or "cDNA" gene includes recombinant genes synthesized by reverse transcription of mRNA and from which intervening sequences (introns) have been removed. Of course, cDNA may also include any complementary part of any gene sequence. The complement could be synthesized, for example, and may not exclude DNA sequences not found in the naturally occurring mRNA.

Cloning vector

A plasmid or phage DNA or other DNA sequence which is able to replicate autonomously in a host cell, and which is characterized by one or a small number of endonuclease recognition sites at which such DNA sequences may be cut in a determinable fashion without loss of an essential biological function of the vehicle, and into which DNA may be spliced in order to bring about its replication and cloning. The cloning vector may further contain a marker suitable for use in the identification of cells transformed with the cloning vehicle. Markers, for example, are tetracycline resistance or ampicillin resistance. The term "cloning vehicle" is sometimes used for "cloning vector."

Expression vector

A vector similar to a cloning vector but which is capable of expressing a gene which has been cloned into it, after transformation into a host. The cloned gene is usually placed under the control of (i.e., operably linked to) certain control sequences such as promoter sequences. Control sequences will vary depending on whether the vector is designed to express the operably linked gene in a prokaryotic or eukaryotic host and may additionally contain transcriptional elements such as enhancer elements, termination sequences, tissue-specificity elements, and/or translational initiation and termination sites.

Programmed cell death

The process in which cell death is genetically programmed. Programmed cell death allows organisms to eliminate cells that have served a developmental purpose but which are no longer beneficial.

Functional Derivative

A "functional derivative" of mIch-2, Ich-1 (Ich-1.sub.L and Ich-1.sub.S ), or Ich-3 is a protein, or DNA encoding a protein, which possesses a biological activity that is substantially similar to the biological activity of the non-recombinant. A functional derivative of may or may not contain post-translational modifications such as covalently linked carbohydrate, depending on the necessity of such modifications for the performance of a specific function. The term "functional derivative" is intended to include the "fragments, " "variants, " "analogues, " or "chemical derivatives" of a molecule. The derivative retains at least one of the naturally-occurring functions of the parent gene or protein. The function can be any of the regulatory gene functions or any of the function(s) of the finally processed protein. The degree of activity of the function need not be quantitatively identical as long as the qualitative function is substantially similar.

Fragment

A "fragment" is meant to refer to any subgenetic sequence of the molecule, such as the peptide core, or a variant of the peptide core.

Description

The present invention relates, inter alia, to isolated DNA encoding ced-3 of C. elegans, mIch-2, Ich-1, and lch-3. The invention also encompasses nucleic acids having the cDNA sequence of ced-3, mIch-2, Ich-1, and Ich-3. The invention also encompasses related sequences in other species that can be isolated without undue experimentation. It will be appreciated that trivial variations in the claimed sequences and fragments derived from the full-length genomic and cDNA genes are encompassed by the invention as well. The invention also encompasses protein sequences encoded by ced-3, mIch-2, Ich-1, and Ich-3. It should also be understood that Ich-1 encompasses both Ich-1.sub.S and Ich-1.sub.L.

ced-3

The genomic sequence of the claimed gene encoding ced-3 is shown in FIGS. 2A-2F. The gene is 7,656 base pairs in length and contains seven introns ranging in size from 54 base pairs to 1,195 base pairs. The four largest introns as well as sequences 5' to the START codon contain repetitive elements, some of which have been previously characterized in the non-coding regions of other C. elegans genes such as fem-1 (Spence et al., Cell 60:981-990 (1990)) and hlh-I (Krause et al., Cell 63:907-919 (1990)). A comparison of the repetitive elements in ced-3 with previously characterized repetitive elements is shown in FIGS. 2A(i)-2A(v) (SEQ ID NOS: 3-33). The START codon of ced-3 is the methionine at position 2232 of the genomic sequence shown in FIGS. 2A-2F.

The cDNA sequence of ced-3 shown in FIGS. 2M-2P (SEQ ID NO: 34). The cDNA is 2,482 base pairs in length with an open reading frame encoding 503 amino acids (SEQ ID NO: 35) and 953 base pairs of 3' untranslated sequence. The last 380 base pairs of the 3' sequence are not essential for the expression of ced-3.

In addition to encompassing the genomic and cDNA sequences of ced-3 from C. elegans, the present invention also encompasses related sequences in other nematode species which can be isolated without undue experimentation. For example, the inventors have shown that ced-3 genes from C. briggsae and C. vulgaris may be isolated using the ced-3 cDNA from C. elegans as a probe (see Example 1).

The invention also encompasses protein products from the ced-3 gene, gene variants, derivatives, and related sequences. As deduced from the DNA sequence, ced-3 is 503 amino acids in length and contains a serine-rich middle region of about 100 amino acids. The amino acid sequence comprising the claimed ced-3 is shown in FIGS. 2A-2F and FIGS. 2M-2P (SEQ ID NO: 2). A comparison of ced-3 of C. elegans with the inferred ced-3 sequences from the related nematode species C. briggsae (SEQ ID NO: 36) and C. vulgaris (SEQ ID NO: 37) indicates that the non-serine-rich region is highly conserved and that the serine-rich region is more variable. The non-serine-rich portion of ced-3 is also homologous with hICE (SEQ ID NO: 39). The C-terminal portions of both ced-3 and hICE are similar to the mouse nedd-2 (SEQ ID NO: 40). The results suggest that ced-3 acts as a cysteine protease in controlling the onset of programmed cell death in C. elegans and that members of the ced-3/ICE/nedd-2 gene family function in programmed cell death in a wide variety of species.

mIch-2

The cDNA sequence (SEQ ID NO: 41) and deduced amino acid sequence (SEQ ID NO: 42) of mIch-2 are shown in FIG. 6. As expected, mIch-2 shows homology to both hICE and mICE as well as to C. elegans ced-3 (see FIGS. 7 and 7A). In contrast to other cell-death genes that have been identified, mIch-2 is preferentially expressed in the thymus and placenta. Example 3 describes how the gene was obtained by screening a mouse thymus cDNA library with a DNA probe derived from hICE under conditions of low stringency. Given the amino acid sequence and cDNA sequence shown in FIGS. 6A-6C, preferred methods of obtaining the mIch-2 gene (either genomic or cDNA) are described below.

Ich-1

nedd2, hICE, mIch-2 and ced-3 are all members of the same gene family. This suggested that new genes might be isolated based upon their homology to identified family members.

Ich-1 is 1456 base pairs in length and contains an open reading frame of 435 amino acids (FIGS. 10A-10B (SEQ ID NOS: 50, 51)). The C-terminal 130 amino acids of Ich-1 are over 87% identical to mouse nedd2. However, Ich-1 contains a much longer open reading frame and has the pentapeptide QACRG which is the active center of the proteins of the ced-3/ICE family. The results indicate that the cDNA isolated by Kumar et al. may not have been synthesized from a fully processed mRNA and that the 5' 1147 base pairs which Kumar et al. reported for nedd2 cDNA may actually represent the sequence of an intron. The sequence reported by Kumar et al. contains a region which could potentially code for QACRG but these amino acids are encoded in a different reading frame (SEQ ID NOS: 44, 49) than that indicated by Kumar et al. (FIG. 8). This suggests that Kumar et al. made an error in cloning.

The coding regions of nedd2 and Ich-1.sub.L are highly homologous. The amino acid sequence of the deduced Ich-1.sub.L protein shares 28% identity with ced-3 and 27% identity with hICE (FIGS. 9, 9A).

Ich-1 mRNA is alternatively spliced into two different forms. One mRNA species encodes a protein product of 435 amino acids, designated Ich-1.sub.L (SEQ ID NO: 51), which contains amino acid sequence homologous to both P20 and P10 subunits of hICE as well as entire ced-3 (28% identity). The other mRNA encodes a 312 amino-acid truncated version of Ich-1, designated Ich-1.sub.S (SEQ ID NO: 53) , that terminates 21 amino acid residues after the QACRG active domain of Ich-1. Expression of Ich-1.sub.L and Ich-1.sub.S has opposite effects on cell death. Overexpression of Ich-1.sub.L induces Rat-1 fibroblast cells to die in culture, while overexpression of the Ich-1.sub.S suppresses Rat-1 cell death induced by serum deprivation. Results herein suggest that Ich-1 may play an important role in both positive and negative regulation of programmed cell death in vertebrate animals.

Ich-3

Ich-3 (SEQ ID NO: 54) was identified based on its sequence homology with hICE and other isolated ICE homologs. Since the Ich-3 clone isolated by PCR only contains the coding region for the C-terminal half of Ich-3, a mouse thymus cDNA library was screened using the Ich-3 insert. Among 2 million clones screened, 9 positive clones were isolated. The sequence herein is from one clone (deposited at the American Type Culture Collection, Rockville, Md., on Sep. 26, 1997 and given accession number ATCC 209304) that contains the complete coding region for Ich-3 gene.

ced-3

There are many standard procedures for cloning genes which are well-known in the art and which can be used to obtain the ced-3 gene (see e.g., Sambrook et al., Molecular Cloning, a Laboratory Manual, 2nd edition, vol. 1-3, Cold Spring Harbor Laboratory Press, 1989). In Example 1, a detailed description is provided of two preferred procedures. The first preferred procedure does not require the availability of ced-3 gene sequence information and is based upon a method described by Ruvkun et al. (Molecular Genetics of Caenorhabditis Elegans Heterochromic Gene lin-14 121: 501-516 (1988)). In brief, Bristol and Bergerac strains of nematode are crossed and restriction fragment length polymorphism mapping is performed on the DNA of the resulting inbred strain. Restriction fragments closely linked to ced-3 are identified and then used as probes to screen cosmid libraries for cosmids carrying all or part of the ced-3 gene. Positive cosmids are injected into a nematode strain in which ced-3 has been mutated. Cosmids carrying active ced-3 genes are identified by their ability to rescue the ced-3 mutant phenotype

A second method for cloning ced-3 genes relies upon the sequence information which has been disclosed herein. Specifically, DNA probes are constructed based upon the sequence of the ced-3 gene of C. elegans. These probes are labelled and used to screen DNA libraries from nematodes or other species. Procedures for carrying out such cloning and screening are described more fully below in connection with the cloning and expression of mIch-2, Ich-1, and Ich-3, and are well-known in the art (see, e.g., Sambrook et al., Molecular Cloning, a Laboratory Manual, 2nd edition (1988)). When hybridizations are carried out under conditions of high stringency, genes are identified which contain sequences corresponding exactly to that of the probe. In this way, the exact same sequence as described by the inventors herein may be obtained. Alternatively, hybridizations may be carried out under conditions of low stringency in order to identify genes in other species which are homologous to ced-3 but which contain structural variations (see Example 1 for a description of how such hybridizations may be used to obtain the ced-3 genes from C. briggsae and C. vulgaris).

The results in Example 2 demonstrate that the products of cell-death genes may be tolerated by cells provided they are expressed at low levels. Therefore, ced-3 may be obtained by incorporating the ced-3 cDNA described above into any of a number of expression vectors well-known in the art and transferring these vectors into appropriate hosts (see Sambrook et al., Molecular Cloning, a Laboratory Manual, vol. 3 (1988)). As described below in connection with the expression of mIch-2, Ich-1, and Ich-3, expression systems may be utilized in which cells are grown under conditions in which a recombinant gene is not expressed and, after cells reach a desired density, expression may be induced. In this way, the tendency of cells which express ced-3 to die may be circumvented.

mIch-2, Ich-1, and Ich-3

DNA encoding mIch-2, lch-1, and Ich-3 may be obtained from either genomic DNA or from cDNA. Genomic DNA may include naturally occurring introns. Moreover, such genomic DNA may be obtained in association with the 5' promoter region of the sequences and/or with the 3' transcriptional termination region. Further, such genomic DNA may be obtained in association with the genetic sequences which encode the 5' non-translated region of the mIch-2, Ich-1, and Ich-3 mRNA and/or with the genetic sequences which encode the 3' non-translated region. To the extent that a host cell can recognize the transcriptional and/or translational regulatory signals associated with the expression of the mRNA and protein, then the 5 and/or 3' non-transcribed regions of the native gene, and/or, the 5' and/or 3 non-translated regions of the mRNA, may be retained and employed for transcriptional and translational regulation.

Genomic DNA can be extracted and purified from any cell containing mouse chromosomes by means well known in the art (for example, see Guide to Molecular Cloning Techniques, S. L. Berger et al., eds., Academic Press (1987)). Alternatively, mRNA can be isolated from any cell which expresses the genes, and used to produce cDNA by means well known in the art (Id.). The preferred sources for mIch-2 are thymus or placental cells. The mRNA coding for any of the proteins may be enriched by techniques commonly used to enrich mRNA preparations for specific sequences, such as sucrose gradient centrifugation.

For cloning into a vector, DNA prepared as described above (either human genomic DNA or preferably cDNA) is randomly sheared or enzymatically cleaved, and ligated into appropriate vectors to form a recombinant gene library. A DNA sequence encoding the protein or its functional derivatives may be inserted into a DNA vector in accordance with conventional techniques. Techniques for such manipulations are disclosed by Sambrook, et al., supra, and are well known in the art.

In a preferred method, oligonucleotide probes specific for the gene are designed from the cDNA sequences shown in the FIGS. 6A-6C, 10A-10B, 10C, and 14-14A. The oligonucleotide may be synthesized by means well known in the art (see, for example, Synthesis and Application of DNA and RNA, S. A. Narang, ed., Academic Press, San Diego, Calif. (1987)) and employed as a probe to identify and isolate the cloned gene by techniques known in the art. Techniques of nucleic acid hybridization and clone identification are disclosed by Maniatis, T., et al. (In: Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratories, Cold Spring Harbor, N.Y. (1982)), and by Hames, B. D., et al. (In: Nucleic Acid Hybridization, A Practical Approach, IRL Press, Washington, D.C. (1985)). Those members of the above-described gene library which are found to be capable of such hybridization are then analyzed to determine the extent and nature of the coding sequences which they contain.

To facilitate the detection of the desired coding sequence, the above-described DNA probe is labeled with a detectable group. This group can be any material having a detectable physical or chemical property. Such materials are well-known in the field of nucleic acid hybridization and any label useful in such methods can be applied to the present invention. Particularly useful are radioactive labels, such as .sup.32 P, .sup.3 H, .sup.14 C, .sup.35 S, .sup.125 I, or the like. Any radioactive label may be employed which provides for an adequate signal and has a sufficient half-life. The oligonucleotide may be radioactively labeled, for example, by "nick-translation" by well-known means, as described in, for example, Rigby, P. J. W., et al., J. Mol. Biol. 113:237(1977) or by T4 DNA polymerase replacement synthesis as described in, for example, Deen, K.C., et al., Anal. Biochem. 135:456 (1983).

Alternatively, oligonucleotide probes may be labeled with a non-radioactive marker such as biotin, an enzyme or a fluorescent group. See, for example, Leary, J. J., et al., Proc. Natl. Acad. Sci. USA 80:4045 (1983); Renz, M., et al., Nucl. Acids Res. 12:3435 (1984); and Renz, M., EMBO J. 6:817 (1983).

For Ich-1, the isolation shown in the Examples was as follows. Two primers were used in the polymerase chain reaction to amplify nedd2 cDNA from embryonic day 15 mouse brain cDNA (Sambrook et al., Molecular Cloning, a Laboratory Manual, vol. 3 (1988)). One primer had the sequence (SEQ ID NO: 57): ATGCTAACTGTCCAAGTCTA and the other primer had the sequence (SEQ ID NO: 58): TCCAACAGCAGGAATAGCA. The cDNA thus amplified was cloned using standard methodology. The cloned mouse nedd2 cDNA was used as a probe to screen a human fetal brain cDNA library purchased from Stratagene. Such methods of screening and isolating clones are well known in the art (Maniatis, T., et al., Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratories, Cold Spring Harbor, N.Y. (1982)); Hames, B. D., etal., Nucleic Acid Hybridization, A Practical Approach, IRL Press, Washington, D.C. (1985)). A human nedd-2 cDNA clone was isolated that encodes a protein much longer than the mouse nedd-2 and contains amino acid sequences homologous to the entire hICE and ced-3. The isolated clone was given the name Ice-ced 3 homolog or Ich-1.

The Ich-1 cDNA may be obtained using the nucleic acid sequence information given in FIGS. 10A-10B or 10C-10E. DNA probes constructed from this sequence can be labeled and used to screen human gene libraries as described herein. Also as discussed herein, Ich-1 may be cloned into expression vectors and expressed in systems in which host cells are grown under conditions in which recombinant genes are not expressed and, after cells reach a desired density, expression is induced. In this way, a tendency of cells which express Ich-1 to die may be circumvented.

One method of making Ich-3 is as follows. mRNA was isolated from embryonic day 14 mouse embryos using Invitrogen's microfast track mRNA isolation kit. The isolated mRNA was reverse transcribed to generate template for PCR amplification. The degenerate PCR primers were: cICEB (SEQ ID NO: 59) {TG(ATCG)CC(ATCG)GGGAA(ATCG)AGGTAGAA} and cICEAs (SEQ ID NO: 60) {ATCAT(ATC)ATCCAGGC(ATCG)TGCAG(AG)GG}. The PCR cycles were set up as follows: 1. 94.degree. C., 3 min; 2. 94.degree. C., 1 min; 3. 48.degree. C., 2 min; 4. 72.degree. C., 3 min; 5. return to "2" 4 cycles; 6. 94.degree. C., 1 min; 7. 55.degree. C., 2 min; 8. 72.degree. C., 3 min; 9. return to "6" 34 cycles; 10. 72.degree. C., 10 min; 11. end. Such PCR generated a band about 400 bp, the predicted size of ICE homologs. The PCR products were cloned into T-tailed blunt-ended pBSKII plasmid vector (Stratagene). Plasmids that contain an insert were analyzed by DNA sequencing.

The Ich-3 cDNA may also be obtained using the nucleic acid sequence information given in FIGS. 14-14A. DNA probes constructed from this sequence can be labeled and used to screen human gene libraries as described herein. Also as discussed herein, Ich-3 may be cloned into expression vectors and expressed in systems in which host cells are grown under conditions in which recombinant genes are not expressed and, after cells reach a desired density, expression is induced.

The methods discussed herein are capable of identifying genetic sequences which encode mIch-2, Ich-1, and Ich-3. In order to further characterize such genetic sequences, and, in order to produce the recombinant protein, it is desirable to express the proteins which these sequences encode.

To express any of the genes herein or their derivatives, transcriptional and translational signals recognizable by an appropriate host are necessary. The cloned coding sequences, obtained through the methods described herein, may be operably linked to sequences controlling transcriptional expression in an expression vector and introduced into a host cell, either prokaryote or eukaryote, to produce recombinant protein or a functional derivative thereof. Depending upon which strand of the sequence is operably linked to the sequences controlling transcriptional expression, it is also possible to express antisense RNA or a functional derivative thereof.

Expression of the protein in different hosts may result in different post-translational modifications which may alter the properties of the protein. Preferably, the present invention encompasses the expression of mIch-2, Ich-1, and Ich-3 or a functional derivative thereof, in eukaryotic cells, and especially mammalian, insect and yeast cells. Especially preferred eukaryotic hosts are mammalian cells either in vivo, or in tissue culture. Mammalian cells provide post-translational modifications which should be similar or identical to those found in the native protein. Preferred mammalian host cells include rat-1 fibroblasts, mouse bone marrow derived mast cells, mouse mast cells immortalized with Kirsten sarcoma virus, or normal mouse mast cells that have been co-cultured with mouse fibroblasts (Razin et al., J. of Immun. 132:1479 (1984); Levi-Schaffer et al., Proc. Natl. Acad. Sci. (USA) 83:6485 (1986) and Reynolds et al., J. Biol. Chem. 263:12783-12791 (1988)).

A nucleic acid molecule, such as DNA, is said to be "capable of expressing" a polypeptide if it contains expression control sequences which contain transcriptional regulatory information and such sequences are "operably linked" to the nucleotide sequence which encodes the polypeptide.

An operable linkage is a linkage in which a coding sequence is connected to a regulatory sequence (or sequences) in such a way as to place expression of the coding sequence under the influence or control of the regulatory sequence. Two DNA sequences (e.g. the coding sequence of protein and a promoter) are said to be operably linked if induction of promoter function results in the transcription of the coding sequence and if the nature of the linkage between the two DNA sequences does not (1) result in the introduction of a frame-shift mutation; (2) interfere with the ability of regulatory sequences to direct the expression of the coding sequence, antisense RNA, or protein; or (3) interfere with the ability of the coding sequence template to be transcribed by the promoter region sequence. Thus, a promoter region would be operably linked to a DNA sequence if the promoter were capable of effecting transcription of that DNA sequence.

The precise nature of the regulatory regions needed for gene expression may vary between species or cell types, but shall in general include, as necessary, 5' non-transcribing and 5' non-translating (non-coding) sequences involved with initiation of transcription and translation respectively, such as the TATA box, capping sequence, CAAT sequence, and the like. Especially, such 5' non-transcribing control sequences will include a region which contains a promoter for transcriptional control of the operably linked gene.

Expression of proteins of the invention in eukaryotic hosts requires the use of regulatory regions functional in such hosts, and preferably eukaryotic regulatory systems. A wide variety of transcriptional and translational regulatory sequences can be employed, depending upon the nature of the eukaryotic host. The transcriptional and translational regulatory signals can also be derived from the genomic sequences of viruses which infect eukaryotic cells, such as adenovirus, bovine papilloma virus, simian virus, herpesvirus, or the like. Preferably, these regulatory signals are associated with a particular gene which is capable of a high level of expression in the host cell.

In eukaryotes, where transcription is not linked to translation, control regions may or may not provide an initiator methionine (AUG) codon, depending on whether the cloned sequence contains such a methionine. Such regions will, in general, include a promoter region sufficient to direct the initiation of RNA synthesis in the host cell. Promoters from heterologous mammalian genes which encode mRNA capable of translation are preferred, and especially, strong promoters such as the promoter for actin, collagen, myosin, etc., can be employed provided they also function as promoters in the host cell. Preferred eukaryotic promoters include the promoter of the mouse metallothionein I gene (Hamer, D., et al., J. Mol. Appl. Gen. 1:273-288 (1982)); the TK promoter of herpesvirus (McKnight, S., Cell 31:355-365 (1982)); the SV40 early promoter (Benoist, C., et al., Nature (London) 290:304-310 (1981)); in yeast, the yeast gal4 gene promoter (Johnston, S. A., et al., Proc. Natl. Acad. Sci. (USA) 79:6971-6975 (1982); Silver, P. A., et al., Proc. Natl. Acad. Sci. (USA) 81:5951-5955 (1984)) or a glycolytic gene promoter may be used.

It is known that translation of eukaryotic mRNA is initiated at the codon which encodes the first methionine. For this reason, it is preferable to ensure that the linkage between a eukaryotic promoter and a DNA sequence which encodes the proteins of the invention or functional derivatives thereof, does not contain any intervening codons which are capable of encoding a methionine. The presence of such codons results either in the formation of a fusion protein or a frame-shift mutation.

If desired, a fusion product of the proteins may be constructed. For example, the sequence coding for the proteins may be linked to a signal sequence which will allow secretion of the protein from, or the compartmentalization of the protein in, a particular host. Such signal sequences may be designed with or without specific protease sites such that the signal peptide sequence is amenable to subsequent removal. Alternatively, the native signal sequence for this protein may be used.

Transcriptional initiation regulatory signals can be selected which allow for repression or activation, so that expression of operably linked genes can be modulated. Of interest are regulatory signals which are temperature-sensitive so that by varying the temperature, expression can be repressed or initiated, or are subject to chemical regulation, e.g., metabolite.

If desired, the non-transcribed and/or non-translated regions 3' to the sequence coding for the proteins can be obtained by the above-described cloning methods. The 3'-non-transcribed region may be retained for transcriptional termination regulatory sequence elements; the 3'-non-translated region may be retained for translational termination regulatory sequence elements, or for those elements which direct polyadenylation in eukaryotic cells. Where native expression control signals do not function satisfactorily in a host cell, functional sequences may be substituted.

The vectors of the invention may further comprise other operably linked regulatory elements such as enhancer sequences, or DNA elements which confer tissue or cell-type specific expression on an operably linked gene.

To transform a mammalian cell with the DNA constructs of the invention many vector systems are available, depending upon whether it is desired to insert the DNA construct into the host cell chromosomal DNA, or to allow it to exist in extrachromosomal form. If the protein encoding sequence and an operably linked promoter are introduced into a recipient eukaryotic cell as a non-replicating DNA (or RNA) molecule, the expression of the protein may occur through the transient expression of the introduced sequence.

In a preferred embodiment, genetically stable transformants may be constructed with vector systems, or transformation systems, whereby mIch-2, Ich-1, or Ich-3 DNA is integrated into the host chromosome. Such integration may occur de novo within the cell or, in a most preferred embodiment, through the aid of a cotransformed vector which functionally inserts itself into the host chromosome, for example, retroviral vectors, transposons or other DNA elements which promote integration of DNA sequences in chromosomes.

Cells which have stably integrated the introduced DNA into their chromosomes are selected by also introducing one or more markers which allow for selection of host cells which contain the expression vector in the chromosome, for example the marker may provide biocide resistance, e.g., resistance to antibiotics, or heavy metals, such as copper, or the like. The selectable marker gene can either be directly linked to the DNA gene sequences to be expressed, or introduced into the same cell by co-transfection.

In another embodiment, the introduced sequence is incorporated into a plasmid or viral vector capable of autonomous replication in the recipient host. Any of a wide variety of vectors may be employed for this purpose. Factors of importance in selecting a particular plasmid or viral vector include: the ease with which recipient cells that contain the vector may be recognized and selected from those recipient cells which do not contain the vector; the number of copies of the vector which are desired in a particular host; and whether it is desirable to be able to "shuttle" the vector between host cells of different species.

Preferred eukaryotic plasmids include those derived from the bovine papilloma virus, vaccinia virus, SV40, and, in yeast, plasmids containing the 2-micron circle, etc., or their derivatives. Such plasmids are well known in the art (Botstein, D., et al., Miami Wntr. Symp. 19:265-274 (1982); Broach, J. R., In: The Molecular Biology of the Yeast Saccharomyces: Life Cycle and Inheritance, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y., p. 445-470 (1981); Broach, J. R., Cell 28:203-204 (1982); Bollon, D. P., et al., J. Clin. Hematol. Oncol. 10:39-48 (1980); Maniatis, T., In: Cell Biology: A Comprehensive Treatise, Vol. 3, Gene Expression, Academic Press, N.Y., pp. 563-608 (1980)), and are commercially available.

Once the vector or DNA sequence containing the construct(s) is prepared for expression, the DNA construct(s) is introduced into an appropriate host cell by any of a variety of suitable means, including transfection. After the introduction of the vector, recipient cells are grown in a medium which selects for the growth of vector-containing cells. Expression of the cloned gene sequence(s) results in the production of the protein, or in the production of a fragment of this protein. This expression can take place in a continuous manner in the transformed cells, or in a controlled manner, for example, expression which follows induction of differentiation of the transformed cells (for example, by administration of bromodeoxyuracil to neuroblastoma cells or the like). The latter is preferred for the expression of the proteins of the invention. By growing cells under conditions in which the proteins are not expressed, cell death may be avoided. When a high cell density is reached, expression of the proteins may be induced and the recombinant protein harvested immediately before death occurs.

The expressed protein is isolated and purified in accordance with conventional procedures, such as extraction, precipitation, gel filtration chromatography, affinity chromatography, electrophoresis, or the like.

The mIch-2, Ich-1, and Ich-3 sequences, obtained through the methods above, will provide sequences which not only encode proteins but which also provide for transcription of mIch-2, Ich-1, and Ich-3 antisense RNA; the antisense DNA sequence will be that sequence found on the opposite strand of the strand transcribing the mRNA. The antisense DNA strand may also be operably linked to a promoter in an expression vector such that transformation with this vector results in a host capable of expression of the antisense RNA in the transformed cell. Antisense DNA and RNA may be used to interact with endogenous mIch-2, Ich-1, or Ich-3 DNA or RNA in a manner which inhibits or represses transcription or translation of the genes in a highly specific manner. Use of antisense nucleic acid to block gene expression is discussed in Lichtenstein, C., Nature 333:801-802 (1988).

ced-3

The ced-3 gene (as well as ced-3 homologs and other members of the ced-3 gene family) may be used for a number of distinct purposes. First, portions of the gene may be used as a probe for identifying genes homologous to ced-3 in other strains of nematode (see Example 1) as well as in other species (see Examples 2 and 3). Such probes may also be used to determine whether the ced-3 gene or homologs of ced-3 are being expressed in cells.

The cell death genes will be used in the development of therapeutic methods for diseases and conditions characterized by cell death. Among diseases and conditions which could potentially be treated are neural and muscular degenerative diseases, myocardial infarction, stroke, virally induced cell death and aging. The discovery that ced-3 is related to ICE suggests that cell death genes may play an important role in inflammation (IL-1.beta. is known to be involved in the inflammatory response). Thus therapeutics based upon ced-3 and related cell death genes may also be developed.

mIch-2, Ich-1, and Ich-3

mIch-2, Ich-1, and Ich-3 will have the same uses as those described in connection with ced-3 (above) and ICE (see below). The gene sequences may be used to construct antisense DNA and RNA oligonucleotides, which, in turn, may be used to prevent programmed cell death in thymus or placental cells. Techniques for inhibiting the expression of genes using antisense DNA or RNA are well-known in the art (Lichtenstein, C., Nature 333:801-802 (1988)). Portions of the claimed DNA sequence may also be used as probes for determining the level of expression. Similarly the protein may be used to generate antibodies that can be used in assaying cellular expression.

Portions of the mIch-2, Ich-1, and Ich-3 genes described above may be used for determining the level of expression of the proteins (mIch-2 in thymus or placental cells as well as in other tissues and organs). Such methods may be useful in determining if these cells have undergone a neoplastic transformation. Probes based upon the gene sequences may be used to isolate similar genes involved in cell death. A portion of the gene may be used in homologous recombination experiments to repair defective genes in cells or, alternatively, to develop strains of mice that are deficient in the gene. Antisense constructs may be transfected into cells, according to the native cellular expression patterns of each gene (placental or thymus cells for mIch-2, for example) in order to develop cells which may be maintained in culture for an extended period of time or indefinitely. Alternatively antisense constructs may be used in cell culture or in vivo to block cell death.

The protein may be used for the purpose of generating polyclonal or monoclonal antibodies using standard techniques well known in the art (Klein, J., Immunology: The Science of Cell-Noncell Discrimination, John Wiley & Sons, N.Y. (1982); Kennett et al., Monoclonal Antibodies, Hybridoma: A New Dimension in Biological Analyses, Plenum Press, N.Y. (1980); Campbell, A., "Monoclonal Antibody Technology," In: Laboratory Techniques in Biochemistry and Molecular Biology 13, Burdon et al. eds., Elseiver, Amsterdam (1984); Harlow and Lane, Antibodies, A Laboratory Manual, Cold Spring Harbor Laboratory, N.Y. (1988)). Such antibodies may be used in assays for determining the expression of the genes. Purified protein would serve as the standard in such assays.

Based upon the sequences of FIGS. 6A-6C, probes may be used to determine whether the mIch-2 gene or homologs of mIch-2 are being expressed in cells. Such probes may be utilized in assays for correlating mIch-2 expression with cellular conditions, e.g. neoplastic transformation, as well as for the purpose of isolating other genes which are homologous to mIch-2.

mIch-2 will be used in the development of therapeutic methods for diseases and conditions characterized by cell death. The diseases and conditions which could potentially be treated include neural and muscular degenerative diseases, myocardial infarction, stroke, virally induced cell death and aging.

Antisense nucleic acids based upon the sequences shown in FIGS. 6A-6C may be used to inhibit mIch-2 expression. Such inhibition will be useful in blocking cell death in cultured cells.

mIch-2 may be used to generate polyclonal or monoclonal antibodies using methods well known in the art (see above). The antibodies may be used in assays for determining the expression of mIch-2. Purified mIch-2 would serve as the standard in such assays.

Based upon the sequences of FIGS. 10A-10B and 10C-10E, probes may be used to determine whether the Ich-1 gene or homologs of Ich-1 are being expressed in cells. Such probes may be utilized in assays for correlating Ich-1 expression with cellular conditions, e.g. neoplastic transformation, as well as for the purpose of isolating other genes which are homologous to Ich-1.

Ich-1 will be used in the development of therapeutic methods for diseases and conditions characterized by cell death. The diseases and conditions which could potentially be treated include neural and muscular degenerative diseases, myocardial infarction, stroke, virally induced cell death and aging.

Antisense nucleic acids based upon the sequences shown in FIGS. 10A-10B and 10C-E, may be used to inhibit Ich-1 expression. Such inhibition will be useful in blocking cell death in cultured cells.

Ich-1 protein may be used to generate polyclonal or monoclonal antibodies using methods well known in the art (see above). The antibodies may be used in assays for determining the expression of Ich-1. Purified Ich-1 would serve as the standard in such assays.

Based upon the sequence of FIGS. 14-14A, probes may be used to determine whether the Ich-3 gene or homologs of Ich-3 are being expressed in cells. Such probes may be utilized in assays for correlating Ich-3 expression with cellular conditions, e.g. neoplastic transformation, as well as for the purpose of isolating other genes which are homologous to Ich-3.

Ich-3 will be used in the development of therapeutic methods for diseases and conditions characterized by cell death. The diseases and conditions which could potentially be treated include neural and muscular degenerative diseases, myocardial infarction, stroke, virally induced cell death and aging.

Antisense nucleic acids based upon the sequence shown in FIGS. 14-14A may be used to inhibit Ich-3 expression. Such inhibition will be useful in blocking cell death in cultured cells.

Ich-3 protein may be used to generate polyclonal or monoclonal antibodies using methods well known in the art (see above). The antibodies may be used in assays for determining the expression of Ich-3. Purified Ich-3 would serve as the standard in such assays. Inhibiting the Enzymatic Activity of ICE

The present invention is directed to preventing the programmed death of vertebrate cells by inhibiting the action of ICE. The detailed structural analysis performed on the ced-3 gene from C. elegans revealed a homology to human and murine ICE which is especially strong at the QACRG active domain of hICE (see FIGS. 3A-3B).

In order to determine if ICE functions as a cell death gene in vertebrates, the mICE gene was cloned, inserted into an expression vector and then transfected into rat cells. A close correlation was found between ICE expression and cell death (see Example 2).

Further support for the function of ICE as a cell death gene was obtained from inhibition studies. In order to determine whether cell death can be prevented by inhibiting the enzymatic action of ICE, cell lines were established which produced a high level of crmA. When these cells were transfected with mICE, it was found that a large percentage of the cells expressing mICE maintained a healthy morphology and did not undergo programmed cell death (Example 2 herein).

Evidence that ICE has a physiological role as a vertebrate cell death gene was also obtained by examining cells engineered to over-express bcl-2, an oncogene known to inhibit programmed cell death and to be overexpressed in many follicular and B cell lymphomas. It was found that cells expressing bcl-2 did not undergo cell death despite the high levels of ICE expression (Example 2 herein). These results suggest that bcl-2 may promote malignancy by inhibiting the action of ICE.

Any method of specifically regulating the action of ICE in order to control programmed cell death in vertebrates is encompassed by the present invention. This would include using not only inhibitors specific to ICE, e.g. crmA, or the inhibitors described by Thornberry et al. (Nature 356:768-774 (1992)), but also any method which specifically prevented the expression of the ICE gene. Thus, antisense RNA or DNA comprised of nucleotide sequences complementary to ICE and capable of inhibiting the transcription or translation of ICE are within the scope of the invention (see Lichtenstein, C., Nature 333:801-802 (1988)).

The ability to prevent vertebrate programmed cell death is of use in developing cells which can be maintained for an indefinite period of time in culture. For example, cells over-expressing crmA may be used as hosts for expressing recombinant proteins. The ability to prevent programmed cell death may allow cells to live independent of normally required growth factors. It has been found that microinjecting crmA mRNA or a crmA-expressing nucleic acid construct into cells allows chicken sympathetic neurons to live in vitro after the removal of neural growth factor. Increasing or Inducing the Activity of ICE

The expression of ICE can be increased in order to cause programmed cell death. For example, homologous recombination can be used to replace a defective region of an ICE gene with its normal counterpart. The level of regulation amenable to manipulation to either increase or decrease the expression of ICE include DNA, RNA, or protein. Genomic DNA, for example, can be mutated by the introduction of selected DNA sequences introduced into the genome by homologous recombination. Any desired mutation can be introduced in vitro and, through gene replacement, either decoding or regulatory sequences of the gene can be manipulated. Extrachromosomal DNA with the appropriate gene sequence can also be introduced into cells to compete with the endogenous product. At the level of RNA, antisense RNA molecules can be introduced, as well as RNA having more or less affinity for the translational apparatus or greater or lesser tendency to be transcribed. At the level of protein, protein counterparts can be designed having a higher or lower activity.

In addition to direct regulation, and particularly an increase in gene expression of ICE, the possibility also exists for indirect regulation by regulating those cellular components that either induce or suppress the expression of ICE. The inventors have found, for example, that TNF-.alpha. induces a program of cell death via the activation of hICE genetic sequences. Thus, a further level of regulation is that of modulating the expression of TNF-.alpha. and its functional counterparts. Thus, any cellular component regulating programmed cell death by means of the ICE/ced-3 pathway can itself be regulated rather than directly regulating the ICEgene. Regulation can occur by any of the means discussed above, for example. The genes in the bcl-2 family, p53 and the genes that are regulated by p53 (such as p21), the proteins in the ras pathway (ras, raf 14-3-3), Fas and the proteins in the cytotoxic T cell granules (such as granzyme B) may all directly and indirectly influence the activity of the ICE family. Accordingly, the regulation can also occur by means of any of these genes and others in such pathways. In this way, it may be possible to prevent the uncontrolled growth of certain malignant cells.

Methods of increasing ICE activity may be used to kill undesired organisms such as parasites. crmA is a viral protein that is important for cowpox infection. This suggests that the prevention of cell death may be important for successful infection and that the promotion of ICE expression may provide a means for blocking infection. Activation of ICE family genes may be used to eliminate cancerous cells or any other unwanted cells. Prevention of cell death by inactivating the ICE family of genes could prevent neuronal degenerative diseases, such as Alzheimer's disease, amylotrophic lateral sclerosis, and cell death associated with stroke, ischemic heart injury, and aging.

Having now generally described this invention, the same will be further described by reference to certain specific examples which are provided herein for purposes of illustration only and are not intended to be limiting unless otherwise specified. All references cited throughout the specification are incorporated by reference in their entirety.

Experimental Procedures

General methods and strains

The techniques used for culturing C. elegans have been described by Brenner (Brenner, S., Genetics 77:71-94 (1974)). All strains were grown at 20.degree. C. The wild-type parent strains were C. elegans variety Bristol strain N2, Bergerac strain EM1002 (Emmons et al., Cell 32:55-65 (1983)), C. briggsae and C. vulgaris. The genetic markers used are described below. These markers have been previously described (Brenner, S., Genetics 77:71-94 (1974)); and Hodgkin et al., Genetics in the Nematode Caenorhabditis Elgens (Wood et al. eds.) pp. 491-584, Cold Spring Harbor, N.Y. (1988)). Genetic nomenclature follows the standard system (Horvitz et al., Mol. Gen. Genet. 175:129-133 (1979)). n11634, n1164, n1165, n1286, n1949, n2426, n2430, n2433), unc-26 (e205), dpy-4 (e1166)

Isolation of additional alleles of ced-3

A non-complementation screen was designed to isolate new alleles of ced-3. Because animals heterozygous for ced3(n717) in trans to a deficiency are viable (Ellis et al., Cell 44:817-829 (1986)), it was expected that animals carrying a complete loss-of-function mutant ced-3 allele in trans to ced-3(n717) would be viable even if homozygotes for the allele were inviable. EMS mutagenized egl-1L4 males were mated with ced-3(n717) unc-26(e205); egl-1(n487); dpy-3(e27) hermaphrodites. egl-1 was used as a marker in this screen. Dominant mutations in egl-1 cause the two hermaphrodite-specific neurons, the HSNs, to undergo programmed cell death (Trent et al., Genetics 104:619-647 (1983)). The HSNs are required for normal egg-laying, and egl-1(n986) hermaphrodites, which lack HSNs are egg-laying defective (Trent et al., Genetics 104:619-647)). The mutant phenotype of egl-1 is suppressed in a ced-3; egl-1 strain because mutations in ced-3 block programmed cell deaths. egl-1 males were mutagenized with EMS and crossed with ced3(n717) unc-26(e205); egl-1(n487); dpy-3(e27). Most cross progeny were egg-laying defective because they were heterozygous for ced-3 and homozygous for egl-1. Rare egglaying competent animals were picked, those animals being candidates for carrying new alleles of ced-3. Four such animals were isolated from about 10,000 F1 cross progeny of EMS-mutagenized animals. These new mutations were made homozygous to confirm that they carried mutations of ced-3.

RFLP mapping

Two cosmid libraries were used extensively in this work--a Sau3A I partial digest genomic library of 7000 clones in the vector pHC79 and a Sau3A I partial digest genomic library of 6000 clones in the vector pJB8 (Coulson et al., Proc. Natl. Acad. Sci. U.S.A. 83:7821-7825 (1986).

Bristol (N2) and Bergerac (EM1002) DNA was digested with various restriction enzymes and probed with different cosmids to look for RFLPs. nP33 is a HindIII RFLP detected by the "right" end of Jc8. The "right" end of Jc8 was made by digesting Jc8 with EcoRI and self-ligating. nP34 is a HindIII RFLP detected by the "left" end of Jc8. The "left" end of Jc8 was made by digesting Jc8 by SalI and self ligating. nP36 and nP37 are both HindIII RFLPs detected by T10H5 and B0564, respectively.

Germ line transformation

The procedure used for microinjection basically follows that of A. Fire (Fire, A., EMBO J. 5:2673-2680 (1986)). Cosmid DNA was twice CsCl gradient purified. Miniprep DNA was used when deleted cosmids were injected and was prepared from 1.5 ml overnight bacterial culture in superbroth. Superbroth was prepared by combining 12 g Bacto tryptone, 24 g yeast extract, 8 ml 50% glycerol and 900 ml H.sub.2 O. The mixture was autoclaved and then 100 ml of 0.17 M KH.sub.2 PO.sub.4 and 0.72 M K.sub.2 HPO.sub.4 were added. The bacterial culture was extracted by the alkaline lysis method as described in Maniatis et al. (Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, Cold Spring Harbor, N.Y. (1983)). DNA was treated with RNase A (37.degree. C., 30 min) and then with protease K (55.degree. C., 30 min). The preparation was phenol- and then chloroform-extracted, precipitated twice (first in 0.3 M Na acetate and second in 0.1 M K acetate, pH 7.2), and resuspended in 5 1 injection buffer as described by A. Fire (Fire, A., EMBO J. 5:2673-2680 (1986)). The DNA concentration for injection was in the range of 100 .mu.g to 1 mg per ml.

All transformation experiments used the ced-1(e1735); unc-31(e928) ced-3(n717) strain. unc-31 was used as a marker for co-transformation (Kim et al., Genes & Dev. 4:357-371 (1990)). ced-1 was present to facilitate scoring of the ced-3 phenotype. The mutations in ced-1 block the engulfment process of cell death, which makes the corpses of the dead cells persist much longer than that in the wild-type (Hedgecock et al., Science 220:1277-1280 (1983)). ced-3 phenotype was scored as the number of dead cells present in the head of young L1 animals. The cosmid C10D8 or the plasmid subclones of C10D8 were mixed with C14G10 (unc-31(+)-containing) at a ratio of 2:1 or 3:1 to increase the chances that an Unc-31(+) transformant would contain the cosmid or plasmid being tested. Usually, 20-30 animals were injected in one experiment. Non-Unc F1 progeny of injected animals were isolated three to four days later. About 1/2 to 1/3 of the non-Unc progeny transmitted the non-Unc phenotype to F2 and established a line of transformants. The young L.sub.1 progeny of such non-Unc transformants were checked for the number of dead cells present in the head using Nomarski optics.

Determination of ced-3 transcript initiation site

Two primers,

Pex 1 (SEQ ID NO: 61): (5'GTTGCACTGCTTTCACGATCTCCCGTCTCT3')

and Pex2 (SEQ ID NO: 62): (5'TCATCGACTTTTAGATGACTAGAGAACATC3'), were used for primer extension. The primers for RT-PCR were:

SL1 (SEQ ID NO: 63) (5'GTTTAATTACCCAAGTTTGAG3')

and log-5 (SEQ ID NO: 64) (5'CCGGTGACATTGGACACTC3'). The products were reamplified using the primers SL1 and oligo10 (5'ACTATTCAACACTTG3'). A product of the expected length was cloned into the PCR1000 vector (Invitrogen) and sequenced.

Determination and analysis of DNA sequence

For DNA sequencing, serial deletions were made according to a procedure developed by Henikoff (Heinkoff, S., Gene 28:351-359 (1984)). DNA sequences were determined using Sequenase and protocols obtained from U.S. Biochemicals with minor modifications.

The ced-3 amino acid sequence was compared with amino acid sequences in the GenBank, PIR and SWISS-PROT databases at the National Center for Biotechnology Information (NCBI) using the blast network service.

Cloning of ced-3 genes from other nematode species

C. briggsae and C. vulgaris ced-3 genes were isolated from corresponding phage genomic libraries using the ced-3 cDNA subclone pJ118 insert as a probe under low stringency conditions (5.times.SSPE, 20% formamide, 0.02% Ficoll, 0.02% BSA, 0.02% polyvinylpyrrolidone, and 1% SDS) at 40.degree. C. overnight and washed in 1.times.SSPE and 0.5% SDS twice at room temperature and twice at 42.degree. C. for 20 min each time.

ced-3 is not essential for viability

All previously described ced-3 alleles were isolated in screens designed to detect viable mutants in which programmed cell death did not occur (Ellis et al., Cell 44:817-829 (1986)). Such screens might systematically have missed classes of ced-3 mutations that result in inviability. Since animals with the genotype of ced-3/deficiency are viable (Ellis et al., Cell 44:817-829 (1986)), a noncomplementation-screening scheme was designed that would allow the isolation of recessive lethal alleles of ced-3. Four new ced-3 alleles (n1163, n1164, n1165, and n1286) were obtained which were viable as homozygotes. These new alleles were isolated at a frequency of about 1 in 2500 mutagenized haploid genomes, approximately the frequency expected for the generation of null mutations in an average C. elegans gene (Brenner, S., Genetics 77:71-94 (1974); Meneely et al., Genetics 92:99-105 (1990); Greenwald et al., Genetics 96:147-160 (1980)).

These results suggest that animals lacking ced-3 gene activity are viable. In support of this hypothesis, molecular analysis has revealed that three ced-3 mutations are nonsense mutations that prematurely terminate ced-3 translation and one alters a highly conserved splice acceptor site (see below). These mutations would be expected to eliminate ced-3 activity completely. Based upon these considerations, it was concluded that ced-3 gene activity is not essential for viability.

ced-3 is contained withina 7.5 kb genomic fragment

The ced-3 gene was cloned using the approach of Ruvkun et al., (Molecular Genetics of the Caenorhabditis elegan Heterochronic Gene lin-14 121:501-516 (1988)). Briefly (For further details, see Experimental Procedures), the C. elegans Bristol strain N2 contains 30 dispersed copies of the transposable element Tc1, whereas the Bergerac strain contains more that 400 copies (Emmons et al., Cell 32:55-65 (1983); Finney M., Ph. D. Thesis, "The Genetics and Molecular Biology of unc-86, a Caenorhabditis elegans Cell Lineage Gene, " Cambridge, Mass. (1987)). By crossing Bristol and Bergerac strains, a series of recombinant inbred strains were generated in which chromosomal material was mostly derived from the Bristol strain with varying amounts of Bergerac-specific chromosome IV-erived material in the region of the ced-3 gene. By probing DNA from these strains with plasmid pCe2001 which contains Tc1 (Emmons et al., Cell 32:55-65 (1983), a 5.1 kb EcoRI Tc1-containing restriction fragment specific to the Bristol strain (restriction fragment length polymorphism nP35) and closely linked to ced-3 was identified.

Cosmids that contained this 5.1 kb restriction fragment were identified and it was found that these cosmids overlapped an existing cosmid contig that had been defined as part of the C. elegans genome project (Coulson et al., Proc. Natl. Acad. Sci. 83:7821-7825 (1986). Four other Bristol-Bergerac restriction fragment length polymorphisms were defined by cosmids in this contig (nP33, np34, nP36, nP37). By mapping these restriciton fragment length polymorphisms with respect to the genes unc-30, ced-3 and unc-26, the physical contiguity was oriented with respect to the genetic map and the region containing the ced-3 gene was narrowed to an interval spanned by three cosmids (FIG. 1).

On Southern blot, three of three+Berg unc-26 recombinants showd the Bristol nP33 pattern while two of two ced-3 +Berg recombinants showd the Bergerac pattern (data not shown). thus, nP33 maps very close or to the right of unc-26. For nP34, two of two ced-3+Berg recombinants and two of three+Berg unc-26 recombinants showed the Bergerac pattern; one of the three+Berg unc-26 recombinant showed the Bristol pattern (data not shown). The genetic distance between ced-3 and unc-26 is about 0.2 mu. Thus, nP34 maps between ced-3 and unc-26, about 0.1 mu to the right of ced-3. Similar experiments mapped nP35, the 5.1 kb Bristol specific Tc1 element, to about 0.1 mu to the right of ced-3.

In order to map n36 and n37, Bristol unc-30 ced-3/++ males were crossed with Bergerac hermaphrodites. From the progeny of heterozygotes of genotype unc-30 ced-3 (Bristol)/++ (Bergerac), Unc-30/non-ced-3 and non-Unc-30/ced-3 animals were picked and DNA was prepared from these strains. nP36 maps very close or to the right of unc-30 since two of two unc-30+Berg recombinants showed Bristol pattern and two of two+Berg ced-3 recombinants showed the Bergerac pattern (data not shown). Similarly, nP37 maps very close or to the right of unc-30 since four of the four+Berg ced-3 showed Bergerac pattern and six of six unc-30+Berg recombinants showed the Bristol pattern (data not shown). These experiments narrowed the region containing the ced-3 gene to an interval spanned by the three cosmids (FIG. 1A).

Cosmids that were candidates for containing the ced-3 gene were microinjected (Fire, A., EMBO J. 5:2673-2680 (1986)) into ced-3 mutant animals to test for rescue of the mutant phenotype. Specifically, cosmid C14G10, which contains the wild-type unc-31 gene and a candidate cosmid were coinjected into ced-1(e1375); unc-31(e928) ced-3(n717) hermaphrodites. Non-unc progeny were isolated and observed to see if the non-Unc phenotype was transmitted to the next generation, thus establishing a line of transformed animals. Young L1 progeny of such transformant lines were examined for the presence of cell deaths using Nomarski optics to see whether the ced-3 phenotype was complemented (see Experimental Procedures). Cosmid C 14G10 alone does not confer ced-3 activity when injected into a ced-3 mutant.

unc-31 was used as a marker for co-transformation (Kim et al., Genes & Devel. 4:357-371 (1990)). ced-1 was present to facilitate scoring of the ced-3 phenotype. Mutations in ced-1 block the engulfment process of programmed cell death, causing the corpses of dead cells to persist much longer than in the wild-type (Hedgecock et al., Science 220:1277-1280 (1983)). Thus, the presence of a corpse indicates a cell that has undergone programmed cell death. The ced-3 phenotype was scored as the number of corpses present in the head of young L1 animals.

As indicated in FIG. 1, of the three cosmids injected (C43C9, W07H6 and C48D1), only C48D1 rescued the ced-3 mutant phenotype. Both non-Unc transformed lines obtained, nisl and nEx2, were rescued. Specifically, L1 ced-1 animals contain an average of 23 cell corpses in the head, and L1 ced-1; ced3 animals contain an average of 0.3 cell corpses in the head (Ellis et al., Cell 44:817-829 (1986)). By contrast, ced-1; unc-31 ced-3; nIs1; and ced-1; unc-31 ced-3; nEx2 animals contained an average of 16.4 and 14.5 cell corpses in the head, respectively. From these results, it was concluded that C48D1 contains the ced-3 gene.

To locate ced-3 more precisely within the cosmid C48D1, this cosmid was subcloned and the subclones tested for their ability to rescue the ced-3 mutant phenotype (FIG. 1A). From these experiments, ced-3 was localized to a DNA fragment of 7.5 kb (pJ7.5).

A 2.8 kb ced-3 transcript is expressed primarily during embryogenesis and independently of ced-4 function

The 7.6 kb pJ107 subclone of C48D1 (FIG. 1A) was used as a probe in a northern blot of polyA+RNA derived from the wild-type C. elegans strain N2. This probe hybridized to a 2.8 kb transcript. Although this transcript is present in 11 different EMS-induced ced-3 mutant strains, subsequent analysis has shown that all 11 tested ced-3 mutant alleles contain mutations in the genomic DNA that encodes this mRNA (see below), thus establishing this RNA as a ced-3 transcript.

The developmental expression pattern of ced-3 was determined by hybridizing a northern blot of RNA from animals at different stages of development with the ced-3 cDNA subclone pJ118 (see below). The ced-3 transcript was found to be most abundant during embryogenesis, when most programmed cell deaths occur, but was also detected during the L1 through L4 larval stages. It is present in relatively high levels in young adults.

Since ced-3 and ced-4 are both required for programmed cell death in C. elegans, and since both are highly expressed during embryonic development (Yuan et al., Dev. 116:309-320 (1992), the possibility existed that one of the genes might regulate the mRNA level of the other. Previous studies have revealed that ced-3 does not regulate ced-4 mRNA levels (Yuan et al., Dev. 116:309-320 (1992)). To determine if ced-4 regulates ced-3 mRNA levels, a northern blot of RNA prepared from ced-4 mutant embryos was probed with the ced-3 cDNA subclone pJ118. It was found that the amount and size of the ced-3 transcript was normal in the ced-4 mutants n1162, n1416, n1894 and n1920. Thus, ced-4 does not appear to affect the steady-state levels of ced-3 mRNA.

ced-3 cDNA and genomic Sequences

To isolate ced-3 cDNA clones, ced-3 genomic DNA pJ40 (FIG. 1A) was used as a probe to screen a cDNA library of the C. elegans wild-type strain N2 (Kim et al., Genes & Dev. 4:357-371 (1990)). The 2.5 kb cDNA clone pJ87 was isolated in this way. On northern blots, pJ87 hybridized to a 2.8 kb transcript and on Southern blots, it hybridized only to bands to which pJ40 hybridizes (data not shown). Thus, pJ87 represents an mRNA transcribed entirely from pJ40 which can rescue the ced-3 mutant phenotype when microinjected into ced-3 mutant animals. To confirm that pJ87 contains the ced-3 cDNA, a frameshift mutation in the SalI site of pJ40 was made corresponding to the SalI site in the pJ87 cDNA. Constructs containing the frameshift mutation failed to rescue the ced-3 phenotype when microinjected into ced-3 mutant animals (6 transformant lines; data not shown), suggesting that ced-3 activity had been eliminated by mutagenizing a region of genomic DNA that corresponds to the pJ87 cDNA.

The DNA sequence of pJ87 is shown in FIGS. 2M-2P. pJ87 contains an insert of 2482 bp with an open reading frame of 503 amino acids. It has 953 bp of 3' untranslated sequence, not all of which is essential for ced-3 expression; genomic constructs that do not contain 380 bp of the 3'-most region (pJ107 and its derivatives, see FIG. 1a) were capable of rescuing ced-3 mutant phenotype. The cDNA ends with a poly-A sequence, suggesting that the complete 3' end of the ced-3 transcript is present.

To confirm the DNA sequence obtained from the ced-3 cDNA and to study the structure of the ced-3 gene, the genomic sequence of the ced-3 gene from the plasmid pJ107 was determined. The insert in pJ107 is 7656 bp in length (FIGS. 2A-2F).

To determine the location and nature of the 5' end of the ced-3 transcript, a combination of primer extension and amplification using the polymerase chain reaction (PCR) was used. Two primers, Pex1 and Pex2, were used for primer extension. The Pex1 reaction yielded two major bands, whereas the Pex2 reaction gave one band. The Pex2 band corresponds in size to the smaller band from the Pex1 reaction, and agrees in length with a possible transcript that is trans-spliced to a C. elegans splice leader (Bektesh et al., Genes & Dev. 2:1277-1283 (1988)) at a consensus splice acceptor at position 2166 of the genomic sequence. The nature of the larger Pex1 band is unclear.

To confirm these observations, wild-type total RNA was reverse-transcribed and then amplified using the primers SL1 and log-5 followed by reamplification using the primers SL1 and oligo10. A product of the expected length was cloned into the PCR1000 vector (Invitrogen) and sequenced. The sequence obtained confirmed the presence of a ced-3 message trans-spliced to SL1 at position 2166 of the genomic sequence. These experiments suggest that a ced-3 transcript is trans-spliced to the C. elegans splice leader SL1 (Bektesh et al., Genes & Dev. 2:1277-1283 (1988)) at a consensus splice acceptor at position 2166 of the genomic sequence. Based upon these observations, it is concluded that the start codon of ced-3 is the methionine encoded at position 2232 of the genomic sequence and that ced-3 is 503 amino acids in length.

The predicted ced-3 is hydrophilic (256/503 residues are charged or polar) and does not contain any obvious potential trans-membrane domains. One region of ced-3 is rich in serines: from amino acid 107 to amino acid 205, 32 of 99 amino acids are serine residues.

The sequences of 12 EMS-induced ced-3 mutations (Table 1) were determined. Eight are missense mutations, three are nonsense mutations, and one alters a conserved G at the splice acceptor site of intron 6. Interestingly, nine of these 12 mutations alter residues within the last 100 amino acids of the protein, and none occurs within the serine-rich region. ______________________________________ Sites of mutations in the ced-3 gene Allele     Mutation Nucleotide Codon Consequence ______________________________________ n717     G to A   6297            Altered splicing n718 G to A 2487  65 G to R n1040 C to T 2310  27 L to F n1129 & n164 C to T 6434 449 A to V n1163 C to T 7020 486 S to F n1165 C to T 5940 403 Nonsense n1286 G to A 6371 428 Nonsense n1949 C to T 6222 412 Nonsense n2426 G to A 6535 483 E to K n2430 C to T 6485 466 A to V n2433 G to A 5757 360 G to S ______________________________________ Nucleotide and codon positions correspond to the numbering in FIGS. 2A-2F

To identify functionally important regions of ced-3, the genomic sequences of the ced-3 genes from the related nematode species C. briggsae and C. vulgaris were cloned and sequenced. Sequence comparison of the three ced-3 genes showed that the relatively non-serine-rich regions of the proteins are more conserved than are serine-rich regions (FIGS. 3A-3B). All 12 EMS-induced ced-3 mutations altered residues that are conserved among the three species. These results suggest that the non-serine-rich region is important for ced-3 function and that the serine rich region is either unimportant or that residues within it are functionally redundant.

ced-3 protein is similar to the mammalian ICE and nedd-2 proteins

A search of the GenBank, PIR and SWISS-PROT databases revealed that the non-serine-rich regions of ced-3 are similar to hICE and mICE (FIGS. 3A-3B). The most highly conserved region among the proteins shown in FIGS. 3A-3B consists of amino acids 246-360 of ced-3 and amino acids 166-287 of the hICE: 49 residues are identical (43% identity). The active site cysteine of hICE is located at cysteine 285 (Thornberry et al., Nature 356:768-774 (1992)). The five-amino-acid peptide (QACRG) around this active cysteine is the longest conserved peptide among mICE and hICE and ced-3.

hICE is composed of two subunits (p20 and p1O) that appear to be proteolytically cleaved from a single proenzyme to the mature enzyme (Thornberry et al., Nature 356:768-774 (1992)). Two cleavage sites in the proenzyme, Asp-Ser at positions 103 and 297 of hICE, are conserved in ced-3 (position 131 and 371, respectively).

The C-terminal portion of ced-3 and the p10 subunit of hICE are similar to the protein product of the murine nedd-2 gene. ced-3, nedd-2 and hICE are 27% identical (FIGS. 3A-3B). nedd-2 does not contain the QACRG peptide at the active site of hICE and mICE (FIG. 3A). Seven of eight point mutations that were analyzed (n718, n1040, n1129, n1164, n2430, n2426 & n2433) result in alterations of amino acids that are conserved or semi-conserved among the three nematode ced-3 proteins, hICE and nedd-2. In particular, the mutation, n2433, introduces a Gly to Ser change near the putative active cysteine (FIGS. 2A-2F, Table 1).

Discussion

The genes ced-3 and ced-4 are the only genes known to be required for programmed cell death to occur in C. elegans (Ellis et al., Cell 44:817-829 (1986)). Genetic and molecular studies have revealed that the ced-3 gene shares a number of features with ced-4 (see Yuan et al., Dev. 116:309-320 (1992)). Like ced-4, ced-3 is not required for viability. It appears to contain the sequence for a single mRNA which is expressed mostly in the embryo, the stage during which most programmed cell death occurs. Furthermore, just as ced-3 gene function is not required for ced-4 gene expression (Yuan et al., Dev. 116:309-320 (1992)), ced-4 gene function is not required for ced-3 gene expression. Thus, these two genes do not appear to control the onset of programmed cell death by acting sequentially in a regulatory transcriptional cascade. Unlike ced-4 (Yuan et al., Dev. Biol. 138:33-41 (1992)), ced-3 is expressed at a substantial level in young adults. This observation suggests that ced-3 expression is not limited to cells undergoing programmed cell death.

The ced-4 amino acid sequence is novel. Two regions show similarity to the EF-hand motif, which binds calcium (Yuan et al., Dev. 116:309-320 (1992)). For this reason it has been suggested that ced-4 protein and hence, programmed cell death in C. elegans, might be regulated by calcium. ced-3 contains a region of 99 amino acids that contain 32 serines. Since serines are common phosphorylation sites (Edelman et al., Ann. Rev. Biochem. 56:567-613 (1987)), ced-3 and hence, programmed cell death in C. elegans, may be regulated by phosphorylation. Phosphorylation has previously been suggested to function in cell death (McConkey et al., J. Immunol. 145:1227-1230 (1990)). McConkey et al. have shown that several agents that elevate cytosolic cAMP level induce thymocyte death. This suggests that protein kinase A may mediate cell death by phosphorylating certain proteins. Although the precise sequence of the serine-rich region varies among the three Caenorhabditis species studied, the relatively high number of serines is conserved in C. elegans, C. briggsae and C. vulgaris. None of the mutations in ced-3 affect the serine-rich region. These observations are consistent with the hypothesis that the presence of serines is more important than the precise amino acid sequence within this region.

Much more striking than the presence of the serine-rich region in ced-3 is the similarity between the non-serine-rich regions of ced-3 and hICE and mICE.

The carboxy half of ced-3 is the region that is the most similar to ICE. A stretch of 115 residues (amino acids 246-360 of ced-3) is 43% identical between ced-3 and hICE. This region in ICE contains a conserved pentapeptide QACRG (positions 361-365 of ced-3), which surrounds the active cysteine. Specific modification of this cysteine in hICE results in complete loss of activity (Thornberry et al., Nature 356:768-774 (1992)). The ced-3 mutation n2433 alters the conserved glycine in this pentapeptide and eliminates ced-3 function. This suggests that this glycine is important for ced-3 activity and is an integral part of the active site of ICE. Interestingly, while the mutations n718 (position 67 of ced-3) and n1040 (position 27 of ced-3) eliminate ced-3 function in vivo, they contain alterations in conserved residues which are outside of the mature P20 subunit of hICE (Thornberry et al., Nature 356:768-774 (1992)). These residues may have a non-catalytic role in both ced-3 and ICE function, e.g., they may maintain a proper conformation for proteolytic activation. The hICE precursor (p45) is proteolytically cleaved at 4 sites (Asp103, Asp19, Asp297 and Asp316) to generate p24, p20, and p10 (Thronberry et al., Nature 356:768-774 (1992)). At least two of the cleavage sites are conserved in ced-3. This indicates that the ced-3 protein is processed.

The similarity between ced-3 and ICE suggests that ced-3 functions as a cysteine protease, controlling programmed cell death by proteolytically activating or inactivating a substrate protein. A substrate for ced-3 could be the product of the ced-4 gene which contains 6 Asp residues. These could be the target of ced-3 (Asp25, Asp151, Asp185, Asp192, Asp459 and Asp541). Alternatively, ced-3 could directly cause cell death by proteolytically cleaving certain proteins or subcellular structures that are crucial for cell viability.

ced-3 and ICE are part of a novel protein family. Thornberry et al. suggested that the sequence GDSPG at position 287 of hICE resembles a GX(S/C)XG motif found in serine and cysteine protease active sites (Nature 356:768-774 (1992)). However, in the three nematode ced-3 proteins examined, only the first glycine is conserved, and in mICE, the S/C is not present. This suggests that the ced-3/ICE family shares little sequence similarity with known protease families.

The similarity between ced-3 and ICE suggests not only that ced-3 functions as a cysteine protease, but also that ICE functions in programmed cell death in vertebrates. Thus, it has been observed that after murine peritoneal macrophages are stimulated with lipopolysaccharide (LPS) and induced to undergo programmed cell death by exposure to extracellular ATP, mature active IL-1.beta. is released into the culture supernatant. In contrast, when cells are injured by scraping, IL-1.beta. is released exclusively as the inactive proform (Hogoquist et al., Proc. Natl. Acad. USA 88:8485-8489 (1991)). These results suggest that ICE is activated upon induction of programmed cell death. ICE transcript has been detected in cells that do not make IL-1.beta. (Cerretti et al., Science 256:97-100 (1992)), suggesting that other ICE substrates exist. This suggests that ICE could mediate programmed cell death by cleaving a substrate other than IL-1.beta..

The carboxy-terminal portions of both ced-3 and the p10 subunit of hICE are similar to the protein encoded by nedd-2. Since nedd-2 lacks the QACRG active domain, it might function to regulate ICE or ICE-like p20 subunits. Interestingly, four ced-3 mutations alter residues conserved between nedd-2 and ced-3. Further, nedd-2 gene expression is high during embryonic brain development, when much programmed cell death occurs. These observations suggest that nedd-2 functions in programmed cell death.

The C. elegans gene ced-9 protects cells from undergoing programmed cell death by directly or indirectly antagonizing the activities of ced-3 and ced-4 (Hengartner et al., Nature 356:494-499 (1992)). bcl-2 also affects the onset of apoptotic cell death. Thus, if hICE or another ced-3/ICE family member is involved in vertebrate programmed cell death, bcl-2 might act by modulating its activity. The fact that bcl-2 is a dominant oncogene suggests that hICE and other ced-3/ICE family members might be recessive oncogenes. The elimination of such cell death genes would prevent normal cell death and promote malignancy, just as overexpression of bcl-2 does.

The mouse ICE homolog (mICE) from a mouse thymus cDNA library (Stratagene) was cloned by low stringency hybridization using hICE as a probe. The clone is identical to the clone isolated by Nett et al. (J. Immun. 149:3245-3259 (1992)) except that base pair 166 is an A and encodes Asn rather than Asp. This may be a DNA polymorphism because the clone was derived from a B6/CBAF1J (C57Black.times.CBA) strain cDNA library (Stratagene), while the Nett et al. clone was derived from a WEH13 cDNA library (Stratagene). Subsequent experiments have shown that this variation is not in a region essential for ICE function (see below).

A transient expression system was developed to determine if overexpression of mICE kills cells. MICE cDNA was fused with the E. coli lac-Z gene and placed under the control of the chicken .beta.-actin promoter (FIG. 4). To test the function of the subunits, P20 and P10, which are processed from a precursor peptide, two additional fusion genes were made (P20/P10-lacZ and P10-lacZ).

The constructs, shown in FIG. 4, were transfected into Rat-1 cells by calcium phosphate precipitation. 24 hours after transfection, cells were fixed and X-gal was added. Healthy living rat cells are flat and well-attached to plates, while dying cells are round and often float into the medium. After 3 hours of color development, most blue cells transfected with intact mICE-lacZ or P20/P10-lacZ were round. However, most blue cells transfected with P10-lacZ or the control lac-Z construct were normal flat cells (Table 2). Similar results were obtained with NG108-15 neuronal cells (not shown). ______________________________________ Overexpression of mICE causes Rat-1 cells to undergo programmed cell death The constructs shown in FIG. 4 were transiently transfected into Rat-1 cells, Rat-1 cells expressing bcl-2 (Rat-1/bcl-2) or Rat-1 cells expressing crmA (Rat-1/crmA). 24 hrs after transfection, cells were fixed and stained with X-gal for 3 hrs. The data shown are the percentage of round blue cells among total number of blue cells. The data were collected from at least three different experiments. Construct  Rat-1       Rat-1/bcl-2 Rat-1/crmA ______________________________________ pact.beta.gal' 1.44 .+-. 0.18 2.22 .+-. 0.53 2.89 .+-. 0.79 p.beta.actM10Z 80.81 .+-. 2.33  9.91 .+-. 2.08 18.83 .+-. 2.86 p.beta.actM11Z 93.33 .+-. 2.68  13.83 .+-. 4.23  24.48 .+-. 2.78 p.beta.actM19Z 2.18 .+-. 0.54 -- -- p.beta.actM12Z 2.44 .+-. 0.98 3.33 .+-. 1.45  2.55 .+-. 0.32 p.beta.act17Z 2.70 .+-. 1.07 -- -- pJ485 1.32 .+-. 0.78 -- -- p.beta.actced38Z 46.73 .+-. 4.65  35.28 .+-. 1.36  34.40 .+-. 2.38 p.beta.actced37Z 3.67 .+-. 1.39 -- ______________________________________ -- Methods: a: Construction of bcl2 expression vector (pJ415): pJ415 was constructed by first inserting 5', the 400 bp BglII/BamHI crmA fragment into the BamHI site of the pBabe/puro vector and then inserting the remaining 1 kb BamHI crmA fragment into the 3'BamHI site in the sense direction. b: Construction of the bcl2 expression vector (pJ436): pJ436 was constructed by inserting an EcoRI/SalI bcl2 fragment into the EcoRI/SalI sites of the pBabe/puro vector. c: Establishing Rat1 cell lines that overexpress crmA and bcl2: pJ415 and pJ436 were electroporated into .PSI.CRE retroviral packaging cells (Danos et al., Proc. Natl. Acad. Sci. (USA) 85:6460-6464 (1988)) using a BioRad electroporating apparatus. Supernatant either from overnight transiently transfected .PSI. CRE cells or from stable lines of .PSI.CRE cells expressing either crmA or bcl2  # were used to infect Rat1 cells overnigh in the presence of 8 .mu.g/ml of polybrene. Resistant cells were selected using 30 .mu.g/ml puromycin for about 10 days. Resistant colonies were cloned and checked for expression using both Northern and Western blots. Bcl2 antibodies were from S. J. Korsmeyer and from DAKO. crmA antiserum was made by immunizing rabbits with an E. coliexpressed crmA fusion protein (pJ434).  # pJ434 was made by inserting an EcoRI/SalI fragment of crmA cDNA into EcoRI/SalI sites of pET21a (Novagen) and fusion protein wa expressed in the E. coli BL21 (DE3) strain. Multiple lines that express either bcl2 or crmA were checked for suppression of mICE induced cell death and all showed similar results.

When cells were stained with rhodamine-coupled anti-.beta. galactosidase antibody and Hoechst dye, it was found that .beta.-galactosidase-positive round cells had condensed, fragmented nuclei. Such nuclei are indicative of programmed cell death. When observed with an electron microscope, the X-gal reaction product was electron dense, allowing cells expressing mICE-lacZ to be distinguished from other cells (Snyder et al., Cell 68:33-51 (1992)). The cells expressing the chimeric gene showed condensed chromatin and membrane blebbing. These are characteristics of cells undergoing programmed cell death (Wyllie, A. H., in Cell Death in Biology and Pathology, 9-34 (1981); Oberhammer et al., Proc. Natl. Acad. Sci. U.S.A. 89:5408-5412 (1992); Jacobson et al., Nature 361:365-369 (1993)). Thus, the results indicate that overexpression of mICE induces programmed cell death and that induction depends on both P20 and P10 subunits.

When color development in Rat-1 cells transfected with mICE-lacZ or P20/P10-lacZ is allowed to proceed for 24 hours, a greater number of flat cells become blue. This result indicates that cells tolerate lower levels of ICE activity.

If mICE is a vertebrate homolog of ced-3, then ced-3 might also be expected to cause cell death in vertebrates. This hypothesis was tested by making a ced-3-lacZ fusion construct and examining its ability to cause cell death using the assay as described above. As expected, the expression of ced-3 caused the death of Rat-1 cells (Table 2).

If mICE functions in a similar way to ced-3, mutations eliminating ced-3 activity in C. elegans should also eliminate its activity in vertebrates. This hypothesis was tested by mutating the Gly residue in the pentapeptide active domain of hICE, QACRG, to Ser. It was found that this mutation eliminated the ability of both mICE and ced-3 to cause rat cell death in Rat-1 cells (Table 2).

crmA specifically inhibits ICE activity (Ray et al., above). To demonstrate that cell death associated with overexpression of mICE is due to the enzymatic activity of mICE, Rat-1 cells were infected with a pBabe retroviral construct (Morgenstern et al., Nucl. Acids Res. 18:3587-3596 (1990)) expressing crmA and cell lines identified which produce high levels of crmA. When the mICE-lacZ construct was transfected into these cell lines, it was found that a large percentage of blue cells had a healthy, flat morphology (Table 2). In addition, a point mutation that changes the Cys residue in the active site pentapeptide, QACRG to a Gly eliminates the ability of mICE to cause cell death (construct p.beta.actM17Z, FIG. 4, Table 2). This result indicates that the proteolytic activity of mICE is essential to its ability to kill cells.

bcl-2 can also prevent or inhibit cell death (Vaux et al., Nufnez et al., Strasser et al., Sentman et al., above). Rat-1 cells were infected with the pBabe retroviral construct expressing bcl-2. Transfection of the mICE-lacZ fusion construct into the cells lines overexpressing bcl-2 showed that a high percentage of blue cells were now healthy (Table 2). Thus, cell death induced by overexpression of mICE can be suppressed by bcl-2. This result indicates that cell death induced by overexpression of mICE is probably caused by activation of a normal programmed cell death mechanism. Thus, taken together, the results all suggest that vertebrate animals have a genetic pathway of programmed cell death similar to that of C. elegans (FIG. 5).

As described above, the genes in the ICE/ced-3 family would be expected to function during the initiation of programmed cell death. In order to identify additional members of this gene family, cDNA encoding hICE was used to screen a mouse thymus cDNA library (Stratagene) under conditions of low stringency. Using this procedure, a new gene was identified and named "mIch-2" (see FIGS. 6A-6C for the cDNA sequence and deduced amino acid sequence of mIch-2).

FIGS. 7 and 7A show that the protein encoded by mIch-2 contains significant homology to hICE, mICE, and ced-3. The sequence homology indicates that mIch-2, like mICE, is a vertebrate cell death gene.

Northern blot analyses showed that the expression of mIch-2, unlike mICE, which is broadly expressed during embryonic development, is restricted to the thymus and placenta, areas in which cell death frequently occurs. In addition, it was found that the expression of mIch-2 in the thymus can be induced by dexamethasone, an agent which causes thymus regression. It is concluded that mIch-2 is a thymus/placenta specific vertebrate cell death gene.

Extensive cell death occurs in the developing nervous system (Oppenheim, R. W., Ann. Rev. Neurosci. 145:453-501 (1991)). Many neurons die during the period of synapse formation. During this critical period, the survival of neurons depends on the availability of neural trophic factors. The survival of isolated primary neurons in vitro depends critically on the presence of such trophic factors (Davies, A. M., Development 100:185-208 (1987)). Removal of such factors induces neuronal cell death, usually within 48 hrs. The death of the sympathetic neurons and sensory neurons whose survival depends on one or more members of the nerve growth factor family (nerve growth factor, brain-derived neurotrophic factor, and neurotrophin-3) can be prevented by microinjection of a bcl-2 expression vector (Garcia, I., et al., Science 258:302-304 (1993); Allsopp et al., 1993). To examine if the genes in the ICE/ced-3 family are involved in neuronal cell death, the ability of crmA (which inhibits ICE) to inhibit the death of chicken dorsal root ganglionic neurons induced by NGF removal was examined. It was found that microinjection of an expression vector containing crmA inhibits the death of DRG neurons as effectively as that of a bcl-2 expression vector (Gagliardini, V., et al., Science 263:826-828 (1994)). This result demonstrates that the genes in the ICE/ced-3 family play a role in regulating neuronal cell death during development.

Results

Cloning of Ich-1

The protein product of the C. elegans cell death gene, ced-3, is homologous to the product of the mouse gene, nedd-2. The nedd-2 cDNA in the data bank has an open reading frame of 171 amino acids and has long 3' and 5' untranslated regions. This 171-amino acid nedd-2 protein does not contain the active domain (SEQ ID NO: 66), QACRG, of ICE and ced-3 proteins and is homologous only to the P10 subunit of mammalian ICE and the C-terminal part of ced-3. While analyzing nedd-2 cDNA, the inventors discovered that it contains a sequence that can potentially encode a QACRG pentapeptide, but that the sequence is in another reading frame. The inventors considered the possibility that the nedd-2 cDNA isolated by Kumar et al. contains cloning artifacts and that another nedd-2 transcript encodes a protein homologous to both the P20 and P10 subunits of ICE.

A mouse nedd-2 probe was made by polymerase chain reaction (PCR). Using this probe, three cDNA libraries were screened: a mouse embryonic day 11.5 cDNA library from CLONTECH (one million clones screened), a human fetal brain cDNA library from James Gusella's laboratory (10 million clones screened), and a human fetal brain cDNA library from Stratagene (one million clones screened). The longest positive cDNA clones were obtained from the Stratagene cDNA library. From the Stratagene library, two cDNA species (pBSH37 and pBSH30) (Deposited on Nov. 8, 1999 at the American Type Culture Collection (ATCC), 10801 University Blvd., Manassas, VA. 20110-2209 ) and assigned numbers PTA-924 and PTA-925 respectively were identified that encode two closely related proteins homologous to the mouse nedd-2 (FIGS. 10A-10E, 11A-11B, and 12A-12C).

The insert of pBSH37 (2.5 kb) encodes a protein of 435 amino acids that contains amino acid sequence similarities to both the P20 and P10 subunits of hICE and the entire ced-3. The insert of pBSH30 (2.2 kb) has an open reading frame of 512 amino acids and contains an additional 61 bp one basepair after the sequence encoding QACRG. This causes an early termination of protein translation. The Northern blot analysis showed that expression of this human gene is different than expression of nedd-2 (Kumar et al.); thus, the sequences were renamed Ich-1.sub.L (pBSH37) (FIGS. 10A-10B) and Ich-1.sub.S (pBSH30) (FIGS. 10C-10E).

A comparison of cDNA sequences revealed that Ich-1.sub.S cDNA differs from Ich-1.sub.L at the 5' end, around the beginning of the initiation of translation, and by the presence of an additional intron in the middle of Ich-1.sub.S cDNA (FIG. 11B). The first difference is at the beginning of the coding region. The putative first methionine of Ich-1.sub.S is 15 amino acids downstream from the first methionine of Ich-1.sub.L ; the first 35 bp of Ich-1.sub.S are different from Ich-1.sub.L and include a stop codon (FIGS. 10A-10B and 10C). PCR analysis using primers specific to the first 35 bp of Ich-1 and the Ich-1.sub.S -specific intron (see below), and human placenta cDNA as template, amplified a DNA fragment of predicted size. This suggests that the 35 bp Ich-1.sub.S -specific sequence is not a cloning artifact and is present in the endogenous Ich-1.sub.S mRNA.

The second difference is distal to the active domain QACRG. Ich-1.sub.S begins to differ from Ich-1.sub.L one basepair after the coding region of the active site QACRG. The difference is caused by a 61 bp insertion, which results in a termination codon 21 amino acids downstream from the insertion. The last two identical basepairs of Ich-1.sub.S and Ich-1.sub.L are AG, the general eukaryotic splicing donor consensus sequence (Mount, 1982).

To eliminate the possibility that the 61 bp insertion in pBSH30 is a result of incomplete RNA processing, both forms of murine Ich-1 were cloned from adult mouse brain mRNA by PCR using primers flanking the insertion site as described (Experimental Procedure). The resulting 233 and 172 bp fragments (FIG. 11B) were cloned separately and sequenced. Three murine Ich-1.sub.L clones and two murine Ich-1.sub.S clones were sequenced. Sequencing confirmed that the murine Ich-1.sub.S contains the same 61 bp insertion as in human Ich-1.sub.S at the same position (FIG. 11A).

Chicken Ich-1 from an embryonic chicken cDNA library (Clontech) was also cloned using a chicken Ich-1 probe obtained by PCR (see Experimental Procedures). Two clones were isolated. One encodes Ich-1.sub.L and the other encodes Ich-1.sub.S which contains a 62 bp insertion at the same position. The DNA sequence of the 62 bp insertion is 72% identical to that of human and murine Ich-1.sub.S and also caused premature termination of protein translation. The extra basepair in the intron of chicken Ich-1.sub.S causes the amino acid sequence of the last 41 amino acids of chicken Ich-1.sub.S to differ from human and murine Ich-1.sub.S ; however, truncation of the protein may be the important point.

To examine the origin of the 61 bp insertion in murine and human Ich-1.sub.S, mouse genomic Ich-1 DNA was cloned. Analysis showed that the 61 bp is from an intron whose sequence is identical in human and mouse Ich-1. The difference between Ich-1.sub.S and Ich-1.sub.L is caused by alternative splicing from the two different 5' splicing donor sequences. The first two basepairs of the 61 bp intron and the two basepairs after the 61 bp intron are GT (FIG. 11A). This sequence is the 100% conserved general eukaryotic splicing donor consensus sequence (Mount, 1982). The DNA sequence at the 3' splicing acceptor site is AG. This sequence is the 100% conserved eukaryotic splicing acceptor sequence (FIG. 11A). Thus, the DNA sequences at the splicing junction are completely consistent with alternative splicing of Ich-1.sub.S.

As the result of an insertion of an intron between coding regions, the open reading frame of Ich-1.sub.S is divided into two: the first encodes a 312 amino acid peptide homologous to the P20 subunit of hICE. The second encodes a 235 amino acid peptide homologous to a part of the P20 subunit and the P10 subunit of hICE. The second is nearly identical to mouse nedd-2 (FIGS. 10-10E). The data suggest that only the first open reading frame is translated in cells. A schematic diagram of Ich-1.sub.L and Ich-1.sub.S is shown in FIG. 11B.

Ich-1.sub.L contains similarities to both ICE (27% identity and 52% similarity) and ced-3 (28% identity and 52% similarity) (FIGS. 12A-12B and 12C). Thus, the homology between Ich-1 and ced-3, Ich-1 and ICE is about equal.

Ich-1 is expressed in many tissues and THP-1 cells which express interleukin-1.beta. converting enzyme

To characterize the function of Ich-1, the expression pattern of Ich-1 was examined. Northern blot analysis of human fetal heart, brain, lung, liver and kidney tissue was done using the insert of pBSH37 as a probe. The probe hybridizes to both Ich-1.sub.S and Ich-1.sub.L transcripts. The analysis showed that 4 kb Ich-1 mRNA is expressed at the same low levels in all tissues examined. When the same Northern blot (completely stripped of the previous probe) was analyzed using the Ich-1.sub.S 61 bp intron as a probe (which hybridizes to Ich-1.sub.S transcript only), it showed that Ich-1.sub.S is expressed in a larger amount in the embryonic heart and brain than in the lung, liver, and kidney. This result demonstrates that in the embryonic lung, liver and kidney, Ich-1.sub.L is expressed to a greater extent than Ich-1.sub.S is. In Northern blot analysis of adult RNA with the pBSH37 probe, Ich-1 is detected in all the tissues examined. The level is higher in placenta, lung, kidney and pancreas than in heart, brain, liver and skeletal muscle.

To study the expression of Ich-1.sub.L and Ich-1.sub.S during mouse embryonic development, a quantitative RT-PCR analysis was developed using specific primers that differentiate between Ich-1.sub.L and Ich-1.sub.S. Primers were synthesized that flank the 61 bp intron sequence of Ich-1.sub.S. The two primers are located in separate exons separated by a 2.8 kb intron in genomic DNA. Thus, the possibility of genomic DNA contamination was eliminated. Ich-1.sub.L and Ich-1.sub.S were amplified simultaneously to produce DNA fragments of 172 bp and 233 bp, respectively. The cDNA templates were reverse-transcribed from mRNA isolated from thymus, adult heart, adult kidney, embryonic 15d brain, and adult brain. Negative (no DNA template) and positive (Ich-1.sub.S and Ich-1.sub.L) controls were used. Acting primers were used on one set of each sample. Analyses showed that only expression of Ich-1.sub.L can be detected in thymus while the expression of both Ich-1.sub.L and Ich-1.sub.S can be detected in heart, kidney, and both embryonic and adult brain. The expression of Ich-1.sub.S was found to be highest in embryonic brain by this PCR analysis. The results are consistent with Northern blot analysis described above. The results were reproducible among multiple mRNA preparations.

To examine whether Ich-1 and hICE are expressed in the same cells, a Northern blot of THP-1 and U937 cells was analyzed with the Ich-1 probe, pBSH37. hICE expression has been detected in these cells (Thornberry, N. A., et al., Nature 356:768-774 (1992); Cerretti, D. P., et al., Science 256:97-100 (1992)). The inventors found that Ich-1 can be detected in THP.1 and U937 cells. Thus, both Ich-1 and hICE are expressed in THP.1 and U937 cells.

Ich-1.sub.S, Ich-1.sub.L and hICE expression were compared in human cell lines. Using a similar quantitative RT-PCR analysis, the expression of Ich-1.sub.L, Ich-1.sub.S and hICE were compared in HeLa, Jurkat, THP.1 and U937 cells. Ich-1.sub.L and Ich-1.sub.S were amplified simultaneously to produce DNA fragments of 234 bp and 295 bp, respectively. hICE was amplified as a fragment of 191 bp. cDNA templates were reversed-transcribed from mRNA isolated from HeLa, Jurkat, THP.1 and U937 cells. Negative (no DNA template) and positive (hICE cDNA) controls were used. pBSH37 and pBSH30 were used as positive controls for Ich-1.sub.L and Ich-1.sub.S expression. Chicken actin cDNA was used as a positive contraol for actin. Expression of Ich-1.sub.S was detected in HeLa and Jurkat cells but no in THP.1 and U937 cells. Bothe hICE and Ich-1 transcripts are present in relatively high level in HeLa cells. The level of Ich-1 transcrip is higher than that of hICE transcript in Jurkat cells. Both hICE and Ich-1 expression is detected in THP.1 and U937 cells.

Using a quantitative RT-PCR analysis, the inventors examined the expression of hICE and Ich-1 in the normal living T-cell hybridoma DO11.10 cells (Haskins, K., et al., Exp. Med 157:1149-1169 (1983)) and dying DO11.10 cells (serum-dprived). The expression of bothe hICE and Ich-1 can be detected in DO11.10 cells. Interestingly, the expression levels of both Ich-1.sub.L and hICE appear to increase in dying DO11.10 cells.

Overexpression of Ich-1.sub.L induces rat-1 fibroblast death

To examine the function of Ich-1.sub.L, the same transient expression system used for ICE (Miura., M., et al., Cell 75:653-660 (1993)) was use dot determine if overexpression of Ich-1 induces programmed cell death. The human Ich-1.sub.L cDNA was fused with the E. coli lacZ gene and fused gene was placed under the control of the chicken .beta.-actin promotor (p.beta.actH37Z). This fusion gene was trasfected into Rat-1 cells by lopfectamine-mediated gene transfer and the expression of the gene was eaxamined using the X-gal reaction. Results showed that most of the blue (X-gal-positive) Rat-1 cells transfected with pBactH37Z were round. these reults are similar to those obtained with cells transfected with mICE-lacZ fusion sequence shown in Table 2. In contract, most blue cells transfected with vector along were falt and healty. This result suggest that the expression of Ich-1.sub.L induces Rat-1 cells to die.

To examine whether the cell death induced by Ich-1 has any cell type specificity and to compalre its effect with that of mICE, mICE-lacZ and Ich-1-lacZ fusion contructs were transfected to HeLa cell, NG108-15 cells, Rat-1 cells, and COS cells. these cells thus expressed mICE-lacZ (p.beta.actM10Z) Ich-1.sub.L -LacZ (p.beta.actH37Z) and Ich-1.sub.S -lac-Z (p.beta.actH30Z1 and lacZ control (pact.beta.gal'). The cell killing effect was assayed as for Table 2. The results are shown in Table 3. __________________________________________________________________________ EFFECTS OF ICH-1 OVEREXPRESSION ON CELLS IN CULTURE Expression cassettes COS       HeLa     NG108-15 Rat-1    Rat-1/bcl-2 Rat-1/crmA __________________________________________________________________________ pact.beta.gal' .cndot. 1.3 + 0.1(983) 2.9 .+-. 0.2(1020) 4.2 .+-. 0.2(1535) 2.9 .+-. 0.2(1470) 3.4 .+-. 0.2(1446) 3.7 .+-. 0.1(1459) p.beta.actM10Z .cndot. 11.0 .+-. 0.2(1080) 93.9 .+-. 0.3(1003) 80.2 .+-. 0.5(1545) 94.2 .+-. 1.1(978) 28.8 .+-. 0.5(691) 45.8 .+-. 1.6(233) p.beta.actH37Z 8.3 .+-. 0.9(1053) 91.4 .+-. 0.2(1076) 68.7 .+-. 1.5(1605) 92.1 .+-. 0.3(1079) 21.5 .+-. 3.2(1335) 80.7 .+-. 0.9(1010) p.beta.actH37ZCS ND 5.6 .+-. 0.1(1039) 5.9 .+-. 0.9(707) 4.1 .+-. 0.2(1477) ND ND p.beta.actH37ZAT ND 8.2 .+-. 0.7(435) 5.2 .+-. 0.2(640) 5.4 .+-. 0.3(1356) ND ND p.beta.actH30Z1 1.3 .+-. 0.2(676) 0.0 .+-. 0.0(40) 0.0 .+-. 0.0(61) 1.8 .+-. 0.4(785) ND ND __________________________________________________________________________ The mICELacZ (p.beta.actM10Z), Ich1.sub.LlacZ (p.beta.actH37Z), Ich1.sub. (S303C)lacZ (p.beta.actH37ZCS), Ich1.sub.L (T352A)lacZ (p.beta.actH37ZAT) Ich1.sub.SlacZ (p.beta.actH30Z1) and control vector alone (pact.beta.gal' were transiently transfected into Rat1 cells, Rat1 cells expressing human bcl2, Rat1 cells expressing cowpox virus crmA gene, HeLa cells, NG10815 cells and COS cells. Cells were fixed lightly 24 hr after transfection an stained with XGal for 3 hr. The  # data (mean .+-. SEM) shown are the percentage of round blue cells among total number of blue cells counted. The numbers in the parentheses are the number of blue cells counted. The data were collected from at least three independent experiments. ND = not determined.

Compared to controls, the cytotoxic effect of Ich-1 and mICE exhibit certain cell type specificities. Expression of Ich-1 or mICE kills Rat-1 cells and HeLa cells effectively (>90% dead). NG108 cells are more resistant to Ich-1 and mICE expression than Rat-1 cells and HeLa cells (68-80% dead). Expression of Ich-1 or mICE cannot kill COS cells.

To confirm that the cell death caused by Ich-1.sub.L expression is apoptosis, the inventors examined the nuclear morphology of the cell death induced by Ich-1 expression. Rat-1 cells were transiently transfected with control pact.beta.gal' vector and 24 hours later, fixed and stained by anti-.beta.-galactosidase antibody or by Hoechst dye 33258 using a protocol from Miura et al. (1993). The nuclear morphology in .beta.-galactosidase-expressing cells is normal and non-condensed. Rat-1 cells were also transiently transfected with p.beta.actH37Z expressing Ich-1.sub.L. The nuclei of round cells expressing the Ich-1.sub.L -lacZ chimeric gene were condensed and fragmented. This is one of the characteristics of cells undergoing apoptosis. Thus, the results suggest that overexpression of Ich-1.sub.L, like that of mICE, causes Rat-1 cells to undergo programmed cell death.

To determine the structure and function of Ich-1.sub.L protein, two mutant Ich-1.sub.L fusion proteins were made: the first is a Ser.fwdarw.Cys 303 in the active site of Ich-1.sub.L ; the second is a Thr.fwdarw.Ala 352 in the putative P10 subunit (FIGS. 12A-12B). The Ala 352 in P10 is an amino acid residue of ced-3 that is conserved in Ich-1.sub.L but not in ICE. The mutant Ich-1.sub.L -lacZ fusion constructs were transfected into Rat-1 cells and expression was examined by the X-gal reaction.

The analysis revealed that the S303C (p.beta.actH37ZCS) and T352A (p.beta.actH37ZAT) mutations eliminated the activity of Ich-1.sub.L completely (Table 3). These results suggest that the ability of Ich-1.sub.L to cause cell death depends upon its enzymatic activity and that only some characteristics of ced-3 are conserved in Ich-1.sub.L.

The cell death induced by overexpression of ICE can be inhibited by bcl-2 and crmA (Miura, M., et al., Cell 75:653-660 (1993)). To examine if the cell death induced by expression of Ich-1.sub.L could also be inhibited by bcl-2 and crmA, Ich-1.sub.L -lacZ fusion construct (p.beta.actH37Z) was transfected into Rat-1 cells that overexpress either bcl-2 or crmA. Cell death was assayed as described for Table 3. The results showed that the cell death induced by overexpression of Ich-1.sub.L could be inhibited effectively by bcl-2 but only marginally by crmA.

Expression of Ich-1.sub.S protects Rat-1 fibroblast death induced by serum removal

Since Ich-1.sub.S contains two open reading frames, it was important to determine which reading frame is functionally translated (FIG. 11A). Ich-1.sub.S was translated in the presence of .sup.35 S-methionine using in vitro transcribed RNA in a reticulocyte lysate as described in Experimental Procedures. The translated products were run on an SDS-polyacrylamide gel with molecular weight standards. Ich-1.sub.S antisense RNA was used as a negative control. Results showed that only the first reading frame was translated.

Second, E. coli lacZ gene was fused to the ends of the first (p.beta.actH30Z1) and second (p.beta.actH30Z2) open reading frames. The constructs were separately transfected into Rat-1 cells and the cells were assayed for color using the X-gal reaction. Results showed that when the lacZ gene was fused to the end of the first open reading frame, blue cells could be detected. Blue cells were not detected when the lacZ gene was fused to the second open reading frame. Thus, it is likely that only the first open reading frame is used in vivo.

To characterize the function of Ich-1.sub.S, the ability of p.beta.actH30Z1 to cause cell death was examined. p.beta.actH30Z1 was transfected into Rat-1 cells, COS cells, HeLa cells and NG108-15 cells, and the X-gal reaction was developed as before. The analysis showed that the expression of p.beta.actH30Z1 did not cause cell death (Table 3).

To examine if Ich-1.sub.S has any protective effect against cell death, a stable Rat-1 cell line that expresses Ich-1.sub.S was established. The cDNA Ich-1.sub.S was cloned into pBabepuro retroviral expression vector (Morgenstern et al., Nucl. Acids Res. 18:3587-3596 (1990)) and transfected into Rat-1 cells. The stable transfectants were selected in puromycin and individual clones were assayed for expression of Ich-1.sub.S by Northern blot analysis. The clones that expressed Ich-1.sub.S were used for analysis and the clones that did not express Ich-1.sub.S were used as negative controls together with untransfected Rat-1 cells. Nomarski micrographs were taken on days 0, 2, 3, and 4 of control Rat-1 cells, Ich-1.sub.S non-expressing Rat-1 cells, crmA expressing Rat-1 cells, and bcl-2 expressing Rat-1 cells in serum-free medium. Trypan blue assay was also performed.

When plated to non-confluent density and washed carefully, 90% of Rat-1 cells die in serum-free medium. However, under these conditions, Rat-1 cells expressing bcl-2 or crmA are resistant to death (FIG. 13). When the ability of the stable Rat-1 cell lines that express human Ich-1.sub.S was tested under serum-free conditions, it was found that they are more resistant to serum deprivation than parental Rat-1 cells and negative control transfectants not expressing Ich-1.sub.S (FIG. 13). These experiments suggest that Ich-1.sub.S has the ability to prevent cell death.

Ich-1.sub.S may prevent cell death by inhibiting Ich-1.sub.L. The inventors thus examined whether Rat-1 cells express Ich-1. Using mouse Ich-1 cDNA as a probe, an mRNA species predictive of the Ich-1 transcript was detected in Rat-1 cells under low stringency conditions.

Discussion

The isolation and characterization of Ich-1, a mammalian gene belonging to the cell death gene family of ICE/ced-3, has been described. Two distinct Ich-1 mRNA species have been identified (Ich-1.sub.L and Ich-1.sub.S). These two cDNAs differ in the 5' region around the translation initiation and in the middle region. The difference in the middle is the result of alternative use of two different 5' splicing donor sites.

The Ich-1 gene is expressed at low levels in embryonic and adult tissues. Ich-1.sub.S is expressed at higher levels than Ich-1.sub.L in embryonic heart and brain. The converse is true in embryonic lung, liver and kidney. Expression of Ich-1.sub.S can be detected in all tissues examined except thymus. The expression of both hICE and Ich-1 can be detected in THP.1 cells, HeLa cells, Jurkat cells, U937 cells, and DO11.10 cells. The expression of both hICE and Ich-1.sub.L appears to increase in dying cells under serum deprived conditions. Overexpression of Ich-1.sub.L in rat fibroblast cells caused programmed cell death prevented by bcl-2. This suggests that Ich-1 is a programmed cell death gene. Overexpression of Ich-1.sub.S, however, did not cause cell death. Stable expression of Ich-1.sub.S prevented Rat-1 cell death induced by serum deprivation. The collective results show that Ich-1 encodes protein products that regulate cell death positively and negatively.

The mouse nedd-2 gene was originally isolated by Kumar et al. (Biochem. & Biophy. Res. Comm. 185:1155-1161 (1992)). The nedd-2 gene was identified as having a transcript of 3.7 kb that is abundantly expressed in embryonic day 10 mouse brain and almost undetectable in adult brain. The nedd-2 cDNA isolated contained an open reading frame of 171 amino acids and long 5' and 3' untranslated regions with stop codons in all reading frames. The 171-amino-acid open reading frame is homologous to P10 subunit of hICE and the C-terminal part of ced-3 (Yuan, J., et al., Cell 75:641-752 (1993)). The amino acid sequence of the C-terminal part of Ich-1.sub.L is 87% identical to the amino acid sequence of the mouse nedd-2 protein from residues 42 to 172 (the first 41 amino acids are different because of the presence of the 61 bp intron). In mouse, nedd-2 is a unique gene (L. Wang, unpublished data). Thus, human Ich-1 and mouse nedd-2 must be the same gene.

In the Northern blot analysis described herein, Ich-1 expression in human fetal brain is not high compared to other tissues tested (heart, lung, liver and kidney) and does not appear to be significantly down-regulated in adult brain. Part of the difference could be explained by the different developmental stages tested: mouse E10 versus human 20-26 week old fetuses. However, Ich-1 expression can be detected in human and mouse adult tissues.

In the studies herein, amplification of the 5' untranslated regions of the mouse nedd-2 cDNA that Kumar et al. reported was not achieved. It is possible that the 5' untranslated region in the Kumar et al. clone was a product of incompletely processed nedd-2 mRNA. Both Ich-1 mRNAs are about 4 kb; since the cDNA clones described herein are 2.5 kb and 2.2 kb for Ich-1.sub.L and Ich-1.sub.S, respectively, these cDNAs are incomplete. However, since they are fully functional in the assay reported herein, the complete coding regions should be encoded in these two cDNAs.

Ich-1 is a new member of the ICE/ced-3 family of cell death genes. Thus, unlike C. elegans, mammals must have multiple members of ICE/ced-3. Ich-1 is even slightly more homologous to ced-3 than mICE. The cell death induced by overexpression of Ich-1 was poorly inhibited by crmA. This result is similar to that with ced-3 (Miura, M., et al., Cell 75:653-660 (1993)).

The nucleotides corresponding to the two amino acid residues of ced-3 that are conserved in Ich-1, but not in ICE, were mutagenized. Results showed that T352A completely eliminated the ability of Ich-1 to cause cell death, despite the fact that the corresponding amino acid in ICE is a Ser. These data also suggest that Ich-1 is mechanistically more similar to ced-3 than ICE, and that Ich-1 and ICE may have evolved independently from ced-3.

The overexpression of ICE and Ich-1 can kill Rat-1 cells and HeLa cells effectively but NG108 cells only moderately. It is possible that NG108 cells express a higher level of ICE and Ich-1 inhibitors. COS cells are completely resistant to the cell killing activity of ICE and Ich-1. COS cells may lack either the activator or the substrates of ICE and Ich-1. This result also suggests that the cytotoxic effects of ICE and Ich-1 have certain specificity and are unlikely to be caused by random cleavage activities of proteases.

Ich-1 encodes protein products that prevent or cause cell death, depending on how the mRNA is processed. Similar regulation has been observed with bcl-x, a bcl-2 related gene (Boise et al., 1993). The bcl-x transcripts can also be processed in two different ways: the larger mRNA, bcl-x.sub.L, encodes a bcl-2 related protein product that can inhibit cell death. Alternative splicing of bcl-x transcript generates another smaller transcript, bcl-x.sub.S. This encodes an internal truncated version of bcl-x that inhibits the ability of bcl-2 to enhance the survival of growth factor-deprived cells. Control of the RNA splicing may be an important regulatory point in programmed cell death.

Ich-1.sub.S could act to prevent cell death by inactivating the activator of cell death or by directly inactivating Ich-1.sub.L. In the transient transfection assay, the expression of Ich-1.sub.L -lacZ fusion gene and the ICE-lacZ fusion gene kill the stable Ich-1.sub.S -expressing cells as efficiently as the control Rat-1 cells (L. Wang, unpublished data). Thus, unlike crmA or bcl-2, the inhibition of cell death by Ich-1.sub.S may be highly dosage-dependent. This could explain why the expression of Ich-1.sub.S provided only partial protection of serum deprived Rat-1 cells. Possibly, only cells expressing high levels of Ich-1s are protected.

crmA has the ability to suppress cell death induced by overexpression of Ich-1.sub.L. The amino acid sequence of crmA is homologous to the members of the serpin superfamily (Pickup et al., 1986), which usually inhibit serine proteases by acting as pseudosubstrates. The nature of interaction of ICE and crmA protein is likely to be similar to the interaction of other serpin and serine proteases. The inhibition of ICE family members by crmA may depend upon both the affinity and relative concentration of ICEs and crmA. The fact that crmA can suppress a certain percentage of cell deaths induced by overexpression of the Ich-1.sub.L suggests that crmA and Ich-1 can bind to each other. It is possible that when the Ich-1 concentration is lower, crmA may be able to suppress cell death induced by Ich-1 to a greater extent. Microinjection of crmA expression construct can effectively suppress the death of dorsal root ganglia neurons induced by nerve growth factor deprivation (Gagliardini, V., et al., Science 263:826-828 (1994)). One or more ICE/ced-3 family members may be responsible for neuronal cell death. When crmA expression construct is microinjected into neurons, the transient concentration of crmA may be very high. Thus, it is possible that crmA may be able to suppress multiple members of ICE/ced-3 family under such conditions despite the fact that their affinity to crmA is not very high.

Since the expression of Ich-1 and ICE can be detected in the same cells, the results described herein suggest that multiple members of ICE/ced-3 family may contribute to cell death induced by a single signal. There are three possible ways that Ice and Ich-1 may act to cause cell death. First, Ich-1 may activate ICE, directly or indirectly, to cause cell death. Second, ICE may inactivate Ich-1, directly or indirectly, to cause cell death. Third, ICE and Ich-1 may act in parallel to cause cell death. In the first scenario, the inhibitor of ICE should inhibit cell death induced by Ich-1. In the second scenario, the inhibitor of Ich-1 should inhibit the cell death induced by ICE. To test this hypothesis, specific inhibitors for each member of ICH are necessary. For the reasons discussed above, it seems likely that crmA can inhibit other members of ICE/ced-3 family as well. These models can be tested directly by "knock-out" mutant mice in which a specific member of the ICE/ced-3 family is mutated.

Experimental Procedures

Cloning and construction of plasmids

The mouse nedd-2 cDNA was isolated using embryonic mouse brain cDNA and the primer pairs specific for the 5' and 3' untranslated regions and the coding region. Primers nedd2/1 (SEQ ID NO: 67) (5'-CAACCCTGTAACTCTTGATT-3') and nedd2/2 (SEQ ID NO: 68) (5'-ACCTCTTTGGAGCTACCAGAA-3') were used for amplifying the 5' untranslated region. Primers nedd2/3 (SEQ ID NO: 69) (5'-CCAGATCTATGCTAACTGTCCAAGTCTA-3') and nedd2/4 (SEQ ID NO: 70) (5'AAGAGCTCCTCCAACAGCAGGAATAGCA-3') were used for amplifying the nedd-2 coding region. Primer nedd2/5 (SEQ ID NO: 71) (AGAAGCACTTGTCTCTGCTC) and nedd2/6 (SEQ ID NO: 72) (5'TTGGCACCTGATGGCAATAC-3') were used for amplifying the 3' untranslated region. 0.5 kb PCR product of nedd-2 coding region was cloned into pBluescript plasmid vector to be used as a probe (Stratagene).

Two human fetal brain cDNA libraries and one mouse embryonic 11.5d cDNA library were screened with murine nedd-2 cDNA probe at low stringency and one mouse embryonic 11.5d cDNA library. The filters were hybridized in 5.times.SSPE, 30% formamide, 1.times.Denhardt's solution, 1% SDS at 42.degree. C. overnight and washed in 1.times.SSPE and 0.5% SDS, twice at room temperature and twice at 45.degree. C. (20 min). The human Ich-1.sub.S (pBSH30) was isolated from the positive clones using a BamHI-Sall fragment of the murine nedd-2 cDNA, a 70 bp fragment which contains 52 bp of the 61 bp intron, as a probe under the same hybridization and washing conditions described above. The phage clones (pBSH37 for Ich-1.sub.L, pBSH30 for Ich-1.sub.S) were excised in vivo to obtain plasmids by an in vivo excision protocol (Stratagene). To construct expression constructs, PCR was performed using synthetic primers. H1 (SEQ ID NO: 73) (5'-GATATCCGCACAAGGAGCTGA-3') and H2 (SEQ ID NO: 74) (5'-CTATAGGTGGGAGGGTGTCC-3') were used for Ich-1.sub.L construction. H3 (SEQ ID NO: 75) (5'-GATATCCAGAGGGAGGGAACGAT-3'), corresponding to sequences in the 5' region of Ich-1.sub.S cDNA and H4 (SEQ ID NO: 76) (5'-GATATCAGAGCAAGAGAGGCGGT-3'), corresponding to the sequences in the 3' region of the first open reading frame (ORF) of Ich-1.sub.S were used for the first ORF of Ich-1.sub.S construction. H3 and H5 (SEQ ID NO: 77) (5'-GATATCGTGGGAGGGTGTCCT-3'), corresponding to the sequences in the 3' region of the second ORF of Ich-1.sub.S were used for the second ORF of Ich-1.sub.S construction. pBSH37 and pBSH30 were used as templates where appropriate. The three PCR products were inserted into the EcoRV site of pBluescript II, and the inserts of these subclones, p.beta.SIIh37, p.beta.SIIh30.1, and p.beta.SIIh30.2, were isolated by digestion with SmaI and KpnI and cloned into SmaI-KpnI sites of BSLacZ (Miura, M., et al., Cell 75:653-660 (1993)). NotI linkers were added to the KpnI site by digesting with KpnI, blunt-ending by T4 polymerase and ligating in the presence of excess NotI linker. These constructs, BSh37Z, BSh30Z1, and BSh30Z2, were digested with NotI and individually cloned into p.beta.actstneoB (which uses the chicken .beta.-actin promoter) (Miyawaki, A., et al., Neuron 5:11-18 (1990)). The final plasmids were designated p.beta.actH37Z, p.beta.actH30Z1 and p.beta.actH30Z2, respectively. pBabeH30 plasmid, used for establishing stable Rat-1 cell lines carrying Ich-1.sub.S, was constructed by inserting the full length Ich-1.sub.S cDNA into the SalI site of pBabe/puro vector (Morgenstern, J. P., et al., Nucl. Acids Res. 18:3587-3596 (1990)).

To mutagenize Cys 303 to a Ser residue in the active domain of Ich-1.sub.L and Ala 352 to a Thr residue in the P10 subunit of Ich-1.sub.L, primers containing mutant sites were synthesized as follows:

(HM1 corresponds with HM2 and HM3 corresponds with HM4. PCRs were performed in two steps. To make the Cys 303 to Ser mutation, in the first round of PCR, the fragments from the N-terminus to the mutation site of Ich-1.sub.L and from the mutant site to the C-terminus of Ich-1.sub.L were synthesized using two primer pairs, T3 and HM1, HM2 and T7, and PBSH37 as a template. In the second round of PCR, the two PCR fragments generated in the first reaction were used as templates and T7 and T3 were used as primers. Two such rounds of PCR generated a full length Ich-1.sub.L mutant. The other mutation was generated in a similar way, using T3 and HM3, HM4 and T7, for the Ala 352 to Thr mutation, as primers for the first PCR. The PCR products were inserted into the EcoRV site of pBluescript II and sequenced. The mutant cDNA inserts were cloned into expression vectors as described above. The mutated clones were designated p.beta.actH37ZCS and p.beta.actH37ZAT.

Cell culture and functional studies

COS cells, Rat-1 cells, HeLa cells, and NG108-15 cells were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum (FCS). The day before transfection, cells were seeded at a density of about 2.5.times.10.sup.5 in each of the 6-well dishes. For each well, 0.7-1 .mu.g of the lacZ chimeric construct and 10 .mu.g of lipofectamine reagent were used according to a protocol from GIBCO BRL (Gaithersburg, Md.). The cells were incubated for 3 hr in serum-free medium containing DNA and lipofectamine. Then an equal volume of growth medium containing 20% serum was added without removing the transfection mixture and incubation was continued for 24 hr. The expression of the chimeric gene in cells in culture was detected as previously described (Miura, M., et al., Cell 75:653-660 (1993)).

To establish Rat-1 cell lines overexpressing Ich-1.sub.S, pBabeH30 was transfected into Rat-1 cells using lipofectamine mediated gene transfer. Resistant cells were selected using 3 .mu.g/ml puromycin for about 10 days. Cells were assayed for expression of Ich-1.sub.S by Northern blot analysis. To examine whether Ich-1.sub.S can render Rat-1 cells resistant to apoptosis under conditions of serum deprivation, Rat-1 cells overexpressing Ich-1.sub.S, untransfected control Rat-1 cells, transfected negative control Rat-1 cells, and Rat-1 cells overexpressing bcl-2 or crmA, were seeded in 24-well dishes at 5.times.10.sup.4 cells in 500 .mu.l of DMEM containing 10% FCS for 24 hr, washed once with serum-free DMEM, and transferred into 500 .mu.l of serum-free DMEM. The cells were harvested at daily intervals and stained with 0.4% trypan blue for 5 min. at room temperature. The numbers of dead and living cells were counted using a haemocytometer.

Jurkat cells, THP.1 cells, and U937 cells were cultured in RPMI 1640 medium (GIBCO) with 10% fetal calf serum.

RNA analysis

The Multiple Tissue Northern (MTN) blots membrane of human fetal and adult tissues (CLONTECH) were probed using human Ich-1.sub.L cDNA or the intron of Ich-1.sub.S cDNA (for fetal tissue) in 5.times.SSPE, 10.times.Denhardt's solution, 50% formamide, 2% SDS, and 100 .mu.g/ml salmon sperm DNA at 42.degree. C. overnight. The blots were washed twice in 2.times.SSPE and 0.05% SDS at room temperature, and twice in 0.1.times.SSPE, and 0.1% SDS for 20 min. at 50.degree. C.

The Multiple Tissue Northern (MTN) blot membrane of human fetal tissue was first probed with a 1.3 kb fragment from the insert of pBSH37, which hybridizes to both Ich-1.sub.L and Ich-1.sub.S. The blot was exposed for two days and developed. Then the blot was stripped by boiling the filter in H.sub.2 O twice for 20 min. After stripping, the filter was re-exposed for three days to ensure that the stripping was complete. Then the filter was re-hybridized with the 70 bp BamHI-SalI fragment derived from mouse nedd-2 gene. This fragment contains 52 bp of the 61 bp intron (which is identical to the human Ich-1.sub.S intron; the remaining 18 bp are from an exon and 5 out of the 18 bp are different from the human Ich-1 sequence). The Northern blot of THP.1 cells and U936 cells was carried out under the same conditions. To detect Ich-.sub.1 expression in Rat-1 cells, hybridization was carried out in 25% formamide and under otherwise identical conditions.

Cloning of murine Ich-1

A murine Ich-1 cDNA was cloned in two steps by PCR. A 5' murine Ich-1 cDNA fragment was amplified using a primer derived from the pBSH37 5' end sequence (SEQ ID NO: 82) (5' ATTCCGCACAAGGAGCTGATGGCC 3') and a primer from the mouse nedd-2 after the active site sequence (SEQ ID NO: 83) (5' GCTGGTCGACACCTCTATC 3') using a mouse embryo cDNA library as template (a gift from D. Nathan). The resulting 945 bp fragment was cloned into the EcoRV site of plasmid pBSKII (Stratagene) and sequenced. A 3' murine Ich-1 cDNA frament was amplified using a human Ich-1 primer further downstream (SEQ ID NO: 84) (5' CAGCTTTTGATGCCTTCTGTGA 3' and a nedd-2 primer downstream from the coding region (SEQ ID NO: 85) (5' CTCCAACAGCAGGAATAGA 3'). The resulting fragment was also cloned in pBSKII and sequenced. The two fragments were then joined together using an unique SalI site at nucleotide 930 from the beginning of the coding region.

Cloning of Chicken Ich-1

A chicken Ich-1 cDNA fragment was obtained using murine Ich-1 degenerate primers. The 5' primer was from murine Ich-1 mucleotide 241 to 268 bp (SEQ ID NO: 86): 5'GC(GATC)TT(TC)GA(TC)GC(GATC)TT(TC(TCG)GA(AG)GC3'. The 3' primer was from murine Ich-1 nucleotide 883 to 908 bp (SEQ ID NO: 87): 5'CA(GATC)GC(CT)TG(TAG)AT(AG)AA(AG)AACAT(CT)TT(GATC)GG3'. The resulting DNA fragment was used as a probe to screen a chicken embryonic libray (CLontech) by high stringency hybridization.

Quantitative PCR Analysis

mRNA was isolated using the MicroFast mRNA isolation kit from Invitrogen. 1 to 2 ug of mRNA was used from reverse transcription by randon priming (Invitrogen) using MMLV (Moloney Murin Leukemia Virus) revesrse transcriptase (Invitrogen). The primers used to amplify murine Ich-1: 5' primer, (SEQ ID NO: 88)5' ATGCTAACTGTCCAAGTCTA 3') and 3' primer (SEQ ID NO: 89) (5' GTCTCATCTTCATCAACTCC 3'). The primers used to amplify human Ich-1: 5' primer (SEQ ID NO: 90) (5'GTTACCTGCACACCGAGTCACG 3') and 3' primer (SEQ ID NO: 91) (5' GCGTGGTTCTTTCCATCTTGTTGGTCA 3'). The primers used to amplify hICE: 5' primer (SEQ ID NO: 92) (5' ACCTTAATATGCAAGACTCTCAAGGAG 3') and 3' primer (SEQ ID NO: 93) (5' GCGGCTTGACTTGTCCATTATTGGATA 3'). Mouse .beta.-actin primers were used as controls to amplify a 350 bp actin fragment from mouse and human tissue. 5' .beta.-actin primer (SEQ ID NO: 94): 5' GACCTGACAGACTACCTCAT 3'. 3' .beta.-actin primer (SEQ ID NO: 95): 5' AGACAGCACTGTGTTGGCAT 3'. The following conditions were used for the PCR reactions: 1.times.reaction buffer (Promega), 1.5 mM MgCl.sub.2, 200 .mu.M dNTP, 2 .mu.M each primers, 1 unit of Taq DNA polymerase (Promega) in a total volume of 50 .mu.l. The DNA was denatured for 4 min at 94.degree. C. prior to 26 PCR cycles (94.degree. C., 1 min/55.degree. C., 1 min/72.degree. C., 2 min). In some of the experiments, Vent polymerase (Biolab) was used.

In vitro transcription and translation of Ich-1.sub.S

To determine which open reading frame of Ich-1.sub.S was expressed, pBluescript plasmid containing Ich-1.sub.S (pBSH30) was linearized at the 3' multiple cloning site with XhoI, purified, and transcribed with T3 RNA polymerase for 2 hr at 37.degree. C. using a protocol from Stratagene. The plasmid was also linearized at the 5' multiple cloning site with NotI, purified, and transcribed with T7 polymerase as an antisense control. The resulting runoff transcripts were extracted with phenol-chloroform and ethanol precipitated. In vitro translation was performed with rabbit reticulocyte lysate (Promega) in the presence of .sup.35 S-methionine for 1 hr. at 30.degree. C. 5 .mu.l lysate was mixed with equal volume of 2.times.SDS gel loading buffer and subjected to SDS-polyacrylamide gel electrophoresis (12%). The gel was dried and exposed to X-ray film.

Experimental Procedures

Cells and tissue culture

HeLa cells were grown in Dulbecco's modified Eagle's medium (DMEM) with 10% fetal bovine serum (FBS). HeLa cells were transfected with pHD1.2 crmA expression vector (Gagliardini, V. et al., Science 263:826-828 (1994)) by calcium phosphate precipitation and two days after transfection, 600 .mu.g/ml of G418 (Gibco) was added for selection. Resistant colonies were cloned by limiting dilution. Dosage response of HeLa and HeLa/crmA cells to TNF-.alpha. treatment was tested as follows. Cells were seeded in DMEM plus 10% fetal calf serum in a 24-well plate at a density of 4.times.10.sup.4 cells per well. After overnight incubation, the cells were washed twice with serum-free DMEM. Drugs were then added to a total volume of 0.2 ml of serum-free DMEM and the cells were incubated for 24 hours. Cells were then trypsinized and dead cells scored on a hemocytometer by trypan blue exclusion (Sigma, St. Louis, Mo.). At least 200 cells were scored per well. Each concentration was tested in duplicate each time.

Western blotting

Cells were lysed in SDS sample buffer and cell lysates were subjected to 15% SDS-PAGE. After electroblotting the proteins to an Immobilon nylon membrane (Millipore), the membrane was blocked with 4% nonfat milk in 25 mM Tris-HCl pH7.5, 150 mM NaCl, 0.2% Tween (TBST). The membrane was incubated with anti-crmA antibody (Gagliardini et al., Science 263:826-828 (1994)) (5 .mu.g/ml) for 1 hour at room temperature and then washed five times with TBST. The membrane was incubated with HRP-conjugated goat anti-rabbit IgG (1/1000 dilution, Amersham) for 30 minutes and washed five times with TBST. crmA protein was detected with an ECL detection kit (Amersham).

DNA transfection

One day before transfection, cells were seeded at a density of about 2.times.10.sup.5 per well in 6-well dishes. For each well, 1 .mu.g of plasmid DNA and 10 .mu.g of lipofectamine reagent was added according to a protocol from Gibco BRL. Cells were incubated for 3 hours in serum-free medium containing DNA and lipofectamine, and then medium was changed to DMEM containing 10% FBS and incubation was continued for 24 hours. The expression of chimeric gene was detected as previously described (Muira et al., Cell 75:653-660 (1993)).

Detection of IL-1.beta. production from HeLa cells

HeLa cells were grown overnight in medium containing 10% fetal calf serum and then the medium was changed to a serum-free DMEM with or without drugs. After 24 hours, cells were scraped off and precipitated. Conditioned medium was collected, dialyzed against distilled water at 4.degree. C. overnight, lyophilized, and the residue dissolved in distilled water. Cell precipitates were extracted with extraction buffer (20 mM HEPES-NaOH pH7.4, 10 mM KCl, 1.5 mM MgCl2, 0.5 mM EDTA, 10 .mu.g/ml PMSF, 10 .mu.g/ml E64, 2 .mu.g/ml pepstatin, 1 .mu.g/ml leupeptin, 0.5 .mu.g/ml aprotinin, 1% NP-40). Insoluble materials were removed by centrifugation. Proteins were separated by 15% SDS-PAGE and IL-1.beta. was detected by immunoblotting using anti-human IL-1.beta. antibody (1/300 dilution, Calbiochem).

Results

Establishment of crmA-expressing HeLa cells

To test the hypothesis that activation of ICE is responsible for TNF-.alpha. induced apoptosis, the inventors first established HeLa cell lines constitutively expressing cowpox virus crmA protein. This protein is a viral serpin that can specifically inhibit ICE activity (Ray, C. A. et al., Cell 69:597-604 (1992)).

HeLa cell clones expressing crmA were analyzed by Western blot analysis with affinity-purified anti-crmA. HeLa cells were transfected with crmA expression vector and selected for G418 resistance as described in "Experimental Procedures" above. Six different G418 resistant HeLa cell clones were analyzed. As a positive control, cell lysate of a Rat-1 cell clone expressing crmA (Miura, H. et al., Cell 75:653-660 (1993)) was applied to the gel. Several HeLa cell clones stably expressing crmA were established.

Overexpression of Ice/ced-3 family gene in HeLa/crmA cells

The cell lines were tested for resistance to cell death induced by ICE overexpression. The overexpression of crmA in HeLa cells suppressed ICE-induced cell death. HeLa cells constitutively expressing crmA were transfected with a chimeric expression vector expressing both the lacZ and the mICE gene (p.beta.actM10Z). Transfection is described above in "Experimental Procedures". One of the HeLa/crmA clones expressing high levels of crmA could efficiently suppress ICE induced cell death. A clone expressing crmA at low levels also could efficiently suppress the ICE induced cell death under the same conditions (viability 69.8.+-.1.2%, Table 4.) ______________________________________ Prevention of apoptosis by CrmA ______________________________________ % round blue cells Expression cassettes HeLa      Hela/CrmA ______________________________________ pact.beta.Gal' 3.2 .+-. 0.8 1.1 .+-. 0.4 p.beta.actM10Z 85.5 .+-. 3.0  46.9 .+-. 7.0 p.beta.actH37Z 91.4 .+-. 4.9  87.5 .+-. 3.0 ______________________________________ Drug treatments % dead cells ______________________________________ control         1.5 .+-. 0.3 5.5 .+-. 1.8 CHX 2.9 .+-. 0.7 3.8 .+-. 0.5 TNF 2.7 .+-. 1.2 2.8 .+-. 1.0 CHX + TNF 68.2 .+-. 1.9  9.7 .+-. 1.2 ______________________________________ Cells were transfected and stained as described herein. Plasmid pact.beta.Gal' is a control LacZ gene expression vector and plasmid p.beta.actM10Z is a mouse Ice/lacZ chimeric gene expression vector (Muira M. et al., Cell 75:653-66 (1993)). Plasmid p.beta.actH37Z is a Ich1/lacZ chimeric gene expression vector (Lin, W. et al., Cell 78:739-750 (1994). # The data (mean .+-. SEM) shown are the percentage of round blue cells among total number of blue cells counted. To see the effects of CHX (20 .mu.g/ml) and the TNF.alpha. (5 ng/ml), cells were treated with drugs for 24 h and cell viabilities were measured by typan blue dye exclusion. The data (mean .+-. SEM) shown are the percentage of dead cells. The data wer collected from at least three independent experiments.

CrmA is a potent and highly specific serpin for ICE. However, cell death induced by overexpression of ced-3 is poorly suppressed by crmA (Miura, M. et al., Cell 75:653-660 (1993)). Ich-1 (nedd-2) has been described above as third member of the ICE/Ced-3 gene family (see also, Kumar, S. et al., Genes Dev. 8:1613-1626 (1994)). As with ICE, overexpression of Ich-1 induces Rat-1 and HeLa cell death efficiently. However, Ich-1 induced cell death is weakly suppressed by overexpression of crmA in HeLa cells (Table 4) and Rat-1 cells. Thus, crmA does not appear to be a general inhibitor of ICE/Ced-3 family protease.

Suppression of TNF.alpha.-induced apoptosis by crmA

The effect of crmA expression on TNF-induced apoptosis was tested. TNF induced cytotoxicity was suppressed by overexpression of crmA. HeLa cells or HeLa/crmA cells were treated with cycloheximide (CHX) (20 .mu.g/ml, Sigma), TNF-.alpha. (5 ng/ml, Sigma), or a combination of both drugs. Cells were photographed 24 hours after drug treatment. Control HeLa and HeLa/crmA cells were tested for the ability to resist increasing amounts of TNF-.alpha. in the presence of 10 .mu.g/ml CHX (FIG. 16). In the presence of CHX, TNF-.alpha. efficiently induced HeLa cell death (White, E. et al., Mol. Cell. Biol. 12:2570-2580 (1992)). Under the same conditions, HeLa cells expressing crmA at high levels are resistant to the TNF-.alpha. cell death stimulus (Table 4). A clone of HeLa/crmA cells that expresses lower levels of crmA was also resistant under the same conditions (% dead cells=30.2.+-.1.2%). The dose response of crmA-expressing HeLa cells to increasing amounts of TNF-.alpha. in the presence of 10 .mu.g/ml of CHX was tested. HeLa/crmA cells are resistant to 0.01 pg/ml to 100 ng/ml of TNF-.alpha. (FIG. 16). After a 24 hour incubation in the presence of 100 ng/ml TNF-.alpha., 83% of the control HeLa cells died compared to 23% of HeLa/crmA cells.

Activation of endogenous ICE after TNF stimulation

The inventors have detected the expression of both ICE and Ich-1 in HeLa cells (Lin, W. et al., Cell 78:739-750 (1994)). Since Ich-1-induced cell death is only weakly suppressed by crmA and crmA appears to be very effective in preventing cell death induced by TNF and CHX treatment, the ICE-mediated cell death pathway may be activated by TNF stimulation and may play a role in HeLa cell death. If this is the case, TNF stimulation should activate endogenous ICE in HeLa cells.

Pro-IL-1.beta. is the only known endogenous substrate for ICE. Active ICE is an oligometric enzyme with p20 and p10 subunits (Thornberry, N. A. et al., Nature 356:768-774 (1992); Cerretti, D. P. et al., Science 256:97-100 (1992)). These subunits are derived from a p45 precursor form of ICE (Thornberry, N. A. et al., Nature 356:768-774 (1992); Cerretti, D. P. et al., Science 256:97-100 (1992)). If ICE is activated after TNF stimulation, the endogenous 33 kd pro-IL-1.beta. should be processed and mature 17.5 kd IL-1.beta.secreted into the medium.

To detect mature IL-1.beta., conditioned medium was collected from HeLa cells with or without TNF stimulation. The processing of pro-IL-1.beta. was analyzed by Western blot. Processing of IL-1.beta. was observed only after induction of apoptosis by TNF-.alpha./CHX in HeLa cells. The following samples were compared: purified mature human IL-1.beta., cell lysates (10 .mu.g protein/lane), conditioned medium (5 .mu.g/lane), serum-free controls, LPS (10 .mu.g/ml, Sigma) treatment, cycloheximide (20 .mu.g/ml) and TNF (5 ng/ml).

The procedure for detecting IL-1.beta. is described above under "Experimental Procedures". Cell viabilities were measured by trypan blue dye exclusion (97.4.+-.1.5% for serum free control, 97.4.+-.0.2% for LPS treatment, 56.3.+-.2.2% for CHX/TNF-.alpha. treatment). The data showed that mature IL-1.beta. was only observed after induction of apoptosis by TNF. These results strongly suggest that TNF stimulation induces apoptosis by activation of an ICE-dependent cell death pathway.

Discussion

The inventors have demonstrated herein that overexpression of ICE induces Rat-1 cells to undergo apoptosis (Miura, M. et al., Cell 75:653-660 (1993)) and expression of crmA can prevent chicken DRG neurons from cell death induced by trophic factor deprivation (Gagliardini, V. et al., Science 263:826-828 (1994)). These results show that ICE has the ability to induce cell death and that inhibition of ICE activity can prevent programmed cell death. However, the results did not show that ICE was, indeed, activated during programmed cell death. Using pro-IL-1.beta. processing as an indicator, the inventors have demonstrated that ICE is activated when HeLa cells are induced to die with TNF-.alpha. and CHX.

ICE has unique substrate specificity which requires an Asp in the P1 position (Sleath et al., J. Biol. Chem 265:14526-14528 (1990)). Only two eukaryotic proteases are reported to cleave after the Asp. The other is granzyme B, a serine protease in the cytotoxic granules of killer T lymphocytes (Odake et al., Biochemistry 30:2217-2227 (1991)). In THP.1 cells and HeLa cells, expression of both ICE and Ich-1 were detected (Wang et al., Cell 78:739-750 (1994)). However, affinity labeling of THP.1 cell lysates with a competitive, irreversible ICE inhibitor, biotinylated tetrapeptide (acyloxy) methyl ketone, resulted in labeling only of ICE (Thornberry et al., Biochemistry 33:3934-3940 (1994)). This suggests that ICE is the only enzyme to cleave proIL-.beta. in the human monocytic cell line, THP.1. The present studies show that crmA cannot prevent cell death induced by Ich-1 in HeLa cells.

How CHX potentiates the TNF cytotoxicity in non-transformed cells is unclear. Most of the cell lines, including HeLa cells, NIH3T3 cells, and TA1 cells, are not killed by TNF alone, but are killed by the combined action of TNF and CHX (Reid et al., J. Biol. Chem. 264:4583-4589 (1991); Reid et al., J. Biol. Chem. 266:16580-16586 (1991)). TNF-.alpha. is a pleiotrophic cytokine which may induce more than one cellular response in a single cell. The presence of CHX may inhibit the synthesis of certain signaling molecules and thus, potentiate the killing activity of TNF. Alternatively, CHX may simply inhibit the synthesis of a general cell survival factor(s) and thus, allow cells to become more sensitive to TNF cytotoxicity.

HeLa cells express predominantly p55 TNF receptor, thought to be responsible for cell death signalling (Engelmann et al., J. Biol. Chem. 265:14497-14504 (1990); Thoma et al., J. Exp. Med. 72:1019-1023 (1990)). TNF p55 receptor triggers the activation of phospholypase A2, protein kinase C, sphingomyelinase, phosphatidylcholine-specific phospholypase C, and NF-kB (Weigmann et al., J. Biol. Chem. 267:17997-18001 (1992); Schutze et al., Cell 71:765-776 (1992)). In TNF p55 receptor knockout mice, TNF-mediated induction of NF-kB is prevented in thymocytes (Pfeffer et al., Cell 73:457-467 (1993)). TNF p55 receptor knockout mice were resistant to lethal doses of either lipopolysaccharides or S. aureus enterotoxin B. This suggests that TNF p55 receptor mediated hepatocyte necrosis (Pfeffer et al., Cell 73:457-467 (1993)). After the stimulation of HeLa cells by TNF-.alpha./CHX, not all the proIL-1.beta. was converted into mature IL-1.beta.. ICE activity is likely to be tightly controlled within the cells. A small amount of active ICE may be sufficient for induction of apoptosis. Even in the mature IL-1.beta.-producing monocytic cell line, THP.1, most of the ICE is the p45 inactive form. In non-LPS-stimulated THP.1 cells, only 0.02% of ICE is in the active form. In stimulated cells, the maximum amount of active ICE is less than 2% of total ICE (Ayala et al., J. Immunol. 153:2592-2599 (1994)). THP.1 cells may have some protective mechanism to prevent the activated ICE from inducing apoptosis. LPS induces the synthesis of a large amount of pro-IL-1.beta., which may, in fact, confer protection on THP.1 cells, because substrates usually are good competitive inhibitors of enzymes.

In addition to the secretion of mature IL-1.beta., there was a significant drop of the proIL-1.beta. level in the cell lysates prepared from TNF-.alpha./CHX-treated cells. This could be the result of secretion of mature IL-1.beta., inhibition of biosynthesis of proIL-1.beta., or increase of proteolytic activity within the dying cells. If, however, the inventors' hypothesis is correct (i.e., that pro-IL-1.beta. does act as a competitive inhibitor of ICE), a reduction in the level of pro-IL-1.beta. would in fact represent a further reduction in cellular defense against apoptosis and could be one of the reasons that CHX can increase the cytotoxicity of TNF-.alpha..

TNF is a central component in the mammalian host inflammatory response (Tracey, K. G. et al., Ann. Rev. Cell. Biol. 9:317-343 (1993)). In models of septic shock, injection of endotoxin (LPS) rapidly induces TNF, IL-1 and IL-6 (Ford, Y. et al., J. Exp. Med. 170:1627-1633 (1989)). Under these conditions, the secretion of IL-1.beta. appears to be dependent upon TNF because passive immunization with TNF monoclonal antibodies during endotoxemia in vivo attenuates the appearance of IL-1.beta. (Fong, Y. et al., J. Exp. Med. 170:1627-1633 (1989)). The results herein show that TNF plays a role in activating ICE, the key enzyme in processing IL-1.beta..

Expression of mitochondrial manganese superoxide dismutase has been shown to promote the survival of tumor cells exposed to TNF (Hirose, K. et al., Mol. Cell. Biol. 13:3301-3310 (1993)). This suggests that the generation of free radicals plays a role in cell death induced by TNF. There are several reports that TNF cytotoxicity is related to the generation of free radicals and lipid peroxides (Hennet, T. et al., Biochem. J. 289:587-592 (1993); Schulze-Osthoff, K. et al., J. Biol. Chem. 267:5317-5323 (1992)). If that is the case, ICE may be activated directly or indirectly by free radicals.

The death of Hela cells induced by TNF is also suppressed by bcl-2 overexpression (the viability is 83.7.+-.2.3% under the experimental conditions described for Table 4). Bcl-2 has been suggested to have the ability to either inhibit the production of free radicals (Kane, D. J. et al., Science 262:1274-1277 (1993)) or prevent free radicals from damaging cells (Hockenberry, D. M. et al., Cell 75:241-251 (1993)). Thus, in HeLa cells, bcl-2 and crmA may suppress cell death induced by TNF through a single biochemical pathway of programmed cell death.

Fas/Apo (ref)-antigen is a member of TNF receptor family (Itoh, N. et al., Cell 66:233-243 (1991)). Apoptosis can be induced by stimulation of Fas-antigen by anti-Fas/anti-Apo antibody (Yonehara, S. et al., J. Exp. Med. 169:1747-1756 (1989)) or Fas-ligand (Suda, T. et al., Cell 75:1169-1178 (1993)), a type II transmembrane protein homologous to TNF. Cell death signalling after the stimulation of Fas-antigen is largely unknown. However, Fas mediated cell death is protected by overexpression of E1b (Hashimoto, S. et al., Intern. Immun. 3:343-351 (1991)) or bcl-2 (Itoh, N. et al., J. Immun. 151:621-627 (1993)). The data presented herein suggest that stimulation of Fas-antigen may also activate ICE/ced-3 cell death pathway. #             SEQUENCE LISTING - -  - - (1) GENERAL INFORMATION: - -    (iii) NUMBER OF SEQUENCES: 95 - -  - - (2) INFORMATION FOR SEQ ID NO:1: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 7653 base - #pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both - -     (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: join(2232..2 - #366, 2430..2576, 2855..3109, 4305 ..4634, 5 - #547..5759, 5817..5942, 6298..6537, 7012 ..7075) - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1: - - AGATCTGAAA TAAGGTGATA AATTAATAAA TTAAGTGTAT TTCTGAGGAA AT - #TTGACTGT     60 - - TTTAGCACAA TTAATCTTGT TTCAGAAAAA AAGTCCAGTT TTCTAGATTT TT - #CCGTCTTA    120 - - TTGTCGAATT AATATCCCTA TTATCACTTT TTCATGCTCA TCCTCGAGCG GC - #ACGTCCTC    180 - - AAAGAATTGT GAGAGCAAAC GCGCTCCCAT TGACCTCCAC ACTCAGCCGC CA - #AAACAAAC    240 - - GTTCGAACAT TCGTGTGTTG TGCTCCTTTT CCGTTATCTT GCAGTCATCT TT - #TGTCGTTT    300 - - TTTTCTTTGT TCTTTTTGTT GAACGTGTTG CTAAGCAATT ATTACATCAA TT - #GAAGAAAA    360 - - GGCTCGCCGA TTTATTGTTG CCAGAAAGAT TCTGAGATTC TCGAAGTCGA TT - #TTATAATA    420 - - TTTAACCTTG GTTTTTGCAT TGTTTCGTTT AAAAAAACCA CTGTTTATGT GA - #AAAACGAT    480 - - TAGTTTACTA ATAAAACTAC TTTTAAACCT TTACCTTTAC CTCACCGCTC CG - #TGTTCATG    540 - - GCTCATAGAT TTTCGATACT CAAATCCAAA AATAAATTTA CGAGGGCAAT TA - #ATGTGAAA    600 - - CAAAAACAAT CCTAAGATTT CCACATGTTT GACCTCTCCG GCACCTTCTT CC - #TTAGCCCC    660 - - ACCACTCCAT CACCTCTTTG GCGGTGTTCT TCGAAACCCA CTTAGGAAAG CA - #GTGTGTAT    720 - - CTCATTTGGT ATGCTCTTTT CGATTTTATA GCTCTTTGTC GCAATTTCAA TG - #CTTTAAAC    780 - - AATCCAAATC GCATTATATT TGTGCATGGA GGCAAATGAC GGGGTTGGAA TC - #TTAGATGA    840 - - GATCAGGAGC TTTCAGGGTA AACGCCCGGT TCATTTTGTA CCACATTTCA TC - #ATTTTCCT    900 - - GTCGTCCTTG GTATCCTCAA CTTGTCCCGG TTTTGTTTTC GGTACACTCT TC - #CGTGATGC    960 - - CACCTGTCTC CGTCTCAATT ATCGTTTAGA AATGTGAACT GTCCAGATGG GT - #GACTCATA   1020 - - TTGCTGCTGC TACAATCCAC TTTCTTTTCT CATCGGCAGT CTTACGAGCC CA - #TCATAAAC   1080 - - TTTTTTTTCC GCGAAATTTG CAATAAACCG GCCAAAAACT TTCTCCAAAT TG - #TTACGCAA   1140 - - TATATACAAT CCATAAGAAT ATCTTCTCAA TGTTTATGAT TTCTTCGCAG CA - #CTTTCTCT   1200 - - TCGTGTGCTA ACATCTTATT TTTATAATAT TTCCGCTAAA ATTCCGATTT TT - #GAGTATTA   1260 - - ATTTATCGTA AAATTATCAT AATAGCACCG AAAACTACTA AAAATGGTAA AA - #GCTCCTTT   1320 - - TAAATCGGCT CGACATTATC GTATTAAGGA ATCACAAAAT TCTGAGAATG CG - #TACTGCGC   1380 - - AACATATTTG ACGGCAAAAT ATCTCGTAGC GAAAACTACA GTAATTCTTT AA - #ATGACTAC   1440 - - TGTAGCGCTT GTGTCGATTT ACGGGCTCAA TTTTTGAAAA TAATTTTTTT TT - #TCGAATTT   1500 - - TGATAACCCG TAAATCGTCA CAACGCTACA GTAGTCATTT AAAGGATTAC TG - #TAGTTCTA   1560 - - GCTACGAGAT ATTTTGCGCG CCAAATATGA CTGTAATACG CATTCTCTGA AT - #TTTGTGTT   1620 - - TCCGTAATAA TTTCACAAGA TTTTGGCATT CCACTTTAAA GGCGCACAGG AT - #TTATTCCA   1680 - - ATGGGTCTCG GCACGCAAAA AGTTTGATAG ACTTTTAAAT TCTCCTTGCA TT - #TTTAATTC   1740 - - AATTACTAAA ATTTTCGTGA ATTTTTCTGT TAAAATTTTT AAAATCAGTT TT - #CTAATATT   1800 - - TTCCAGGCTG ACAAACAGAA ACAAAAACAC AACAAACATT TTAAAAATCA GT - #TTTCAAAT   1860 - - TAAAAATAAC GATTTCTCAT TGAAAATTGT GTTTTATGTT TGCGAAAATA AA - #AGAGAACT   1920 - - GATTCAAAAC AATTTTAACA AAAAAAAACC CCAAAATTCG CCAGAAATCA AG - #ATAAAAAA   1980 - - TTCAAGAGGG TCAAAATTTT CCGATTTTAC TGACTTTCAC CTTTTTTTTC GT - #AGTTCAGT   2040 - - GCAGTTGTTG GAGTTTTTGA CGAAAACTAG GAAAAAAATC GATAAAAATT AC - #TCAAATCG   2100 - - AGCTGAATTT TGAGGACAAT GTTTAAAAAA AAACACTATT TTTCCAATAA TT - #TCACTCAT   2160 - - TTTCAGACTA AATCGAAAAT CAAATCGTAC TCTGACTACG GGTCAGTAGA GA - #GGTCAACC   2220 - - ATCAGCCGAA G ATG ATG CGT CAA GAT AGA AGG AGC - #TTG CTA GAG AGG AAC    2270 Met Met Arg - #Gln Asp Arg Arg Ser Leu Leu Glu Arg Asn 1   - #            5      - #            10 - - ATT ATG ATG TTC TCT AGT CAT CTA AAA GTC GA - #T GAA ATT CTC GAA GTT 2318 Ile Met Met Phe Ser Ser His Leu Lys Val As - #p Glu Ile Leu Glu Val 15             - #     20             - #     25 - - CTC ATC GCA AAA CAA GTG TTG AAT AGT GAT AA - #T GGA GAT ATG ATT AAT 2366 Leu Ile Ala Lys Gln Val Leu Asn Ser Asp As - #n Gly Asp Met Ile Asn 30                 - # 35                 - # 40                 - # 45 - - GTGAGTTTTT AATCGAATAA TAATTTTAAA AAAAAATTGA TAATATAAAG AA - #TATTTTTG   2426 - - CAG TCA TGT GGA ACG GTT CGC GAG AAG AGA CG - #G GAG ATC GTG AAA GCA     2474 Ser Cys Gly Thr Val Arg Glu Lys - #Arg Arg Glu Ile Val Lys Ala - #   50               - #   55               - #   60 - - GTG CAA CGA CGG GGA GAT GTG GCG TTC GAC GC - #G TTT TAT GAT GCT CTT 2522 Val Gln Arg Arg Gly Asp Val Ala Phe Asp Al - #a Phe Tyr Asp Ala Leu 65 - #                 70 - #                 75 - - CGC TCT ACG GGA CAC GAA GGA CTT GCT GAA GT - #T CTT GAA CCT CTC GCC 2570 Arg Ser Thr Gly His Glu Gly Leu Ala Glu Va - #l Leu Glu Pro Leu Ala 80     - #             85     - #             90 - - AGA TCG TAGGTTTTTA AAGTTCGGCG CAAAAGCAAG GGTCTCACGG AA - #AAAAGAGG 2626 Arg Ser - - CGGATCGTAA TTTTGCAACC CACCGGCACG GTTTTTTCCT CCGAAAATCG GA - #AATTATGC   2686 - - ACTTTCCCAA ATATTTGAAG TGAAATATAT TTTATTTACT GAAAGCTCGA GT - #GATTATTT   2746 - - ATTTTTTAAC ACTAATTTTC GTGGCGCAAA AGGCCATTTT GTAGATTTGC CG - #AAAATACT   2806 - - TGTCACACAC ACACACACAC ATCTCCTTCA AATATCCCTT TTTCCAGT GTT - #GAC TCG    2863 - #                  - #                 Val - # Asp Ser - #                  - #                  - #95 - - AAT GCT GTC GAA TTC GAG TGT CCA ATG TCA CC - #G GCA AGC CAT CGT CGG 2911 Asn Ala Val Glu Phe Glu Cys Pro Met Ser Pr - #o Ala Ser His Arg Arg 100          - #       105          - #       110 - - AGC CGC GCA TTG AGC CCC GCC GGC TAC ACT TC - #A CCG ACC CGA GTT CAC 2959 Ser Arg Ala Leu Ser Pro Ala Gly Tyr Thr Se - #r Pro Thr Arg Val His 115              - #   120              - #   125 - - CGT GAC AGC GTC TCT TCA GTG TCA TCA TTC AC - #T TCT TAT CAG GAT ATC 3007 Arg Asp Ser Val Ser Ser Val Ser Ser Phe Th - #r Ser Tyr Gln Asp Ile 130                 1 - #35                 1 - #40                 1 - #45 - - TAC TCA AGA GCA AGA TCT CGT TCT CGA TCG CG - #T GCA CTT CAT TCA TCG     3055 Tyr Ser Arg Ala Arg Ser Arg Ser Arg Ser Ar - #g Ala Leu His Ser Ser 150  - #               155  - #               160 - - GAT CGA CAC AAT TAT TCA TCT CCT CCA GTC AA - #C GCA TTT CCC AGC CAA 3103 Asp Arg His Asn Tyr Ser Ser Pro Pro Val As - #n Ala Phe Pro Ser Gln 165      - #           170      - #           175 - - CCT TGT ATGTTGATGC GAACACTAAA TTCTGAGAAT GCGCATTACT CA - #ACATATTT 3159 Pro Ser - - GACGCGCAAA TATCTCGTAG CGAAAAATAC AGTAACCCTT TAAATGACTA TT - #GTAGTGTC   3219 - - GATTTACGGG CTCGATTTTC GAAACGAATA TATGCTCGAA TTGTGACAAC GA - #ATTTTAAT   3279 - - TTGTCATTTT TGTGTTTTCT TTTGATATTT TTGATCAATT AATAAATTAT TT - #CCGTAAAC   3339 - - AGACACCAGC GCTACAGTAC TCTTTTAAAG AGTTACAGTA GTTTTCGCTT CA - #AGATATTT   3399 - - TGAAAAGAAT TTTAAACATT TTGAAAAAAA ATCATCTAAC ATGTGCCAAA AC - #GCTTTTTT   3459 - - CAAGTTTCGC AGATTTTTTG ATTTTTTTCA TTCAAGATAT GCTTATTAAC AC - #ATATAATT   3519 - - ATCATTAATG TGAATTTCTT GTAGAAATTT TGGGCTTTTC GTTCTAGTAT GC - #TCTACTTT   3579 - - TGAAATTGCT CAACGAAAAA ATCATGTGGT TTGTTCATAT GAATGACGAA AA - #ATAGCAAT   3639 - - TTTTTATATA TTTTCCCCTA TTCATGTTGT GCAGAAAAAT AGTAAAAAAG CG - #CATGCATT   3699 - - TTTCGACATT TTTTACATCG AACGACAGCT CACTTCACAT GCTGAAGACG AG - #AGACGCGG   3759 - - AGAAATACCA CACATCTTTC TGCGTCTCTC GTCTTCAGCA TGTGAAATGG GA - #TCTCGGTC   3819 - - GATGTAAAAA AATGTCGAAT AATGTAAAAA ATGCATGCGT TTTTTTACAC TT - #TTCTGCAC   3879 - - AAATGAATAG GGGGAAAATG TATTAAAATA CATTTTTTGT ATTTTTCAAC AT - #CACATGAT   3939 - - TAACCCCATT ATTTTTTCGT TGAGCAACTT AAAAAGTAGA GAATATTAGA GC - #GAAAACCA   3999 - - AAATTTCTTC AAGATATTAC CTTTATTGAT AATTATAGAT GTTAATAAGC AT - #ATCTTGAA   4059 - - TGAAAGTCAG CAAAAATATG TGCGAAACAC CTGAAAAAAA TCAAAAATTC TG - #CGAAAATT   4119 - - GAAAAAATGC ATTAAAATAC ATTTTTGCAT TTTTCTACAT CACATGAATG TA - #GAAAATTA   4179 - - AAAGGGAAAT CAAAATTTCT AGAGGATATA ATTGAATGAA ACATTGCGAA AT - #TAAAATGT   4239 - - GCGAAACGTC AAAAAAGAGG AAATTTGGGT ATCAAAATCG ATCCTAAAAC CA - #ACACATTT   4299 - - CAGCA TCC GCC AAC TCT TCA TTC ACC GGA TGC - #TCT TCT CTC GGA TAC 4346 Ser Ala Asn Ser Ser Phe Thr - #Gly Cys Ser Ser Leu Gly Tyr 180            - #     185            - #     190 - - AGT TCA AGT CGT AAT CGC TCA TTC AGC AAA GC - #T TCT GGA CCA ACT CAA 4394 Ser Ser Ser Arg Asn Arg Ser Phe Ser Lys Al - #a Ser Gly Pro Thr Gln 195              - #   200              - #   205 - - TAC ATA TTC CAT GAA GAG GAT ATG AAC TTT GT - #C GAT GCA CCA ACC ATA 4442 Tyr Ile Phe His Glu Glu Asp Met Asn Phe Va - #l Asp Ala Pro Thr Ile 210                 2 - #15                 2 - #20                 2 - #25 - - AGC CGT GTT TTC GAC GAG AAA ACC ATG TAC AG - #A AAC TTC TCG AGT CCT     4490 Ser Arg Val Phe Asp Glu Lys Thr Met Tyr Ar - #g Asn Phe Ser Ser Pro 230  - #               235  - #               240 - - CGT GGA ATG TGC CTC ATC ATA AAT AAT GAA CA - #C TTT GAG CAG ATG CCA 4538 Arg Gly Met Cys Leu Ile Ile Asn Asn Glu Hi - #s Phe Glu Gln Met Pro 245      - #           250      - #           255 - - ACA CGG AAT GGT ACC AAG GCC GAC AAG GAC AA - #T CTT ACC AAT TTG TTC 4586 Thr Arg Asn Gly Thr Lys Ala Asp Lys Asp As - #n Leu Thr Asn Leu Phe 260          - #       265          - #       270 - - AGA TGC ATG GGC TAT ACG GTT ATT TGC AAG GA - #C AAT CTG ACG GGA AGG 4634 Arg Cys Met Gly Tyr Thr Val Ile Cys Lys As - #p Asn Leu Thr Gly Arg 275              - #   280              - #   285 - - GTACGGCGAA ATTATATTAC CCAAACGCGA AATTTGCCAT TTTGCGCCGA AA - #ATGTGGCG   4694 - - CCCGGTCTCG ACACGACAAT TTGTGTTAAA TGCAAAAATG TATAATTTTG CA - #AAAAACAA   4754 - - AATTTTGAAC TTCCGCGAAA ATGATTTACC TAGTTTCGAA ATTTTCGTTT TT - #TCCGGCTA   4814 - - CATTATGTGT TTTTTCTTAG TTTTTCTATA ATATTTGATG TAAAAAACCG TT - #TGTAAATT   4874 - - TTCAGACAAT TTTCCGCATA CAAAACTTGA TAGCACGAAA TCAATTTTCT GA - #ATTTTCAA   4934 - - AATTATCCAA AAATGCACAA TTTAAAATTT GTGAAAATTG GCAAACGGTG TT - #TCAATATG   4994 - - AAATGTATTT TTAAAAACTT TAAAAACCAC TCCGGAAAAG CAATAAAAAT CA - #AAACAACG   5054 - - TCACAATTCA AATTCAAAAG TTATTCATCC GATTTGTTTA TTTTTGCAAA AT - #TTGAAAAA   5114 - - ATCATGAAGG ATTTAGAAAA GTTTTATAAC ATTTTTTCTA GATTTTTCAA AA - #TTTTTTTT   5174 - - AACAAATCGA GAAAAAGAGA ATGAAAAATC GATTTTAAAA ATATCCACAG CT - #TCGAGAGT   5234 - - TTGAAATTAC AGTACTCCTT AAAGGCGCAC ACCCCATTTG CATTGGACCA AA - #AATTTGTC   5294 - - GTGTCGAGAC CAGGTACCGT AGTTTTTGTC GCAAAAATTG CACCATTGGA CA - #ATAAACCT   5354 - - TCCTAATCAC CAAAAAGTAA AATTGAAATC TTCGAAAAGC CAAAAAATTC AA - #AAAAAAAG   5414 - - TCGAATTTCG ATTTTTTTTT TGGTTTTTTG GTCCCAAAAA CCAAAAAAAT CA - #ATTTTCTG   5474 - - CAAAATACCA AAAAGAAACC CGAAAAAATT TCCCAGCCTT GTTCCTAATG TA - #AACTGATA   5534 - - TTTAATTTCC AG GGA ATG CTC CTG ACA ATT CGA GAC - # TTT GCC AAA CAC 5582 Gly Met Le - #u Leu Thr Ile Arg Asp Phe Ala Lys His 290    - #             295    - #             300 - - GAA TCA CAC GGA GAT TCT GCG ATA CTC GTG AT - #T CTA TCA CAC GGA GAA 5630 Glu Ser His Gly Asp Ser Ala Ile Leu Val Il - #e Leu Ser His Gly Glu 305      - #           310      - #           315 - - GAG AAT GTG ATT ATT GGA GTT GAT GAT ATA CC - #G ATT AGT ACA CAC GAG 5678 Glu Asn Val Ile Ile Gly Val Asp Asp Ile Pr - #o Ile Ser Thr His Glu 320          - #       325          - #       330 - - ATA TAT GAT CTT CTC AAC GCG GCA AAT GCT CC - #C CGT CTG GCG AAT AAG 5726 Ile Tyr Asp Leu Leu Asn Ala Ala Asn Ala Pr - #o Arg Leu Ala Asn Lys 335              - #   340              - #   345 - - CCG AAA ATC GTT TTT GTG CAG GCT TGT CGA GG - #C G GTTCGTTTT TTATTTTAAT  5779 Pro Lys Ile Val Phe Val Gln Ala Cys Arg Gl - #y Glu 350                 3 - #55                 3 - #60 - - TTTAATATAA ATATTTTAAA TAAATTCATT TTCAG AA CGT CGT G - #AC AAT GGA TTC   5834 - #                  - #      Arg Arg Asp Asn Gly Phe - #                  - #                  - #365 - - CCA GTC TTG GAT TCT GTC GAC GGA GTT CCT GC - #A TTT CTT CGT CGT GGA 5882 Pro Val Leu Asp Ser Val Asp Gly Val Pro Al - #a Phe Leu Arg Arg Gly 370          - #       375          - #       380 - - TGG GAC AAT CGA GAC GGG CCA TTG TTC AAT TT - #T CTT GGA TGT GTG CGG 5930 Trp Asp Asn Arg Asp Gly Pro Leu Phe Asn Ph - #e Leu Gly Cys Val Arg 385              - #   390              - #   395 - - CCG CAA GTT CAG GTTGCAATTT AATTTCTTGA ATGAGAATAT TC - #CTTCAAAA 5982 Pro Gln Val Gln 400 - - AATCTAAAAT AGATTTTTAT TCCAGAAAGT CCCGATCGAA AAATTGCGAT AT - #AATTACGA   6042 - - AATTTGTGAT AAAATGACAA ACCAATCAGC ATCGTCGATC TCCGCCCACT TC - #ATCGGATT   6102 - - GGTTTGAAAG TGGGCGGAGT GAATTGCTGA TTGGTCGCAG TTTTCAGTTT AG - #AGGGAATT   6162 - - TAAAAATCGC CTTTTCGAAA ATTAAAAATT GATTTTTTCA ATTTTTTCGA AA - #AATATTCC   6222 - - GATTATTTTA TATTCTTTGG AGCGAAAGCC CCGTCCTGTA AACATTTTTA AA - #TGATAATT   6282 - - AATAAATTTT TGCAG CAA GTG TGG AGA AAG AAG CCG - #AGC CAA GCT GAC ATT    6333 Gln - #Val Trp Arg Lys Lys Pro Ser Gln Ala Asp I - #le - #   405              - #   410              - # 415 - - CTG ATT CGA TAC GCA ACG ACA GCT CAA TAT GT - #T TCG TGG AGA AAC AGT     6381 Leu Ile Arg Tyr Ala Thr Thr Ala Gln Tyr Va - #l Ser Trp Arg Asn Ser 420  - #               425  - #               430 - - GCT CGT GGA TCA TGG TTC ATT CAA GCC GTC TG - #T GAA GTG TTC TCG ACA 6429 Ala Arg Gly Ser Trp Phe Ile Gln Ala Val Cy - #s Glu Val Phe Ser Thr 435      - #           440      - #           445 - - CAC GCA AAG GAT ATG GAT GTT GTT GAG CTG CT - #G ACT GAA GTC AAT AAG 6477 His Ala Lys Asp Met Asp Val Val Glu Leu Le - #u Thr Glu Val Asn Lys 450          - #       455          - #       460 - - AAG GTC GCT TGT GGA TTT CAG ACA TCA CAG GG - #A TCG AAT ATT TTG AAA 6525 Lys Val Ala Cys Gly Phe Gln Thr Ser Gln Gl - #y Ser Asn Ile Leu Lys 465              - #   470              - #   475 - - CAG ATG CCA GAG GTACTTGAAA CAAACAATGC ATGTCTAACT TT - #TAAGGACA 6577 Gln Met Pro Glu 480 - - CAGAAAAATA GGCAGAGGCT CCTTTTGCAA GCCTGCCGCG CGTCAACCTA GA - #ATTTTAGT   6637 - - TTTTAGCTAA AATGATTGAT TTTGAATATT TTATGCTAAT TTTTTTGCGT TA - #AATTTTGA   6697 - - AATAGTCACT ATTTATCGGG TTTCCAGTAA AAAATGTTTA TTAGCCATTG GA - #TTTTACTG   6757 - - AAAACGAAAA TTTGTAGTTT TTCAACGAAA TTTATCGATT TTTAAATGTA AA - #AAAAAATA   6817 - - GCGAAAATTA CATCAACCAT CAAGCATTTA AGCCAAAATT GTTAACTCAT TT - #AAAAATTA   6877 - - ATTCAAAGTT GTCCACGAGT ATTACACGGT TGGCGCGCGG CAAGTTTGCA AA - #ACGACGCT   6937 - - CCGCCTCTTT TTCTGTGCGG CTTGAAAACA AGGGATCGGT TTAGATTTTT CC - #CCAAAATT   6997 - - TAAATTAAAT TTCAG ATG ACA TCC CGC CTG CTC AAA - #AAG TTC TAC TTT TGG    7048 Met - #Thr Ser Arg Leu Leu Lys Lys Phe Tyr Phe T - #rp - #   485              - #   490              - # 495 - - CCG GAA GCA CGA AAC TCT GCC GTC TAAAATTCAC TC - #GTGATTCA TTGCCCAAT T    7102 Pro Glu Ala Arg Asn Ser Ala Val 500 - - GATAATTGTC TGTATCTTCT CCCCCAGTTC TCTTTCGCCC AATTAGTTTA AA - #ACCATGTG   7162 - - TATATTGTTA TCCTATACTC ATTTCACTTT ATCATTCTAT CATTTCTCTT CC - #CATTTTCA   7222 - - CACATTTCCA TTTCTCTACG ATAATCTAAA ATTATGACGT TTGTGTCTCG AA - #CGCATAAT   7282 - - AATTTTAATA ACTCGTTTTG AATTTGATTA GTTGTTGTGC CCAGTATATA TG - #TATGTACT   7342 - - ATGCTTCTAT CAACAAAATA GTTTCATAGA TCATCACCCC AACCCCACCA AC - #CTACCGTA   7402 - - CCATATTCAT TTTTGCCGGG AATCAATTTC GATTAATTTT AACCTATTTT TT - #CGCCACAA   7462 - - AAAATCTAAT ATTTGAATTA ACGAATAGCA TTCCCATCTC TCCCGTGCCG GA - #ATGCCTCC   7522 - - CGGCCTTTTA AAGTTCGGAA CATTTGGCAA TTATGTATAA ATTTGTAGGT CC - #CCCCCATC   7582 - - ATTTCCCGCC CATCATCTCA AATTGCATTC TTTTTTCGCC GTGATATCCC GA - #TTCTGGTC   7642 - - AGCAAAGATC T               - #                  - # - #     7653 - -  - - (2) INFORMATION FOR SEQ ID NO:2: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 503 amino - #acids (B) TYPE: amino acid (D) TOPOLOGY: linear - -     (ii) MOLECULE TYPE: protein - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2: - - Met Met Arg Gln Asp Arg Arg Ser Leu Leu Gl - #u Arg Asn Ile Met Met 1               5 - #                 10 - #                 15 - - Phe Ser Ser His Leu Lys Val Asp Glu Ile Le - #u Glu Val Leu Ile Ala 20     - #             25     - #             30 - - Lys Gln Val Leu Asn Ser Asp Asn Gly Asp Me - #t Ile Asn Ser Cys Gly 35         - #         40         - #         45 - - Thr Val Arg Glu Lys Arg Arg Glu Ile Val Ly - #s Ala Val Gln Arg Arg 50             - #     55             - #     60 - - Gly Asp Val Ala Phe Asp Ala Phe Tyr Asp Al - #a Leu Arg Ser Thr Gly 65                 - # 70                 - # 75                 - # 80 - - His Glu Gly Leu Ala Glu Val Leu Glu Pro Le - #u Ala Arg Ser Val Asp 85 - #                 90 - #                 95 - - Ser Asn Ala Val Glu Phe Glu Cys Pro Met Se - #r Pro Ala Ser His Arg 100      - #           105      - #           110 - - Arg Ser Arg Ala Leu Ser Pro Ala Gly Tyr Th - #r Ser Pro Thr Arg Val 115          - #       120          - #       125 - - His Arg Asp Ser Val Ser Ser Val Ser Ser Ph - #e Thr Ser Tyr Gln Asp 130              - #   135              - #   140 - - Ile Tyr Ser Arg Ala Arg Ser Arg Ser Arg Se - #r Arg Ala Leu His Ser 145                 1 - #50                 1 - #55                 1 - #60 - - Ser Asp Arg His Asn Tyr Ser Ser Pro Pro Va - #l Asn Ala Phe Pro Ser 165  - #               170  - #               175 - - Gln Pro Ser Ser Ala Asn Ser Ser Phe Thr Gl - #y Cys Ser Ser Leu Gly 180      - #           185      - #           190 - - Tyr Ser Ser Ser Arg Asn Arg Ser Phe Ser Ly - #s Ala Ser Gly Pro Thr 195          - #       200          - #       205 - - Gln Tyr Ile Phe His Glu Glu Asp Met Asn Ph - #e Val Asp Ala Pro Thr 210              - #   215              - #   220 - - Ile Ser Arg Val Phe Asp Glu Lys Thr Met Ty - #r Arg Asn Phe Ser Ser 225                 2 - #30                 2 - #35                 2 - #40 - - Pro Arg Gly Met Cys Leu Ile Ile Asn Asn Gl - #u His Phe Glu Gln Met 245  - #               250  - #               255 - - Pro Thr Arg Asn Gly Thr Lys Ala Asp Lys As - #p Asn Leu Thr Asn Leu 260      - #           265      - #           270 - - Phe Arg Cys Met Gly Tyr Thr Val Ile Cys Ly - #s Asp Asn Leu Thr Gly 275          - #       280          - #       285 - - Arg Gly Met Leu Leu Thr Ile Arg Asp Phe Al - #a Lys His Glu Ser His 290              - #   295              - #   300 - - Gly Asp Ser Ala Ile Leu Val Ile Leu Ser Hi - #s Gly Glu Glu Asn Val 305                 3 - #10                 3 - #15                 3 - #20 - - Ile Ile Gly Val Asp Asp Ile Pro Ile Ser Th - #r His Glu Ile Tyr Asp 325  - #               330  - #               335 - - Leu Leu Asn Ala Ala Asn Ala Pro Arg Leu Al - #a Asn Lys Pro Lys Ile 340      - #           345      - #           350 - - Val Phe Val Gln Ala Cys Arg Gly Glu Arg Ar - #g Asp Asn Gly Phe Pro 355          - #       360          - #       365 - - Val Leu Asp Ser Val Asp Gly Val Pro Ala Ph - #e Leu Arg Arg Gly Trp 370              - #   375              - #   380 - - Asp Asn Arg Asp Gly Pro Leu Phe Asn Phe Le - #u Gly Cys Val Arg Pro 385                 3 - #90                 3 - #95                 4 - #00 - - Gln Val Gln Gln Val Trp Arg Lys Lys Pro Se - #r Gln Ala Asp Ile Leu 405  - #               410  - #               415 - - Ile Arg Tyr Ala Thr Thr Ala Gln Tyr Val Se - #r Trp Arg Asn Ser Ala 420      - #           425      - #           430 - - Arg Gly Ser Trp Phe Ile Gln Ala Val Cys Gl - #u Val Phe Ser Thr His 435          - #       440          - #       445 - - Ala Lys Asp Met Asp Val Val Glu Leu Leu Th - #r Glu Val Asn Lys Lys 450              - #   455              - #   460 - - Val Ala Cys Gly Phe Gln Thr Ser Gln Gly Se - #r Asn Ile Leu Lys Gln 465                 4 - #70                 4 - #75                 4 - #80 - - Met Pro Glu Met Thr Ser Arg Leu Leu Lys Ly - #s Phe Tyr Phe Trp Pro 485  - #               490  - #               495 - - Glu Ala Arg Asn Ser Ala Val 500 - -  - - (2) INFORMATION FOR SEQ ID NO:3: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 132 base - #pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3: - - GTATTAAGGA ATCACAAAAT TCTGAGAATG CGTACTGCGC AACATATTTG AC - #GGCAAAAT     60 - - ATCTCGTAGC GAAAACTACA GTAATTCTTT AAATGACTAC TGTAGCGCTT GT - #GTCGATTT    120 - - ACGGGCTCAA TT              - #                  - # - #      132 - -  - - (2) INFORMATION FOR SEQ ID NO:4: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 125 base - #pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4: - - AAAATTCAGA GAATGCGTAT TACAGTCATA TTTGGCGCGC AAAATATCTC GT - #AGCTAGAA     60 - - CTACAGTAAT CCTTTAAATG ACTACTGTAG CGTTGTGACG ATTTACGGGT TA - #TCAAAATT    120 - - CGAAA                 - #                  - #                  - #           125 - -  - - (2) INFORMATION FOR SEQ ID NO:5: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 116 base - #pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5: - - AAATTCTGAG AATGCGCATT ACTCAACATA TTTGACGCGC AAATATCTCG TA - #GCGAAAAT     60 - - ACAGTAACCC TTTAAATGAC TATTGTAGTG TCGATTTACG GGCTCGATTT TC - #GAAA 116 - -  - - (2) INFORMATION FOR SEQ ID NO:6: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 73 base - #pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6: - - TATCTTGAAG CGAAAACTAC TGTAACTCTT TAAAAGAGTA CTGTAGCGCT GG - #TGTCTGTT     60 - - TACGGAAATA ATT              - #                  - # - #      73 - -  - - (2) INFORMATION FOR SEQ ID NO:7: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 132 base - #pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7: - - GTATTACGGC AAGAAATAAT TATGAGAATG CCTATTGCGC ACCATAGTTG AC - #GCGCAAAA     60 - - TATCTCGTAG CGAAAACTAC AGTAACTCTT TGAATGACTA CTGTAGCGCT TG - #TTTCGATT    120 - - TACGGGCTCG TT              - #                  - # - #      132 - -  - - (2) INFORMATION FOR SEQ ID NO:8: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 111 base - #pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8: - - GTATAACGGT AACACACAAT TCTGAGAATG CGTATTGCAC AACACATTTG AC - #GCGCAAAA     60 - - TATCTCGTAG CGAAAACTAC AGTGATTCGC TGAATGAATA CGGTAGGGTC G - # 111 - -  - - (2) INFORMATION FOR SEQ ID NO:9: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 122 base - #pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9: - - CTATTACGGG AGTACAAAAT TCTGAGAATG CGTACTGCGC AACATATTTG AC - #GCGCAAAA     60 - - TATTTCGTAT CGAAAACTAC AGTAATTCGT TTATTGGCTA CTGTGCGTGT TG - #ATTTACGG    120 - - GC                  - #                  - #                  - # 122 - -  - - (2) INFORMATION FOR SEQ ID NO:10: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 124 base - #pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10: - - GGGAGCACAA AATTCTGACT ATGAGAATGC GTATAAGCAC AAAATATTTC GT - #AGCGAAAA     60 - - CTACAGTAAT TTGTCAAGGG ACTACTGTAG CTAGCGCTTG TGTCGATTTA CG - #GAGCTCGA    120 - - TTTT                 - #                  - #                  - # 124 - -  - - (2) INFORMATION FOR SEQ ID NO:11: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 74 base - #pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11: - - TATAGGAAAA ATTGAATGAT CAATTGCGCA AAATATTGAC AAACTACGTA AG - #TAGTAGTG     60 - - TTTTACGGTT GAAA              - #                  - # - #     74 - -  - - (2) INFORMATION FOR SEQ ID NO:12: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 270 base - #pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12: - - TCATTCAAGA TATGCTTATT AACACATATA ATTATCATTA ATGTGAATTT CT - #TGTAGAAA     60 - - TTTTGGGCTT TTCGTTCTAG TATGCTCTAC TTTTGAAATT GCTCAACGAA AA - #AATCATGT    120 - - GGTTTGTTCA TATGAATGAC GAAAAATAGC AATTTTTTAT ATATTTTCCC CT - #ATTCATGT    180 - - TGTGCAGAAA AATAGTAAAA AAGCGCATGC ATTTTTCGAC ATTTTTTACA TC - #GAACGACA    240 - - GCTCACTTCA CATGCTGAAG ACGAGAGACG         - #                  - # 270 - -  - - (2) INFORMATION FOR SEQ ID NO:13: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 281 base - #pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13: - - TCATTCAAGA TATGCTTATT AACATCTATA ATTATCAATA AAGGTAATAT CT - #TGAAGAAA     60 - - TTTTGGTTTT CGCTCTAATA TTCTCTACTT TTTAAGTTGC TCAACGAAAA AA - #TAATGGGG    120 - - TTAATCATGT GATGTTGAAA AATACAAAAA ATGTATTTTA ATACATTTTC CC - #CCTATTCA    180 - - TTTGTGCAGA AAAGTGTAAA AAAACGCATG CATTTTTTAC ATTATTCGAC AT - #TTTTTTAC    240 - - ATCGACCGAG ATCCCATTTC ACATGCTGAA GACGAGAGAC G    - # - #  281 - -  - - (2) INFORMATION FOR SEQ ID NO:14: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 226 base - #pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:14: - - TCATTCAAGA TATGCTTATT AACATATAAT TATCATAAGA ATTCTTGAGA AA - #TTTTGGTT     60 - - TTCGTCTATA TCTCTACTTT TAATTGCTCA ACGAAAAAAT CATGTGATGG AA - #AAATAAAT    120 - - TTTTATAATT TTCCCCTATT CATTTGTGCA GAAAATGTAA AAAACGCATG CA - #TTTTTCGA    180 - - CATTTTTTAC ATCGACGAAC CATTCACATG CTGAAGACGA GAGACG   - # 226 - -  - - (2) INFORMATION FOR SEQ ID NO:15: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 108 base - #pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both - -         (xi) SEQUENCE DESCRIPTION: SEQ - #ID NO:15: CTTCGAG AGTTTGAAAT TACAGTACTC CTTAAAGGCG CACACCCCAT TTGCA - #TTGGA 60 - - CCAAAAATTT GTCGTGTCGA GACCAGGTAC CGTAGTTTTT GTCGCAAA  - # 108 - -  - - (2) INFORMATION FOR SEQ ID NO:16: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 31 base - #pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:16: - - ACAAATTGTC GTGTCGAGAC CGGGCGCCAC A        - #                  - # 31 - -  - - (2) INFORMATION FOR SEQ ID NO:17: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 46 base - #pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:17: - - CAGCAACAAA TGTTTGAAAT TACAGTAATC TTTAAAGGCG CACACC   - # 46 - -  - - (2) INFORMATION FOR SEQ ID NO:18: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 49 base - #pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:18: - - AACAAAACTT TGTCGTGTCG AGACCGGGTA CCGTATTTTT AATTGCAAA  - # 49 - -  - - (2) INFORMATION FOR SEQ ID NO:19: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 44 base - #pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:19: - - CTGCAACGAA AGTCTGAAAT TACAGTACCC CTTAAAGGCG CATA   - # - # 44 - -  - - (2) INFORMATION FOR SEQ ID NO:20: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 95 base - #pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:20: - - GTTAGAAACT AGAGTACCTC TTAAAGGCGC ACATCCTTTC CCACCTATCG AA - #AATTTGTC     60 - - GTGTCGAGAC CGGGTAGCTA ATTTTATGCC AAAAA       - # - #       95 - -  - - (2) INFORMATION FOR SEQ ID NO:21: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 114 base - #pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:21: - - CAGCAACAAA AGTTTGAAAT TACAGTGCTC TTTAAAGGCA CACACCTTTT TA - #CATTTAAC     60 - - AAAAAAGTGT CGCTTCGAGA CCGGGTACCG TGTTTTTGGC GCAAAAATCG CT - #AT 114 - -  - - (2) INFORMATION FOR SEQ ID NO:22: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 114 base - #pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:22: - - CAGAAGCGAA AATTTGAAAT TACAGTACTC TTTAAACGCT CAACCCCGTT TC - #TATTCAAT     60 - - AGAAAGTTGT CGTTTCGAGA CCGGACACCG TATTTTTGGC GCAAAATATA CC - #TG 114 - -  - - (2) INFORMATION FOR SEQ ID NO:23: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 107 base - #pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:23: - - GATTGTTGAA AATTACAGTA ATCTTTAAAG GCGCACACAC GTTTGTATTT TA - #CAGAAAAT     60 - - TCTCGTTTCG AGACCGAACA CAGTATTTTT GGCGGAGAAA TTCTAAA   - # 107 - -  - - (2) INFORMATION FOR SEQ ID NO:24: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base - #pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:24: - - TTTGTCGTGT CGAGACCTGG            - #                  - # - # 20 - -  - - (2) INFORMATION FOR SEQ ID NO:25: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 103 base - #pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:25: - - TTTTTAAACT ACAGTACTCT TTAGGAGCGC ACATTTTTTC GCATTTAACA AA - #TTTTTGTC     60 - - GTGGCGAGAC CTGATACCGT ATTTTTAGGT CAAGATTACT AGG    - # - #103 - -  - - (2) INFORMATION FOR SEQ ID NO:26: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 42 base - #pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:26: - - ACCGTTTGAA ACTACAGTAC TCTTTAAAGG CGCGTTTGTC GT    - # - #  42 - -  - - (2) INFORMATION FOR SEQ ID NO:27: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 42 base - #pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:27: - - CGCTAAATAA GTTTAGCCAA TTTAATTCGC GAGACCCTTT AA    - # - #  42 - -  - - (2) INFORMATION FOR SEQ ID NO:28: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 77 base - #pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:28: - - AACCAATCAG CATCGTCGAT CTCCGCCCAC TTCATCGGAT TGGTTTGAAA GT - #GGGCGGAG     60 - - TGAATTGCTG ATTGGTC             - #                  - # - #   77 - -  - - (2) INFORMATION FOR SEQ ID NO:29: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 77 base - #pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:29: - - AACCAATTAG CGACTTCGGA ATTTCCATAC TTAATCTGAT TGGTTGAAGA AT - #GGGCAGAG     60 - - CGAATTGCTG ATTGGCC             - #                  - # - #   77 - -  - - (2) INFORMATION FOR SEQ ID NO:30: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 56 base - #pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:30: - - AACCAATAGC CTCGTCACTT ATCGATTGGT TAATGGGCGA GGAATTGCTG AT - #TGGC 56 - -  - - (2) INFORMATION FOR SEQ ID NO:31: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 59 base - #pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:31: - - TTTTAAGGAC ACAGAAAAAT AGGCAGAGGC TCCTTTTGCA AGCCTGCCGC GC - #GTCAACC      59 - -  - - (2) INFORMATION FOR SEQ ID NO:32: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 60 base - #pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:32: - - TTTCAAGCCG CACAGAAAAA GAGGCGGAGC GTCGTTTTGC AAACTTGCCG CG - #CGCCAACC     60 - -  - - (2) INFORMATION FOR SEQ ID NO:33: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 48 base - #pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:33: - - TTTAAGCACA GAAAAAAGGC GAGTCTTTTG CAACTGCCGC GCGCAACC  - # 48 - -  - - (2) INFORMATION FOR SEQ ID NO:34: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2482 base - #pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both - -     (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 16..1527 - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:34: - - AACCATCAGC CGAAG ATG ATG CGT CAA GAT AGA AGG - #AGC TTG CTA GAG AGG 51 Met - #Met Arg Gln Asp Arg Arg Ser Leu Leu Glu A - #rg - # 1               5  - #                10 - - AAC ATT ATG ATG TTC TCT AGT CAT CTA AAA GT - #C GAT GAA ATT CTC GAA 99 Asn Ile Met Met Phe Ser Ser His Leu Lys Va - #l Asp Glu Ile Leu Glu 15         - #         20         - #         25 - - GTT CTC ATC GCA AAA CAA GTG TTG AAT AGT GA - #T AAT GGA GAT ATG ATT 147 Val Leu Ile Ala Lys Gln Val Leu Asn Ser As - #p Asn Gly Asp Met Ile 30             - #     35             - #     40 - - AAT TCA TGT GGA ACG GTT CGC GAG AAG AGA CG - #G GAG ATC GTG AAA GCA 195 Asn Ser Cys Gly Thr Val Arg Glu Lys Arg Ar - #g Glu Ile Val Lys Ala 45                 - # 50                 - # 55                 - # 60 - - GTG CAA CGA CCG GGA GAT GTG GCG TTC GAC GC - #G TTT TAT GAT GCT CTT 243 Val Gln Arg Pro Gly Asp Val Ala Phe Asp Al - #a Phe Tyr Asp Ala Leu 65 - #                 70 - #                 75 - - CGC TCT ACG GGA CAC GAA GGA CTT GCT GAA GT - #T CTT GAA CCT CTC GCC 291 Arg Ser Thr Gly His Glu Gly Leu Ala Glu Va - #l Leu Glu Pro Leu Ala 80     - #             85     - #             90 - - AGA TCT GTT GAC TCG AAT GCT GTC GAA TTC GA - #G TGT CCA ATG TCA CCG 339 Arg Ser Val Asp Ser Asn Ala Val Glu Phe Gl - #u Cys Pro Met Ser Pro 95         - #        100         - #        105 - - GCA AGC CAT CGT CGG AGC CGC GCA TTG AGC CC - #C GCC GGC TAC ACT TCA 387 Ala Ser His Arg Arg Ser Arg Ala Leu Ser Pr - #o Ala Gly Tyr Thr Ser 110              - #   115              - #   120 - - CCG ACC CGA GTT CAC CGT GAC AGC GTC TCT TC - #A GTG TCA TCA TTC ACT 435 Pro Thr Arg Val His Arg Asp Ser Val Ser Se - #r Val Ser Ser Phe Thr 125                 1 - #30                 1 - #35                 1 - #40 - - TCT TAT CAG GAT ATC TAC TCA AGA GCA AGA TC - #T CGT TCT CGA TCG CGT      483 Ser Tyr Gln Asp Ile Tyr Ser Arg Ala Arg Se - #r Arg Ser Arg Ser Arg 145  - #               150  - #               155 - - GCA CTT CAT TCA TCG GAT CGA CAC AAT TAT TC - #A TCT CCT CCA GTC AAC 531 Ala Leu His Ser Ser Asp Arg His Asn Tyr Se - #r Ser Pro Pro Val Asn 160      - #           165      - #           170 - - GCA TTT CCC AGC CAA CCT TCA TCC GCC AAC TC - #T TCA TTC ACC GGA TGC 579 Ala Phe Pro Ser Gln Pro Ser Ser Ala Asn Se - #r Ser Phe Thr Gly Cys 175          - #       180          - #       185 - - TCT TCT CTC GGA TAC AGT TCA AGT CGT AAT CG - #C TCA TTC AGC AAA GCT 627 Ser Ser Leu Gly Tyr Ser Ser Ser Arg Asn Ar - #g Ser Phe Ser Lys Ala 190              - #   195              - #   200 - - TCT GGA CCA ACT CAA TAC ATA TTC CAT GAA GA - #G GAT ATG AAC TTT GTC 675 Ser Gly Pro Thr Gln Tyr Ile Phe His Glu Gl - #u Asp Met Asn Phe Val 205                 2 - #10                 2 - #15                 2 - #20 - - GAT GCA CCA ACC ATA AGC CGT GTT TTC GAC GA - #G AAA ACC ATG TAC AGA      723 Asp Ala Pro Thr Ile Ser Arg Val Phe Asp Gl - #u Lys Thr Met Tyr Arg 225  - #               230  - #               235 - - AAC TTC TCG AGT CCT CGT GGA ATG TGC CTC AT - #C ATA AAT AAT GAA CAC 771 Asn Phe Ser Ser Pro Arg Gly Met Cys Leu Il - #e Ile Asn Asn Glu His 240      - #           245      - #           250 - - TTT GAG CAG ATG CCA ACA CGG AAT GGT ACC AA - #G GCC GAC AAG GAC AAT 819 Phe Glu Gln Met Pro Thr Arg Asn Gly Thr Ly - #s Ala Asp Lys Asp Asn 255          - #       260          - #       265 - - CTT ACC AAT TTG TTC AGA TGC ATG GGC TAT AC - #G GTT ATT TGC AAG GAC 867 Leu Thr Asn Leu Phe Arg Cys Met Gly Tyr Th - #r Val Ile Cys Lys Asp 270              - #   275              - #   280 - - AAT CTG ACG GGA AGG GGA ATG CTC CTG ACA AT - #T CGA GAC TTT GCC AAA 915 Asn Leu Thr Gly Arg Gly Met Leu Leu Thr Il - #e Arg Asp Phe Ala Lys 285                 2 - #90                 2 - #95                 3 - #00 - - CAC GAA TCA CAC GGA GAT TCT GCG ATA CTC GT - #G ATT CTA TCA CAC GGA      963 His Glu Ser His Gly Asp Ser Ala Ile Leu Va - #l Ile Leu Ser His Gly 305  - #               310  - #               315 - - GAA GAG AAT GTG ATT ATT GGA GTT GAT GAT AT - #A CCG ATT AGT ACA CAC 1011 Glu Glu Asn Val Ile Ile Gly Val Asp Asp Il - #e Pro Ile Ser Thr His 320      - #           325      - #           330 - - GAG ATA TAT GAT CTT CTC AAC GCG GCA AAT GC - #T CCC CGT CTG GCG AAT 1059 Glu Ile Tyr Asp Leu Leu Asn Ala Ala Asn Al - #a Pro Arg Leu Ala Asn 335          - #       340          - #       345 - - AAG CCG AAA ATC GTT TTT GTG CAG GCT TGT CG - #A GGC GAA CGT CGT GAC 1107 Lys Pro Lys Ile Val Phe Val Gln Ala Cys Ar - #g Gly Glu Arg Arg Asp 350              - #   355              - #   360 - - AAT GGA TTC CCA GTC TTG GAT TCT GTC GAC GG - #A GTT CCT GCA TTT CTT 1155 Asn Gly Phe Pro Val Leu Asp Ser Val Asp Gl - #y Val Pro Ala Phe Leu 365                 3 - #70                 3 - #75                 3 - #80 - - CGT CGT GGA TGG GAC AAT CGA GAC GGG CCA TT - #G TTC AAT TTT CTT GGA     1203 Arg Arg Gly Trp Asp Asn Arg Asp Gly Pro Le - #u Phe Asn Phe Leu Gly 385  - #               390  - #               395 - - TGT GTG CGG CCG CAA GTT CAG CAA GTG TGG AG - #A AAG AAG CCG AGC CAA 1251 Cys Val Arg Pro Gln Val Gln Gln Val Trp Ar - #g Lys Lys Pro Ser Gln 400      - #           405      - #           410 - - GCT GAC ATT CTG ATT CGA TAC GCA ACG ACA GC - #T CAA TAT GTT TCG TGG 1299 Ala Asp Ile Leu Ile Arg Tyr Ala Thr Thr Al - #a Gln Tyr Val Ser Trp 415          - #       420          - #       425 - - AGA AAC AGT GCT CGT GGA TCA TGG TTC ATT CA - #A GCC GTC TGT GAA GTG 1347 Arg Asn Ser Ala Arg Gly Ser Trp Phe Ile Gl - #n Ala Val Cys Glu Val 430              - #   435              - #   440 - - TTC TCG ACA CAC GCA AAG GAT ATG GAT GTT GT - #T GAG CTG CTG ACT GAA 1395 Phe Ser Thr His Ala Lys Asp Met Asp Val Va - #l Glu Leu Leu Thr Glu 445                 4 - #50                 4 - #55                 4 - #60 - - GTC AAT AAG AAG GTC GCT TGT GGA TTT CAG AC - #A TCA CAG GGA TCG AAT     1443 Val Asn Lys Lys Val Ala Cys Gly Phe Gln Th - #r Ser Gln Gly Ser Asn 465  - #               470  - #               475 - - ATT TTG AAA CAG ATG CCA GAG ATG ACA TCC CG - #C CTG CTC AAA AAG TTC 1491 Ile Leu Lys Gln Met Pro Glu Met Thr Ser Ar - #g Leu Leu Lys Lys Phe 480      - #           485      - #           490 - - TAC TTT TGG CCG GAA GCA CGA AAC TCT GCC GT - #C TAAAATTCAC TCGTGATTC A   1544 Tyr Phe Trp Pro Glu Ala Arg Asn Ser Ala Va - #l 495          - #       500 - - TTGCCCAATT GATAATTGTC TGTATCTTCT CCCCCAGTTC TCTTTCGCCC AA - #TTAGTTTA   1604 - - AAACCATGTG TATATTGTTA TCCTATACTC ATTTCACTTT ATCATTCTAT CA - #TTTCTCTT   1664 - - CCCATTTTCA CACATTTCCA TTTCTCTACG ATAATCTAAA ATTATGACGT TT - #GTGTCTCG   1724 - - AACGCATAAT AATTTTAATA ACTCGTTTTG AATTTGATTA GTTGTTGTGC CC - #AGTATATA   1784 - - TGTATGTACT ATGCTTCTAT CAACAAAATA GTTTCATAGA TCATCACCCC AA - #CCCCACCA   1844 - - ACCTACCGTA CCATATTCAT TTTTGCCGGG AATCAATTTC GATTAATTTT AA - #CCTATTTT   1904 - - TTCGCCACAA AAAATCTAAT ATTTGAATTA ACGAATAGCA TTCCCATCTC TC - #CCGTGCCG   1964 - - GAACTCCCGG CCTTTTAAAG TTCGGAACAT TTGGCCAATT ATGTATAAAA TT - #TTGTAGGT   2024 - - CCCCCCCATC ATTTCCCGCC CATCATCTCA AATTGCATTC TTTTTTCGCC GT - #GATATCCC   2084 - - GATTCTGGTC AGCAAAGATC TTTCTCATAG CCCATTCCAT TCGAGCTTTC TA - #ATAGGAAT   2144 - - TTGAAAATTT TCGAAATTCC AGTAAATAAT ATTGGAAAAT GGATTTTTCG AG - #TTTTCAGC   2204 - - AACACAAATT TACTTGAAAC CCCATTTTCC AAAATTTCAA TTTTTTCAAA TT - #TCCCGCTA   2264 - - TCTTCCAAAA TACTCTTGTA CGTTTATTAT ATTTCCCTCG TTTTTCTTCG AT - #TCCTCCTC   2324 - - TCCGCGCACC CAATAAGTTT TATATATGTT GAGATTTATA TAGCTTGTTA TT - #ATAATTAT   2384 - - ATATTTATAG ATTATTATAG TTGCTTTTCT CGCCGTATGT TTGTGTGTGT GT - #GATTGGTA   2444 - - TACATAGATA AAAGAAAACA AGGTAAAAAA AGGAATTC      - # - #   2482 - -  - - (2) INFORMATION FOR SEQ ID NO:35: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 503 amino - #acids (B) TYPE: amino acid (D) TOPOLOGY: linear - -     (ii) MOLECULE TYPE: protein - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:35: - - Met Met Arg Gln Asp Arg Arg Ser Leu Leu Gl - #u Arg Asn Ile Met Met 1               5 - #                 10 - #                 15 - - Phe Ser Ser His Leu Lys Val Asp Glu Ile Le - #u Glu Val Leu Ile Ala 20     - #             25     - #             30 - - Lys Gln Val Leu Asn Ser Asp Asn Gly Asp Me - #t Ile Asn Ser Cys Gly 35         - #         40         - #         45 - - Thr Val Arg Glu Lys Arg Arg Glu Ile Val Ly - #s Ala Val Gln Arg Pro 50             - #     55             - #     60 - - Gly Asp Val Ala Phe Asp Ala Phe Tyr Asp Al - #a Leu Arg Ser Thr Gly 65                 - # 70                 - # 75                 - # 80 - - His Glu Gly Leu Ala Glu Val Leu Glu Pro Le - #u Ala Arg Ser Val Asp 85 - #                 90 - #                 95 - - Ser Asn Ala Val Glu Phe Glu Cys Pro Met Se - #r Pro Ala Ser His Arg 100      - #           105      - #           110 - - Arg Ser Arg Ala Leu Ser Pro Ala Gly Tyr Th - #r Ser Pro Thr Arg Val 115          - #       120          - #       125 - - His Arg Asp Ser Val Ser Ser Val Ser Ser Ph - #e Thr Ser Tyr Gln Asp 130              - #   135              - #   140 - - Ile Tyr Ser Arg Ala Arg Ser Arg Ser Arg Se - #r Arg Ala Leu His Ser 145                 1 - #50                 1 - #55                 1 - #60 - - Ser Asp Arg His Asn Tyr Ser Ser Pro Pro Va - #l Asn Ala Phe Pro Ser 165  - #               170  - #               175 - - Gln Pro Ser Ser Ala Asn Ser Ser Phe Thr Gl - #y Cys Ser Ser Leu Gly 180      - #           185      - #           190 - - Tyr Ser Ser Ser Arg Asn Arg Ser Phe Ser Ly - #s Ala Ser Gly Pro Thr 195          - #       200          - #       205 - - Gln Tyr Ile Phe His Glu Glu Asp Met Asn Ph - #e Val Asp Ala Pro Thr 210              - #   215              - #   220 - - Ile Ser Arg Val Phe Asp Glu Lys Thr Met Ty - #r Arg Asn Phe Ser Ser 225                 2 - #30                 2 - #35                 2 - #40 - - Pro Arg Gly Met Cys Leu Ile Ile Asn Asn Gl - #u His Phe Glu Gln Met 245  - #               250  - #               255 - - Pro Thr Arg Asn Gly Thr Lys Ala Asp Lys As - #p Asn Leu Thr Asn Leu 260      - #           265      - #           270 - - Phe Arg Cys Met Gly Tyr Thr Val Ile Cys Ly - #s Asp Asn Leu Thr Gly 275          - #       280          - #       285 - - Arg Gly Met Leu Leu Thr Ile Arg Asp Phe Al - #a Lys His Glu Ser His 290              - #   295              - #   300 - - Gly Asp Ser Ala Ile Leu Val Ile Leu Ser Hi - #s Gly Glu Glu Asn Val 305                 3 - #10                 3 - #15                 3 - #20 - - Ile Ile Gly Val Asp Asp Ile Pro Ile Ser Th - #r His Glu Ile Tyr Asp 325  - #               330  - #               335 - - Leu Leu Asn Ala Ala Asn Ala Pro Arg Leu Al - #a Asn Lys Pro Lys Ile 340      - #           345      - #           350 - - Val Phe Val Gln Ala Cys Arg Gly Glu Arg Ar - #g Asp Asn Gly Phe Pro 355          - #       360          - #       365 - - Val Leu Asp Ser Val Asp Gly Val Pro Ala Ph - #e Leu Arg Arg Gly Trp 370              - #   375              - #   380 - - Asp Asn Arg Asp Gly Pro Leu Phe Asn Phe Le - #u Gly Cys Val Arg Pro 385                 3 - #90                 3 - #95                 4 - #00 - - Gln Val Gln Gln Val Trp Arg Lys Lys Pro Se - #r Gln Ala Asp Ile Leu 405  - #               410  - #               415 - - Ile Arg Tyr Ala Thr Thr Ala Gln Tyr Val Se - #r Trp Arg Asn Ser Ala 420      - #           425      - #           430 - - Arg Gly Ser Trp Phe Ile Gln Ala Val Cys Gl - #u Val Phe Ser Thr His 435          - #       440          - #       445 - - Ala Lys Asp Met Asp Val Val Glu Leu Leu Th - #r Glu Val Asn Lys Lys 450              - #   455              - #   460 - - Val Ala Cys Gly Phe Gln Thr Ser Gln Gly Se - #r Asn Ile Leu Lys Gln 465                 4 - #70                 4 - #75                 4 - #80 - - Met Pro Glu Met Thr Ser Arg Leu Leu Lys Ly - #s Phe Tyr Phe Trp Pro 485  - #               490  - #               495 - - Glu Ala Arg Asn Ser Ala Val 500 - -  - - (2) INFORMATION FOR SEQ ID NO:36: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 503 amino - #acids (B) TYPE: amino acid (D) TOPOLOGY: both - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:36: - - Met Met Arg Gln Asp Arg Trp Ser Leu Leu Gl - #u Arg Asn Ile Leu Glu 1               5   - #                10  - #                15 - - Phe Ser Ser Lys Leu Gln Ala Asp Leu Ile Le - #u Asp Val Leu Ile Ala 20      - #            25      - #            30 - - Lys Gln Val Leu Asn Ser Asp Asn Gly Asp Me - #t Ile Asn Ser Cys Arg 35          - #        40          - #        45 - - Thr Glu Arg Asp Asn Glu Lys Glu Ile Val Ly - #s Ala Val Gln Arg Arg 50              - #    55              - #    60 - - Gly Asp Glu Ala Phe Asp Ala Phe Tyr Asp Al - #a Leu Arg Asp Thr Gly 65                  - #70                  - #75                  - #80 - - His Asn Asp Leu Ala Asp Val Leu Met Pro Le - #u Ser Arg Pro Asn Pro 85  - #                90  - #                95 - - Val Pro Met Glu Cys Pro Met Ser Pro Ser Se - #r His Arg Arg Ser Arg 100      - #           105      - #           110 - - Ala Leu Ser Pro Pro Gly Tyr Ala Ser Pro Th - #r Arg Val His Arg Asp 115          - #       120          - #       125 - - Ser Ile Ser Ser Val Ser Ser Phe Thr Ser Th - #r Tyr Gln Asp Val Tyr 130              - #   135              - #   140 - - Ser Arg Ala Arg Ser Ser Ser Arg Ser Ser Ar - #g Pro Leu Gln Ser Ser 145                 1 - #50                 1 - #55                 1 - #60 - - Asp Arg His Asn Tyr Met Ser Ala Ala Thr Se - #r Phe Pro Ser Gln Pro 165  - #               170  - #               175 - - Ser Ser Ala Asn Ser Ser Phe Thr Gly Cys Al - #a Ser Leu Gly Tyr Ser 180      - #           185      - #           190 - - Ser Ser Arg Asn Arg Ser Phe Ser Lys Thr Se - #r Ala Gln Ser Gln Tyr 195          - #       200          - #       205 - - Ile Phe His Glu Glu Asp Met Asn Tyr Val As - #p Ala Pro Thr Ile His 210              - #   215              - #   220 - - Arg Val Phe Asp Glu Lys Thr Met Tyr Arg As - #n Phe Ser Ser Pro Arg 225                 2 - #30                 2 - #35                 2 - #40 - - Gly Leu Cys Leu Ile Ile Asn Asn Glu His Ph - #e Glu Gln Met Pro Thr 245  - #               250  - #               255 - - Arg Asn Gly Thr Lys Ala Asp Lys Asp Asn Le - #u Thr Asn Ile Phe Arg 260      - #           265      - #           270 - - Cys Met Gly Tyr Thr Val Ile Cys Lys Asp As - #n Leu Thr Gly Arg Glu 275          - #       280          - #       285 - - Met Leu Ser Thr Ile Arg Ser Phe Gly Arg As - #n Asp Met His Gly Asp 290              - #   295              - #   300 - - Ser Ala Ile Leu Val Ile Leu Ser His Gly Gl - #u Glu Asn Val Ile Ile 305                 3 - #10                 3 - #15                 3 - #20 - - Gly Val Asp Asp Val Ser Val Asn Val His Gl - #u Ile Tyr Asp Leu Leu 325  - #               330  - #               335 - - Asn Ala Ala Asn Ala Pro Arg Leu Ala Asn Ly - #s Pro Lys Leu Val Phe 340      - #           345      - #           350 - - Val Gln Ala Cys Arg Gly Glu Arg Arg Asp As - #n Gly Phe Pro Val Leu 355          - #       360          - #       365 - - Asp Ser Val Asp Gly Val Pro Ser Leu Ile Ar - #g Arg Gly Trp Asp Asn 370              - #   375              - #   380 - - Arg Asp Gly Pro Leu Phe Asn Phe Leu Gly Cy - #s Val Arg Pro Gln Val 385                 3 - #90                 3 - #95                 4 - #00 - - Gln Gln Val Trp Arg Lys Lys Pro Ser Gln Al - #a Asp Met Leu Ile Ala 405  - #               410  - #               415 - - Tyr Ala Thr Thr Ala Gln Tyr Val Ser Trp Ar - #g Asn Ser Ala Arg Gly 420      - #           425      - #           430 - - Ser Trp Phe Ile Gln Ala Val Cys Glu Val Ph - #e Ser Leu His Ala Lys 435          - #       440          - #       445 - - Asp Met Asp Val Val Glu Leu Leu Thr Glu Va - #l Asn Lys Lys Val Ala 450              - #   455              - #   460 - - Cys Gly Phe Gln Thr Ser Gln Gly Ser Asn Il - #e Leu Lys Gln Met Pro 465                 4 - #70                 4 - #75                 4 - #80 - - Glu Leu Thr Ser Arg Leu Leu Lys Lys Phe Ty - #r Phe Trp Pro Glu Asp 485  - #               490  - #               495 - - Arg Gly Arg Asn Ser Ala Val 500 - -  - - (2) INFORMATION FOR SEQ ID NO:37: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 497 amino - #acids (B) TYPE: amino acid (D) TOPOLOGY: both - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:37: - - Met Met Arg Gln Asp Arg Arg Asn Leu Leu Gl - #u Arg Asn Ile Leu Val 1               5   - #                10  - #                15 - - Phe Ser Asn Lys Leu Gln Ser Glu Gln Ile Le - #u Glu Val Leu Ile Ala 20      - #            25      - #            30 - - Lys Gln Ile Leu Asn Ala Asp Asn Gly Asp Va - #l Ile Asn Ser Cys Arg 35          - #        40          - #        45 - - Thr Glu Arg Asp Lys Arg Lys Glu Gln Val Ly - #s Ala Val Gln Arg Arg 50              - #    55              - #    60 - - Gly Asp Val Ala Phe Asp Arg Phe Tyr Asp Al - #a Leu Arg Asp Thr Gly 65                  - #70                  - #75                  - #80 - - His His Glu Leu Ala Ala Val Leu Glu Pro Le - #u Ala Arg Thr Asp Leu 85  - #                90  - #                95 - - Gly Cys Pro Met Ser Pro Ala Ser His Arg Ar - #g Ser Arg Ala Leu Ser 100      - #           105      - #           110 - - Pro Ser Thr Phe Ser Ser Pro Thr Arg Val Hi - #s Arg Asp Ser Val Ser 115          - #       120          - #       125 - - Ser Val Ser Ser Phe Thr Ser Thr Tyr Gln As - #p Val Tyr Thr Arg Ala 130              - #   135              - #   140 - - Arg Ser Thr Ser Arg Ser Ser Arg Pro Leu Hi - #s Thr Ser Asp Arg His 145                 1 - #50                 1 - #55                 1 - #60 - - Asn Tyr Val Ser Pro Ser Asn Ser Phe Gln Se - #r Gln Pro Ala Ser Ala 165  - #               170  - #               175 - - Asn Ser Ser Phe Thr Gly Ser Ser Ser Leu Gl - #y Tyr Ser Ser Ser Arg 180      - #           185      - #           190 - - Thr Arg Ser Tyr Ser Lys Ala Ser Ala His Se - #r Gln Tyr Ile Phe His 195          - #       200          - #       205 - - Glu Glu Asp Met Asn Tyr Val Asp Ala Pro Th - #r Ile His Arg Val Phe 210              - #   215              - #   220 - - Asp Glu Lys Thr Met Tyr Arg Asn Phe Ser Th - #r Pro Arg Gly Leu Cys 225                 2 - #30                 2 - #35                 2 - #40 - - Leu Ile Ile Asn Asn Glu His Phe Glu Gln Me - #t Pro Thr Arg Asn Gly 245  - #               250  - #               255 - - Thr Lys Pro Asp Lys Asp Asn Ile Ser Asn Le - #u Phe Arg Cys Met Gly 260      - #           265      - #           270 - - Tyr Ile Val His Cys Lys Asp Asn Leu Thr Gl - #y Arg Met Met Leu Thr 275          - #       280          - #       285 - - Ile Arg Asp Phe Ala Lys Asn Glu Thr His Gl - #y Asp Ser Ala Ile Leu 290              - #   295              - #   300 - - Val Ile Leu Ser His Gly Glu Glu Asn Val Il - #e Ile Gly Val Asp Asp 305                 3 - #10                 3 - #15                 3 - #20 - - Val Ser Val Asn Val His Glu Ile Tyr Asp Le - #u Leu Asn Ala Ala Asn 325  - #               330  - #               335 - - Ala Pro Arg Leu Ala Asn Lys Pro Lys Leu Va - #l Phe Val Gln Ala Cys 340      - #           345      - #           350 - - Arg Gly Glu Arg Arg Asp Val Gly Phe Pro Va - #l Leu Asp Ser Val Asp 355          - #       360          - #       365 - - Gly Val Pro Ala Leu Ile Arg Arg Gly Trp As - #p Lys Gly Asp Gly Pro 370              - #   375              - #   380 - - Asn Phe Leu Gly Cys Val Arg Pro Gln Ala Gl - #n Gln Val Trp Arg Lys 385                 3 - #90                 3 - #95                 4 - #00 - - Lys Pro Ser Gln Ala Asp Ile Leu Ile Ala Ty - #r Ala Thr Thr Ala Gln 405  - #               410  - #               415 - - Tyr Val Ser Trp Arg Asn Ser Ala Arg Gly Se - #r Trp Phe Ile Gln Ala 420      - #           425      - #           430 - - Val Cys Glu Val Phe Ser Leu His Ala Lys As - #p Met Asp Val Val Glu 435          - #       440          - #       445 - - Leu Leu Thr Glu Val Asn Lys Lys Val Ala Cy - #s Gly Phe Gln Thr Ser 450              - #   455              - #   460 - - Gln Gly Ala Asn Ile Leu Lys Gln Met Pro Gl - #u Leu Thr Ser Arg Leu 465                 4 - #70                 4 - #75                 4 - #80 - - Leu Lys Lys Phe Tyr Phe Trp Pro Glu Asp Ar - #g Asn Arg Ser Ser Ala 485  - #               490  - #               495 - - Val - -  - - (2) INFORMATION FOR SEQ ID NO:38: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 402 amino - #acids (B) TYPE: amino acid (D) TOPOLOGY: both - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:38: - - Met Ala Asp Lys Ile Leu Arg Ala Lys Arg Ly - #s Gln Phe Ile Asn Ser 1               5   - #                10  - #                15 - - Val Ser Ile Gly Thr Ile Asn Gly Leu Leu As - #p Glu Leu Leu Glu Lys 20      - #            25      - #            30 - - Arg Val Leu Asn Gln Glu Glu Met Asp Lys Il - #e Lys Leu Ala Asn Ile 35          - #        40          - #        45 - - Thr Ala Met Asp Lys Ala Arg Asp Leu Cys As - #p His Val Ser Lys Lys 50              - #    55              - #    60 - - Gly Pro Gln Ala Ser Gln Ile Phe Ile Thr Ty - #r Ile Cys Asn Glu Asp 65                  - #70                  - #75                  - #80 - - Cys Tyr Leu Ala Gly Ile Leu Glu Leu Gln Se - #r Ala Pro Ser Ala Glu 85  - #                90  - #                95 - - Thr Phe Val Ala Thr Glu Asp Ser Lys Gly Gl - #y His Pro Ser Ser Ser 100      - #           105      - #           110 - - Glu Thr Lys Glu Glu Gln Asn Lys Glu Asp Gl - #y Thr Phe Pro Gly Leu 115          - #       120          - #       125 - - Thr Gly Thr Leu Lys Phe Cys Pro Leu Glu Ly - #s Ala Gln Lys Leu Trp 130              - #   135              - #   140 - - Lys Glu Asn Pro Ser Glu Ile Tyr Pro Ile Me - #t Asn Thr Thr Thr Arg 145                 1 - #50                 1 - #55                 1 - #60 - - Thr Arg Leu Ala Leu Ile Ile Cys Asn Thr Gl - #u Phe Gln His Leu Ser 165  - #               170  - #               175 - - Pro Arg Val Gly Ala Gln Val Asp Leu Arg Gl - #u Met Lys Leu Leu Leu 180      - #           185      - #           190 - - Glu Asp Leu Gly Tyr Thr Val Lys Val Lys Gl - #u Asn Leu Thr Ala Leu 195          - #       200          - #       205 - - Glu Met Val Lys Glu Val Lys Glu Phe Ala Al - #a Cys Pro Glu His Lys 210              - #   215              - #   220 - - Thr Ser Asp Ser Thr Phe Leu Val Phe Met Se - #r His Gly Ile Gln Glu 225                 2 - #30                 2 - #35                 2 - #40 - - Gly Ile Cys Gly Thr Thr Tyr Ser Asn Glu Va - #l Ser Asp Ile Leu Lys 245  - #               250  - #               255 - - Val Asp Thr Ile Phe Gln Met Met Asn Thr Le - #u Lys Cys Pro Ser Leu 260      - #           265      - #           270 - - Lys Asp Lys Pro Lys Val Ile Ile Ile Gln Al - #a Cys Arg Gly Glu Lys 275          - #       280          - #       285 - - Gln Gly Val Val Leu Leu Lys Asp Ser Val Ar - #g Asp Ser Glu Glu Asp 290              - #   295              - #   300 - - Phe Leu Thr Asp Ala Ile Phe Glu Asp Asp Gl - #y Ile Lys Lys Ala His 305                 3 - #10                 3 - #15                 3 - #20 - - Ile Glu Lys Asp Phe Ile Ala Phe Cys Ser Se - #r Thr Pro Asp Asn Val 325  - #               330  - #               335 - - Ser Trp Arg His Pro Val Arg Gly Ser Leu Ph - #e Ile Glu Ser Leu Ile 340      - #           345      - #           350 - - Lys His Met Lys Glu Tyr Ala Trp Ser Cys As - #p Leu Glu Asp Ile Phe 355          - #       360          - #       365 - - Arg Lys Val Arg Phe Ser Phe Glu Gln Pro Gl - #u Phe Arg Leu Gln Met 370              - #   375              - #   380 - - Pro Thr Ala Asp Arg Val Thr Leu Ile Lys Ar - #g Phe Tyr Leu Phe Pro 385                 3 - #90                 3 - #95                 4 - #00 - - Gly His - -  - - (2) INFORMATION FOR SEQ ID NO:39: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 404 amino - #acids (B) TYPE: amino acid (D) TOPOLOGY: both - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:39: - - Met Ala Asp Lys Val Leu Lys Glu Lys Arg Ly - #s Leu Phe Ile Arg Ser 1               5   - #                10  - #                15 - - Met Gly Glu Gly Thr Ile Asn Gly Leu Leu As - #p Glu Leu Leu Gln Thr 20      - #            25      - #            30 - - Arg Val Leu Asn Lys Glu Glu Met Glu Lys Va - #l Lys Arg Glu Asn Ala 35          - #        40          - #        45 - - Thr Val Met Asp Lys Thr Arg Ala Leu Ile As - #p Ser Val Ile Pro Lys 50              - #    55              - #    60 - - Gly Ala Gln Ala Cys Gln Ile Cys Ile Thr Ty - #r Ile Cys Glu Glu Asp 65                  - #70                  - #75                  - #80 - - Ser Tyr Leu Ala Gly Thr Leu Gly Leu Ser Al - #a Asp Gln Thr Ser Gly 85  - #                90  - #                95 - - Asn Tyr Leu Asn Met Gln Asp Ser Gln Gly Va - #l Ile Ser Ser Phe Pro 100      - #           105      - #           110 - - Ala Pro Gln Ala Val Gln Asp Asn Pro Ala Me - #t Pro Thr Ser Ser Gly 115          - #       120          - #       125 - - Ser Glu Gly Asn Val Lys Leu Cys Ser Ile Gl - #u Glu Ala Gln Arg Ile 130              - #   135              - #   140 - - Trp Lys Gln Lys Ser Ala Glu Ile Tyr Pro Il - #e Met Asp Lys Ser Ser 145                 1 - #50                 1 - #55                 1 - #60 - - Arg Thr Arg Leu Ala Leu Ile Ile Cys Asn Ph - #e Glu Phe Asp Ser Ile 165  - #               170  - #               175 - - Pro Arg Arg Thr Gly Ala Glu Val Asp Ile Th - #r Gly Met Thr Met Leu 180      - #           185      - #           190 - - Leu Gln Asn Leu Gly Tyr Ser Val Asp Val Ly - #s Lys Asn Leu Thr Ala 195          - #       200          - #       205 - - Ser Asp Met Thr Thr Glu Leu Glu Ala Phe Al - #a His Arg Pro Glu His 210          - #       215          - #       220          - #225 - - Lys Thr Ser Asp Ser Thr Phe Leu Val Phe Me - #t Ser His Gly Ile Arg 230  - #               235  - #               240 - - Glu Gly Ile Cys Gly Lys Lys His Ser Glu Gl - #n Val Pro Asp Ile Leu 245      - #           250      - #           255 - - Gln Leu Asn Ala Ile Phe Asn Met Leu Asn Th - #r Lys Asn Cys Pro Ser 260          - #       265          - #       270 - - Leu Lys Asp Lys Pro Lys Val Ile Ile Ile Gl - #n Ala Cys Arg Gly Asp 275              - #   280              - #   285 - - Ser Pro Gly Val Val Trp Phe Lys Asp Ser Va - #l Gly Val Ser Gly Asn 290                 2 - #95                 3 - #00                 3 - #05 - - Leu Ser Leu Pro Thr Thr Glu Glu Phe Glu As - #p Asp Ala Ile Lys Lys 310  - #               315  - #               320 - - Ala His Ile Glu Lys Asp Phe Ile Ala Phe Cy - #s Ser Ser Thr Pro Asp 325      - #           330      - #           335 - - Asn Val Ser Trp Arg His Pro Thr Met Gly Se - #r Val Phe Ile Gly Arg 340          - #       345          - #       350 - - Leu Ile Glu His Met Gln Glu Tyr Ala Cys Se - #r Cys Asp Val Glu Glu 355              - #   360              - #   365 - - Ile Phe Arg Lys Val Arg Phe Ser Phe Glu Gl - #n Pro Asp Gly Arg Ala 370                 3 - #75                 3 - #80                 3 - #85 - - Gln Met Pro Thr Thr Glu Arg Val Thr Leu Th - #r Arg Cys Phe Tyr Leu 390  - #               395  - #               400 - - Phe Pro Gly His - -  - - (2) INFORMATION FOR SEQ ID NO:40: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 171 amino - #acids (B) TYPE: amino acid (D) TOPOLOGY: both - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:40: - - Met Leu Thr Val Gln Val Tyr Arg Thr Ser Gl - #n Lys Cys Ser Ser Ser 1               5   - #                10  - #                15 - - Lys His Val Val Glu Val Ile Leu Asp Pro Le - #u Gly Thr Ser Phe Cys 20      - #            25      - #            30 - - Ser Leu Leu Pro Pro Pro Leu Leu Leu Tyr Gl - #u Thr Asp Arg Gly Val 35          - #        40          - #        45 - - Asp Gln Gln Asp Gly Lys Asn His Thr Gln Se - #r Pro Gly Cys Glu Glu 50              - #    55              - #    60 - - Ser Asp Ala Gly Lys Glu Glu Leu Met Lys Me - #t Arg Leu Pro Thr Arg 65                  - #70                  - #75                  - #80 - - Ser Asp Met Ile Cys Gly Tyr Ala Cys Leu Ly - #s Gly Asn Ala Ala Met 85  - #                90  - #                95 - - Arg Asn Thr Lys Arg Gly Ser Trp Tyr Ile Gl - #u Ala Leu Thr Gln Val 100      - #           105      - #           110 - - Phe Ser Glu Arg Ala Cys Asp Met His Val Al - #a Asp Met Leu Val Lys 115          - #       120          - #       125 - - Val Asn Ala Leu Ile Lys Glu Arg Glu Gly Ty - #r Ala Pro Gly Thr Glu 130              - #   135              - #   140 - - Phe His Arg Cys Lys Glu Met Ser Glu Tyr Cy - #s Ser Thr Leu Cys Gln 145                 1 - #50                 1 - #55                 1 - #60 - - Gln Leu Tyr Leu Phe Pro Gly Tyr Pro Pro Th - #r 165  - #               170 - -  - - (2) INFORMATION FOR SEQ ID NO:41: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1350 base - #pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both - -     (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 35..1156 - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:41: - - TCTTCACAGT GCGAAAGAAC TGAGGCTTTT TCTC ATG GCT GAA A - #AC AAA CAC 52 - #                  - #  Met Ala Glu Asn Lys His - #                  - #    1              - # 5 - - CCT GAC AAA CCA CTT AAG GTG TTG GAA CAG CT - #G GGC AAA GAA GTC CTT 100 Pro Asp Lys Pro Leu Lys Val Leu Glu Gln Le - #u Gly Lys Glu Val Leu 10     - #             15     - #             20 - - ACG GAG TAC CTA GAA AAA TTA GTA CAA AGC AA - #T GTA CTG AAA TTA AAG 148 Thr Glu Tyr Leu Glu Lys Leu Val Gln Ser As - #n Val Leu Lys Leu Lys 25         - #         30         - #         35 - - GAG GAA GAT AAA CAA AAA TTT AAC AAT GCT GA - #A CGC AGT GAC AAG CGT 196 Glu Glu Asp Lys Gln Lys Phe Asn Asn Ala Gl - #u Arg Ser Asp Lys Arg 40             - #     45             - #     50 - - TGG GTT TTT GTA GAT GCC ATG AAA AAG AAA CA - #C AGC AAA GTA GGT GAA 244 Trp Val Phe Val Asp Ala Met Lys Lys Lys Hi - #s Ser Lys Val Gly Glu 55                 - # 60                 - # 65                 - # 70 - - ATG CTT CTC CAG ACA TTC TTC AGT GTG GAC CC - #A GGC AGC CAC CAT GGT 292 Met Leu Leu Gln Thr Phe Phe Ser Val Asp Pr - #o Gly Ser His His Gly 75 - #                 80 - #                 85 - - GAA GCT AAT CTG GAA ATG GAG GAA CCA GAA GA - #A TCA TTG AAC ACT CTC 340 Glu Ala Asn Leu Glu Met Glu Glu Pro Glu Gl - #u Ser Leu Asn Thr Leu 90     - #             95     - #            100 - - AAG CTT TGT TCC CCT GAA GAG TTC ACA AGG CT - #T TGC AGA GAA AAG ACA 388 Lys Leu Cys Ser Pro Glu Glu Phe Thr Arg Le - #u Cys Arg Glu Lys Thr 105          - #       110          - #       115 - - CAA GAA ATT TAC CCA ATA AAG GAG GCC AAT GG - #C CGT ACA CGA AAG GCT 436 Gln Glu Ile Tyr Pro Ile Lys Glu Ala Asn Gl - #y Arg Thr Arg Lys Ala 120              - #   125              - #   130 - - CTT ATC ATA TGC AAT ACA GAG TTC AAA CAT CT - #C TCA CTG AGG TAT GGG 484 Leu Ile Ile Cys Asn Thr Glu Phe Lys His Le - #u Ser Leu Arg Tyr Gly 135                 1 - #40                 1 - #45                 1 - #50 - - GCT AAA TTT GAC ATC ATT GGT ATG AAA GGC CT - #T CTT GAA GAC TTA GGC      532 Ala Lys Phe Asp Ile Ile Gly Met Lys Gly Le - #u Leu Glu Asp Leu Gly 155  - #               160  - #               165 - - TAC GAT GTG GTG GTG AAA GAG GAG CTT ACA GC - #A GAG GGC ATG GAG TCA 580 Tyr Asp Val Val Val Lys Glu Glu Leu Thr Al - #a Glu Gly Met Glu Ser 170      - #           175      - #           180 - - GAG ATG AAA GAC TTT GCT GCA CTC TCA GAA CA - #C CAG ACA TCA GAC AGC 628 Glu Met Lys Asp Phe Ala Ala Leu Ser Glu Hi - #s Gln Thr Ser Asp Ser 185          - #       190          - #       195 - - ACA TTC CTG GTG CTA ATG TCT CAT GGC ACA CT - #G CAT GGC ATT TGT GGA 676 Thr Phe Leu Val Leu Met Ser His Gly Thr Le - #u His Gly Ile Cys Gly 200              - #   205              - #   210 - - ACA ATG CAC AGT GAA AAA ACT CCA GAT GTG CT - #A CAG TAT GAT ACC ATC 724 Thr Met His Ser Glu Lys Thr Pro Asp Val Le - #u Gln Tyr Asp Thr Ile 215                 2 - #20                 2 - #25                 2 - #30 - - TAT CAG ATA TTC AAC AAT TGC CAC TGT CCA GG - #T CTA CGA GAC AAA CCC      772 Tyr Gln Ile Phe Asn Asn Cys His Cys Pro Gl - #y Leu Arg Asp Lys Pro 235  - #               240  - #               245 - - AAA GTC ATC ATT GTG CAG GCC TGC AGA GGT GG - #G AAC TCT GGA GAA ATG 820 Lys Val Ile Ile Val Gln Ala Cys Arg Gly Gl - #y Asn Ser Gly Glu Met 250      - #           255      - #           260 - - TGG ATC AGA GAG TCT TCA AAA CCC CAG TTG TG - #C AGA GGT GTA GAT CTA 868 Trp Ile Arg Glu Ser Ser Lys Pro Gln Leu Cy - #s Arg Gly Val Asp Leu 265          - #       270          - #       275 - - CCT AGG AAT ATG GAA GCT GAT GCT GTC AAG CT - #G AGC CAC GTG GAG AAG 916 Pro Arg Asn Met Glu Ala Asp Ala Val Lys Le - #u Ser His Val Glu Lys 280              - #   285              - #   290 - - GAC TTC ATT GCC TTC TAC GCT ACA ACC CCA CA - #T CAC TTG TCC TAC CGA 964 Asp Phe Ile Ala Phe Tyr Ala Thr Thr Pro Hi - #s His Leu Ser Tyr Arg 295                 3 - #00                 3 - #05                 3 - #10 - - GAC AAA ACA GGA GGC TCT TAC TTC ATC ACT AG - #A CTC ATT TCC TGC TTC     1012 Asp Lys Thr Gly Gly Ser Tyr Phe Ile Thr Ar - #g Leu Ile Ser Cys Phe 315  - #               320  - #               325 - - CGG AAA CAT GCT TGC TCT TGT CAT CTC TTT GA - #T ATA TTC CTG AAG GTG 1060 Arg Lys His Ala Cys Ser Cys His Leu Phe As - #p Ile Phe Leu Lys Val 330      - #           335      - #           340 - - CAA CAA TCA TTT GAA AAG GCA AGT ATT CAT TC - #C CAG ATG CCC ACC ATT 1108 Gln Gln Ser Phe Glu Lys Ala Ser Ile His Se - #r Gln Met Pro Thr Ile 345          - #       350          - #       355 - - GAT CGG GCA ACC TTG ACA AGA TAT TTC TAC CT - #C TTT CCT GGC AAC TGAGAACA1163 Asp Arg Ala Thr Leu Thr Arg Tyr Phe Tyr Le - #u Phe Pro Gly Asn 360              - #   365              - #   370 - - GCAACAAGCA ACTGAATCTC ATTTCTTCAG CTTGAAGAAG TGATCTTGGC CA - #AGGATCAC   1223 - - ATTCTATTCC TGAAATTCCA GAACTAGTGA AATTAAGGAA AGAATACTTA TG - #AATTCAAG   1283 - - ACCAGCCTAA GCAACACAGT GGGATTCTGT TCGATAGACA AGCAAACAAG CA - #AAAATAAA   1343 - - AAAAAAA                 - #                  - # - #        1350 - -  - - (2) INFORMATION FOR SEQ ID NO:42: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 373 amino - #acids (B) TYPE: amino acid (D) TOPOLOGY: linear - -     (ii) MOLECULE TYPE: protein - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:42: - - Met Ala Glu Asn Lys His Pro Asp Lys Pro Le - #u Lys Val Leu Glu Gln 1               5 - #                 10 - #                 15 - - Leu Gly Lys Glu Val Leu Thr Glu Tyr Leu Gl - #u Lys Leu Val Gln Ser 20     - #             25     - #             30 - - Asn Val Leu Lys Leu Lys Glu Glu Asp Lys Gl - #n Lys Phe Asn Asn Ala 35         - #         40         - #         45 - - Glu Arg Ser Asp Lys Arg Trp Val Phe Val As - #p Ala Met Lys Lys Lys 50             - #     55             - #     60 - - His Ser Lys Val Gly Glu Met Leu Leu Gln Th - #r Phe Phe Ser Val Asp 65                 - # 70                 - # 75                 - # 80 - - Pro Gly Ser His His Gly Glu Ala Asn Leu Gl - #u Met Glu Glu Pro Glu 85 - #                 90 - #                 95 - - Glu Ser Leu Asn Thr Leu Lys Leu Cys Ser Pr - #o Glu Glu Phe Thr Arg 100      - #           105      - #           110 - - Leu Cys Arg Glu Lys Thr Gln Glu Ile Tyr Pr - #o Ile Lys Glu Ala Asn 115          - #       120          - #       125 - - Gly Arg Thr Arg Lys Ala Leu Ile Ile Cys As - #n Thr Glu Phe Lys His 130              - #   135              - #   140 - - Leu Ser Leu Arg Tyr Gly Ala Lys Phe Asp Il - #e Ile Gly Met Lys Gly 145                 1 - #50                 1 - #55                 1 - #60 - - Leu Leu Glu Asp Leu Gly Tyr Asp Val Val Va - #l Lys Glu Glu Leu Thr 165  - #               170  - #               175 - - Ala Glu Gly Met Glu Ser Glu Met Lys Asp Ph - #e Ala Ala Leu Ser Glu 180      - #           185      - #           190 - - His Gln Thr Ser Asp Ser Thr Phe Leu Val Le - #u Met Ser His Gly Thr 195          - #       200          - #       205 - - Leu His Gly Ile Cys Gly Thr Met His Ser Gl - #u Lys Thr Pro Asp Val 210              - #   215              - #   220 - - Leu Gln Tyr Asp Thr Ile Tyr Gln Ile Phe As - #n Asn Cys His Cys Pro 225                 2 - #30                 2 - #35                 2 - #40 - - Gly Leu Arg Asp Lys Pro Lys Val Ile Ile Va - #l Gln Ala Cys Arg Gly 245  - #               250  - #               255 - - Gly Asn Ser Gly Glu Met Trp Ile Arg Glu Se - #r Ser Lys Pro Gln Leu 260      - #           265      - #           270 - - Cys Arg Gly Val Asp Leu Pro Arg Asn Met Gl - #u Ala Asp Ala Val Lys 275          - #       280          - #       285 - - Leu Ser His Val Glu Lys Asp Phe Ile Ala Ph - #e Tyr Ala Thr Thr Pro 290              - #   295              - #   300 - - His His Leu Ser Tyr Arg Asp Lys Thr Gly Gl - #y Ser Tyr Phe Ile Thr 305                 3 - #10                 3 - #15                 3 - #20 - - Arg Leu Ile Ser Cys Phe Arg Lys His Ala Cy - #s Ser Cys His Leu Phe 325  - #               330  - #               335 - - Asp Ile Phe Leu Lys Val Gln Gln Ser Phe Gl - #u Lys Ala Ser Ile His 340      - #           345      - #           350 - - Ser Gln Met Pro Thr Ile Asp Arg Ala Thr Le - #u Thr Arg Tyr Phe Tyr 355          - #       360          - #       365 - - Leu Phe Pro Gly Asn 370 - -  - - (2) INFORMATION FOR SEQ ID NO:43: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 441 amino - #acids (B) TYPE: amino acid (D) TOPOLOGY: linear - -     (ii) MOLECULE TYPE: protein - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:43: - - Ile Pro His Lys Glu Leu Met Ala Ala Asp Ar - #g Gly Arg Arg Ile Leu 1               5 - #                 10 - #                 15 - - Gly Val Cys Gly Met His Pro His His Gln Gl - #u Thr Leu Lys Lys Asn 20     - #             25     - #             30 - - Arg Val Val Leu Ala Lys Gln Leu Leu Leu Se - #r Glu Leu Leu Glu His 35         - #         40         - #         45 - - Leu Leu Glu Lys Asp Ile Ile Thr Leu Glu Me - #t Arg Glu Leu Ile Gln 50             - #     55             - #     60 - - Ala Lys Val Gly Ser Phe Ser Gln Asn Val Gl - #u Leu Leu Asn Leu Leu 65                 - # 70                 - # 75                 - # 80 - - Pro Lys Arg Gly Pro Gln Ala Phe Asp Ala Ph - #e Cys Glu Ala Leu Arg 85 - #                 90 - #                 95 - - Glu Thr Lys Gln Gly His Leu Glu Asp Met Le - #u Leu Thr Thr Leu Ser 100      - #           105      - #           110 - - Gly Leu Gln His Val Leu Pro Pro Leu Ser Cy - #s Asp Tyr Asp Leu Ser 115          - #       120          - #       125 - - Leu Pro Phe Pro Val Cys Glu Ser Cys Pro Le - #u Tyr Lys Lys Leu Arg 130              - #   135              - #   140 - - Leu Ser Thr Asp Thr Val Glu His Ser Leu As - #p Asn Lys Asp Gly Pro 145                 1 - #50                 1 - #55                 1 - #60 - - Val Cys Leu Gln Val Lys Pro Cys Thr Pro Gl - #u Phe Tyr Gln Thr His 165  - #               170  - #               175 - - Phe Gln Leu Ala Tyr Arg Leu Gln Ser Arg Pr - #o Arg Gly Leu Ala Leu 180      - #           185      - #           190 - - Val Leu Ser Asn Val His Phe Thr Gly Glu Ly - #s Glu Leu Glu Phe Arg 195          - #       200          - #       205 - - Ser Gly Gly Asp Val Asp His Ser Thr Leu Va - #l Thr Leu Phe Lys Leu 210              - #   215              - #   220 - - Leu Gly Tyr Asp Val His Val Leu Cys Asp Gl - #n Thr Ala Gln Glu Met 225                 2 - #30                 2 - #35                 2 - #40 - - Gln Glu Lys Leu Gln Asn Phe Ala Gln Leu Pr - #o Ala His Arg Val Thr 245  - #               250  - #               255 - - Asp Ser Cys Ile Val Ala Leu Leu Ser His Gl - #y Val Glu Gly Ala Ile 260      - #           265      - #           270 - - Tyr Gly Val Asp Gly Lys Leu Leu Gln Leu Gl - #n Glu Val Phe Gln Leu 275          - #       280          - #       285 - - Phe Asp Asn Ala Asn Cys Pro Ser Leu Gln As - #n Lys Pro Lys Met Phe 290              - #   295              - #   300 - - Phe Ile Gln Ala Cys Arg Gly Asp Glu Thr As - #p Arg Gly Val Asp Gln 305                 3 - #10                 3 - #15                 3 - #20 - - Gln Asp Gly Lys Asn His Ala Gly Ser Pro Gl - #y Cys Glu Glu Ser Asp 325  - #               330  - #               335 - - Ala Gly Lys Glu Lys Leu Pro Lys Met Arg Le - #u Pro Thr Arg Ser Asp 340      - #           345      - #           350 - - Met Ile Cys Gly Tyr Ala Cys Leu Lys Gly Th - #r Ala Ala Met Arg Asn 355          - #       360          - #       365 - - Thr Lys Arg Gly Ser Trp Tyr Ile Glu Ala Le - #u Ala Gln Val Phe Ser 370              - #   375              - #   380 - - Glu Arg Ala Cys Asp Met His Val Ala Asp Me - #t Leu Val Lys Val Asn 385                 3 - #90                 3 - #95                 4 - #00 - - Ala Leu Ile Lys Asp Arg Glu Gly Tyr Ala Pr - #o Gly Thr Glu Phe His 405  - #               410  - #               415 - - Arg Cys Lys Glu Met Ser Glu Tyr Cys Ser Th - #r Leu Cys Arg His Leu 420      - #           425      - #           430 - - Tyr Leu Phe Pro Gly His Pro Pro Thr 435          - #       440 - -  - - (2) INFORMATION FOR SEQ ID NO:44: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 120 base - #pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both - -     (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: join(1..6, - #10..118) - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:44: - - TTC TGG TAG CTC CAA GAG GTT TTT CGA CTT TT - #T GAC AAT GCT AAC TGT 48 Phe Trp     Leu Gln Glu Val Phe Arg - #Leu Phe Asp Asn Ala Asn Cys 1               5 - #                 10 - #                 15 - - CCA AGT CTA CAG AAC AAG CCA AAA ATG TTC TT - #C ATC CAA GCA TGT CGT 96 Pro Ser Leu Gln Asn Lys Pro Lys Met Phe Ph - #e Ile Gln Ala Cys Arg 20     - #             25     - #             30 - - GGA GGT GCT ATT GGA TCC CTT GGG     - #                  - # 120 Gly Gly Ala Ile Gly Ser Leu Gly 35 - -  - - (2) INFORMATION FOR SEQ ID NO:45: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 39 amino - #acids (B) TYPE: amino acid (D) TOPOLOGY: linear - -     (ii) MOLECULE TYPE: protein - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:45: - - Phe Trp Leu Gln Glu Val Phe Arg Leu Phe As - #p Asn Ala Asn Cys Pro 1               5 - #                 10 - #                 15 - - Ser Leu Gln Asn Lys Pro Lys Met Phe Phe Il - #e Gln Ala Cys Arg Gly 20     - #             25     - #             30 - - Gly Ala Ile Gly Ser Leu Gly 35 - -  - - (2) INFORMATION FOR SEQ ID NO:46: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 120 base - #pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both - -     (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 2..119 - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:46: - - T TCT GGT AGC TCC AAG AGG TTT TTC GAC TTT - #TTG ACA ATG CTA ACT 46 Ser Gly Ser Ser Lys Arg Phe Phe Asp P - #he Leu Thr Met Leu Thr 1              - # 5                 - # 10                 - # 15 - - GTC CAA GTC TAC AGA ACA AGC CAA AAA TGT TC - #T TCA TCC AAG CAT GTC 94 Val Gln Val Tyr Arg Thr Ser Gln Lys Cys Se - #r Ser Ser Lys His Val 20 - #                 25 - #                 30 - - GTG GAG GTG CTA TTG GAT CCC TTG GG    - #                  - # 120 Val Glu Val Leu Leu Asp Pro Leu Gly 35 - -  - - (2) INFORMATION FOR SEQ ID NO:47: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 40 amino - #acids (B) TYPE: amino acid (D) TOPOLOGY: linear - -     (ii) MOLECULE TYPE: protein - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:47: - - Ser Gly Ser Ser Lys Arg Phe Phe Asp Phe Le - #u Thr Met Leu Thr Val 1               5 - #                 10 - #                 15 - - Gln Val Tyr Arg Thr Ser Gln Lys Cys Ser Se - #r Ser Lys His Val Val 20     - #             25     - #             30 - - Glu Val Leu Leu Asp Pro Leu Gly 35         - #         40 - -  - - (2) INFORMATION FOR SEQ ID NO:48: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 120 base - #pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both - -     (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 3..120 - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:48: - - TT CTG GTA GCT CCA AGA GGT TTT TCG ACT TTT - # TGA CAA TGC TAA CTG 47 Leu Val Ala Pro Arg Gly Phe Ser Thr - #Phe     Gln Cys     Leu 1             - #  5                - #  10                - #  15 - - TCC AAG TCT ACA GAA CAA GCC AAA AAT GTT CT - #T CAT CCA AGC ATG TCG 95 Ser Lys Ser Thr Glu Gln Ala Lys Asn Val Le - #u His Pro Ser Met Ser 20 - #                 25 - #                 30 - - TGG AGG TGC TAT TGG ATC CCT TGG G    - #                  - # 120 Trp Arg Cys Tyr Trp Ile Pro Trp Ala 35 - -  - - (2) INFORMATION FOR SEQ ID NO:49: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 38 amino - #acids (B) TYPE: amino acid (D) TOPOLOGY: linear - -     (ii) MOLECULE TYPE: protein - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:49: - - Leu Val Ala Pro Arg Gly Phe Ser Thr Phe Gl - #n Cys Leu Ser Lys Ser 1               5 - #                 10 - #                 15 - - Thr Glu Gln Ala Lys Asn Val Leu His Pro Se - #r Met Ser Trp Arg Cys 20     - #             25     - #             30 - - Tyr Trp Ile Pro Trp Ala 35 - -  - - (2) INFORMATION FOR SEQ ID NO:50: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1456 base - #pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown - -     (ii) MOLECULE TYPE: DNA - -     (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 14..1316 - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:50: - - GCACAAGGAG CTG ATG GCC GCT GAC AGG GGA CGC AG - #G ATA TTG GGA GTG 49 Met Ala - #Ala Asp Arg Gly Arg Arg Ile Leu Gly Val 1 - #              5    - #              10 - - TGT GGC ATG CAT CCT CAT CAT CAG GAA ACT CT - #A AAA AAG AAC CGA GTG 97 Cys Gly Met His Pro His His Gln Glu Thr Le - #u Lys Lys Asn Arg Val 15         - #         20         - #         25 - - GTG CTA GCC AAA CAG CTG TTG TTG AGC GAA TT - #G TTA GAA CAT CTT CTG 145 Val Leu Ala Lys Gln Leu Leu Leu Ser Glu Le - #u Leu Glu His Leu Leu 30             - #     35             - #     40 - - GAG AAG GAC ATC ATC ACC TTG GAA ATG AGG GA - #G CTC ATC CAG GCC AAA 193 Glu Lys Asp Ile Ile Thr Leu Glu Met Arg Gl - #u Leu Ile Gln Ala Lys 45                 - # 50                 - # 55                 - # 60 - - GTG GGC AGT TTC AGC CAG AAT GTG GAA CTC CT - #C AAC TTG CTG CCT AAG 241 Val Gly Ser Phe Ser Gln Asn Val Glu Leu Le - #u Asn Leu Leu Pro Lys 65 - #                 70 - #                 75 - - AGG GGT CCC CAA GCT TTT GAT GCC TTC TGT GA - #A GCA CTG AGG GAG ACC 289 Arg Gly Pro Gln Ala Phe Asp Ala Phe Cys Gl - #u Ala Leu Arg Glu Thr 80     - #             85     - #             90 - - AAG CAA GGC CAC CTG GAG GAT ATG TTG CTC AC - #C ACC CTT TCT GGG CTT 337 Lys Gln Gly His Leu Glu Asp Met Leu Leu Th - #r Thr Leu Ser Gly Leu 95         - #        100         - #        105 - - CAG CAT GTA CTC CCA CCG TTG AGC TGT GAC TA - #C GAC TTG AGT CTC CCT 385 Gln His Val Leu Pro Pro Leu Ser Cys Asp Ty - #r Asp Leu Ser Leu Pro 110              - #   115              - #   120 - - TTT CCG GTG TGT GAG TCC TGT CCC CTT TAC AA - #G AAG CTC CGC CTG TCG 433 Phe Pro Val Cys Glu Ser Cys Pro Leu Tyr Ly - #s Lys Leu Arg Leu Ser 125                 1 - #30                 1 - #35                 1 - #40 - - ACA GAT ACT GTG GAA CAC TCC CTA GAC AAT AA - #A GAT GGT CCT GTC TGC      481 Thr Asp Thr Val Glu His Ser Leu Asp Asn Ly - #s Asp Gly Pro Val Cys 145  - #               150  - #               155 - - CTT CAG GTG AAG CCT TGC ACT CCT GAA TTT TA - #T CAA ACA CAC TTC CAG 529 Leu Gln Val Lys Pro Cys Thr Pro Glu Phe Ty - #r Gln Thr His Phe Gln 160      - #           165      - #           170 - - CTG GCA TAT AGG TTG CAG TCT CGG CCT CGT GG - #C CTA GCA CTG GTG TTG 577 Leu Ala Tyr Arg Leu Gln Ser Arg Pro Arg Gl - #y Leu Ala Leu Val Leu 175          - #       180          - #       185 - - AGC AAT GTG CAC TTC ACT GGA GAG AAA GAA CT - #G GAA TTT CGC TCT GGA 625 Ser Asn Val His Phe Thr Gly Glu Lys Glu Le - #u Glu Phe Arg Ser Gly 190              - #   195              - #   200 - - GGG GAT GTG GAC CAC AGT ACT CTA GTC ACC CT - #C TTC AAG CTT TTG GGC 673 Gly Asp Val Asp His Ser Thr Leu Val Thr Le - #u Phe Lys Leu Leu Gly 205                 2 - #10                 2 - #15                 2 - #20 - - TAT GAC GTC CAT GTT CTA TGT GAC CAG ACT GC - #A CAG GAA ATG CAA GAG      721 Tyr Asp Val His Val Leu Cys Asp Gln Thr Al - #a Gln Glu Met Gln Glu 225  - #               230  - #               235 - - AAA CTG CAG AAT TTT GCA CAG TTA CCT GCA CA - #C CGA GTC ACG GAC TCC 769 Lys Leu Gln Asn Phe Ala Gln Leu Pro Ala Hi - #s Arg Val Thr Asp Ser 240      - #           245      - #           250 - - TGC ATC GTG GCA CTC CTC TCG CAT GGT GTG GA - #G GGC GCC ATC TAT GGT 817 Cys Ile Val Ala Leu Leu Ser His Gly Val Gl - #u Gly Ala Ile Tyr Gly 255          - #       260          - #       265 - - GTG GAT GGG AAA CTG CTC CAG CTC CAA GAG GT - #T TTT CAG CTC TTT GAC 865 Val Asp Gly Lys Leu Leu Gln Leu Gln Glu Va - #l Phe Gln Leu Phe Asp 270              - #   275              - #   280 - - AAC GCC AAC TGC CCA AGC CTA CAG AAC AAA CC - #A AAA ATG TTC TTC ATC 913 Asn Ala Asn Cys Pro Ser Leu Gln Asn Lys Pr - #o Lys Met Phe Phe Ile 285                 2 - #90                 2 - #95                 3 - #00 - - CAG GCC TGC CGT GGA GAT GAG ACT GAT CGT GG - #G GTT GAC CAA CAA GAT      961 Gln Ala Cys Arg Gly Asp Glu Thr Asp Arg Gl - #y Val Asp Gln Gln Asp 305  - #               310  - #               315 - - GGA AAG AAC CAC GCA GGA TCC CCT GGG TGC GA - #G GAG AGT GAT GCC GGT 1009 Gly Lys Asn His Ala Gly Ser Pro Gly Cys Gl - #u Glu Ser Asp Ala Gly 320      - #           325      - #           330 - - AAA GAA AAG TTG CCG AAG ATG AGA CTG CCC AC - #G CGC TCA GAC ATG ATA 1057 Lys Glu Lys Leu Pro Lys Met Arg Leu Pro Th - #r Arg Ser Asp Met Ile 335          - #       340          - #       345 - - TGC GGC TAT GCC TGC CTC AAA GGG ACT GCC GC - #C ATG CGG AAC ACC AAA 1105 Cys Gly Tyr Ala Cys Leu Lys Gly Thr Ala Al - #a Met Arg Asn Thr Lys 350              - #   355              - #   360 - - CGA GGT TCC TGG TAC ATC GAG GCT CTT GCT CA - #A GTG TTT TCT GAG CGG 1153 Arg Gly Ser Trp Tyr Ile Glu Ala Leu Ala Gl - #n Val Phe Ser Glu Arg 365                 3 - #70                 3 - #75                 3 - #80 - - GCT TGT GAT ATG CAC GTG GCC GAC ATG CTG GT - #T AAG GTG AAC GCA CTT     1201 Ala Cys Asp Met His Val Ala Asp Met Leu Va - #l Lys Val Asn Ala Leu 385  - #               390  - #               395 - - ATC AAG GAT CGG GAA GGT TAT GCT CCT GGC AC - #A GAA TTC CAC CGG TGC 1249 Ile Lys Asp Arg Glu Gly Tyr Ala Pro Gly Th - #r Glu Phe His Arg Cys 400      - #           405      - #           410 - - AAG GAA ATG TCT GAA TAC TGC AGC ACT CTG TG - #C CGC CAC CTC TAC CTG 1297 Lys Glu Met Ser Glu Tyr Cys Ser Thr Leu Cy - #s Arg His Leu Tyr Leu 415          - #       420          - #       425 - - TTC CCA GGA CAC CCT CCC ACA TGATGTCACC TCCCCATCA - #T CCACGCCA 1346 Phe Pro Gly His Pro Pro Thr 430 - - AGTGGAAGCC ACTGGACCAC AGGAGGTGTG ATAGAGCCTT TGATCTTCAG GA - #TGCACGGT   1406 - - TTCTGTTCTG CCCCCTCAGG GATGTGGGAA TCTCCCAGAC TTGTTTCCTG  - # 1456 - -  - - (2) INFORMATION FOR SEQ ID NO:51: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 435 amino - #acids (B) TYPE: amino acid (D) TOPOLOGY: linear - -     (ii) MOLECULE TYPE: protein - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:51: - - Met Ala Ala Asp Arg Gly Arg Arg Ile Leu Gl - #y Val Cys Gly Met His 1               5 - #                 10 - #                 15 - - Pro His His Gln Glu Thr Leu Lys Lys Asn Ar - #g Val Val Leu Ala Lys 20     - #             25     - #             30 - - Gln Leu Leu Leu Ser Glu Leu Leu Glu His Le - #u Leu Glu Lys Asp Ile 35         - #         40         - #         45 - - Ile Thr Leu Glu Met Arg Glu Leu Ile Gln Al - #a Lys Val Gly Ser Phe 50             - #     55             - #     60 - - Ser Gln Asn Val Glu Leu Leu Asn Leu Leu Pr - #o Lys Arg Gly Pro Gln 65                 - # 70                 - # 75                 - # 80 - - Ala Phe Asp Ala Phe Cys Glu Ala Leu Arg Gl - #u Thr Lys Gln Gly His 85 - #                 90 - #                 95 - - Leu Glu Asp Met Leu Leu Thr Thr Leu Ser Gl - #y Leu Gln His Val Leu 100      - #           105      - #           110 - - Pro Pro Leu Ser Cys Asp Tyr Asp Leu Ser Le - #u Pro Phe Pro Val Cys 115          - #       120          - #       125 - - Glu Ser Cys Pro Leu Tyr Lys Lys Leu Arg Le - #u Ser Thr Asp Thr Val 130              - #   135              - #   140 - - Glu His Ser Leu Asp Asn Lys Asp Gly Pro Va - #l Cys Leu Gln Val Lys 145                 1 - #50                 1 - #55                 1 - #60 - - Pro Cys Thr Pro Glu Phe Tyr Gln Thr His Ph - #e Gln Leu Ala Tyr Arg 165  - #               170  - #               175 - - Leu Gln Ser Arg Pro Arg Gly Leu Ala Leu Va - #l Leu Ser Asn Val His 180      - #           185      - #           190 - - Phe Thr Gly Glu Lys Glu Leu Glu Phe Arg Se - #r Gly Gly Asp Val Asp 195          - #       200          - #       205 - - His Ser Thr Leu Val Thr Leu Phe Lys Leu Le - #u Gly Tyr Asp Val His 210              - #   215              - #   220 - - Val Leu Cys Asp Gln Thr Ala Gln Glu Met Gl - #n Glu Lys Leu Gln Asn 225                 2 - #30                 2 - #35                 2 - #40 - - Phe Ala Gln Leu Pro Ala His Arg Val Thr As - #p Ser Cys Ile Val Ala 245  - #               250  - #               255 - - Leu Leu Ser His Gly Val Glu Gly Ala Ile Ty - #r Gly Val Asp Gly Lys 260      - #           265      - #           270 - - Leu Leu Gln Leu Gln Glu Val Phe Gln Leu Ph - #e Asp Asn Ala Asn Cys 275          - #       280          - #       285 - - Pro Ser Leu Gln Asn Lys Pro Lys Met Phe Ph - #e Ile Gln Ala Cys Arg 290              - #   295              - #   300 - - Gly Asp Glu Thr Asp Arg Gly Val Asp Gln Gl - #n Asp Gly Lys Asn His 305                 3 - #10                 3 - #15                 3 - #20 - - Ala Gly Ser Pro Gly Cys Glu Glu Ser Asp Al - #a Gly Lys Glu Lys Leu 325  - #               330  - #               335 - - Pro Lys Met Arg Leu Pro Thr Arg Ser Asp Me - #t Ile Cys Gly Tyr Ala 340      - #           345      - #           350 - - Cys Leu Lys Gly Thr Ala Ala Met Arg Asn Th - #r Lys Arg Gly Ser Trp 355          - #       360          - #       365 - - Tyr Ile Glu Ala Leu Ala Gln Val Phe Ser Gl - #u Arg Ala Cys Asp Met 370              - #   375              - #   380 - - His Val Ala Asp Met Leu Val Lys Val Asn Al - #a Leu Ile Lys Asp Arg 385                 3 - #90                 3 - #95                 4 - #00 - - Glu Gly Tyr Ala Pro Gly Thr Glu Phe His Ar - #g Cys Lys Glu Met Ser 405  - #               410  - #               415 - - Glu Tyr Cys Ser Thr Leu Cys Arg His Leu Ty - #r Leu Phe Pro Gly His 420      - #           425      - #           430 - - Pro Pro Thr - -  - - (2) INFORMATION FOR SEQ ID NO:52: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2167 base - #pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both - -     (ii) MOLECULE TYPE: DNA - -     (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 89..1019 - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:52: - - AGAGGGAGGG AACGATTTAA GGAGCGAATA CTACTGGTAA ACTAATGGAA GA - #AATCTGCT     60 - - GCACCACTGG ATATTGGGAG TGTGTGGC ATG CAT CCT CAT CAT - #CAG GAA ACT 112 - #             Met His Pro - #His His Gln Glu Thr - #               1   - #            5 - - CTA AAA AAG AAC CGA GTG GTG CTA GCC AAA CA - #G CTG TTG TTG AGC GAA 160 Leu Lys Lys Asn Arg Val Val Leu Ala Lys Gl - #n Leu Leu Leu Ser Glu 10             - #     15             - #     20 - - TTG TTA GAA CAT CTT CTG GAG AAG GAC ATC AT - #C ACC TTG GAA ATG AGG 208 Leu Leu Glu His Leu Leu Glu Lys Asp Ile Il - #e Thr Leu Glu Met Arg 25                 - # 30                 - # 35                 - # 40 - - GAG CTC ATC CAG GCC AAA GTG GGC AGT TTC AG - #C CAG AAT GTG GAA CTC 256 Glu Leu Ile Gln Ala Lys Val Gly Ser Phe Se - #r Gln Asn Val Glu Leu 45 - #                 50 - #                 55 - - CTC AAC TTG CTG CCT AAG AGG GGT CCC CAA GC - #T TTT GAT GCC TTC TGT 304 Leu Asn Leu Leu Pro Lys Arg Gly Pro Gln Al - #a Phe Asp Ala Phe Cys 60     - #             65     - #             70 - - GAA GCA CTG AGG GAG ACC AAG CAA GGC CAC CT - #G GAG GAT ATG TTG CTC 352 Glu Ala Leu Arg Glu Thr Lys Gln Gly His Le - #u Glu Asp Met Leu Leu 75         - #         80         - #         85 - - ACC ACC CTT TCT GGG CTT CAG CAT GTA CTC CC - #A CCG TTG AGC TGT GAC 400 Thr Thr Leu Ser Gly Leu Gln His Val Leu Pr - #o Pro Leu Ser Cys Asp 90             - #     95             - #    100 - - TAC GAC TTG AGT CTC CCT TTT CCG GTG TGT GA - #G TCC TGT CCC CTT TAC 448 Tyr Asp Leu Ser Leu Pro Phe Pro Val Cys Gl - #u Ser Cys Pro Leu Tyr 105                 1 - #10                 1 - #15                 1 - #20 - - AAG AAG CTC CGC CTG TCG ACA GAT ACT GTG GA - #A CAC TCC CTA GAC AAT      496 Lys Lys Leu Arg Leu Ser Thr Asp Thr Val Gl - #u His Ser Leu Asp Asn 125  - #               130  - #               135 - - AAA GAT GGT CCT GTC TGC CTT CAG GTG AAG CC - #T TGC ACT CCT GAA TTT 544 Lys Asp Gly Pro Val Cys Leu Gln Val Lys Pr - #o Cys Thr Pro Glu Phe 140      - #           145      - #           150 - - TAT CAA ACA CAC TTC CAG CTG GCA TAT AGG TT - #G CAG TCT CGG CCT CGT 592 Tyr Gln Thr His Phe Gln Leu Ala Tyr Arg Le - #u Gln Ser Arg Pro Arg 155          - #       160          - #       165 - - GGC CTA GCA CTG GTG TTG AGC AAT GTG CAC TT - #C ACT GGA GAG AAA GAA 640 Gly Leu Ala Leu Val Leu Ser Asn Val His Ph - #e Thr Gly Glu Lys Glu 170              - #   175              - #   180 - - CTG GAA TTT CGC TCT GGA GGG GAT GTG GAC CA - #C AGT ACT CTA GTC ACC 688 Leu Glu Phe Arg Ser Gly Gly Asp Val Asp Hi - #s Ser Thr Leu Val Thr 185                 1 - #90                 1 - #95                 2 - #00 - - CTC TTC AAG CTT TTG GGC TAT GAC GTC CAT GT - #T CTA TGT GAC CAG ACT      736 Leu Phe Lys Leu Leu Gly Tyr Asp Val His Va - #l Leu Cys Asp Gln Thr 205  - #               210  - #               215 - - GCA CAG GAA ATG CAA GAG AAA CTG CAG AAT TT - #T GCA CAG TTA CCT GCA 784 Ala Gln Glu Met Gln Glu Lys Leu Gln Asn Ph - #e Ala Gln Leu Pro Ala 220      - #           225      - #           230 - - CAC CGA GTC ACG GAC TCC TGC ATC GTG GCA CT - #C CTC TCG CAT GGT GTG 832 His Arg Val Thr Asp Ser Cys Ile Val Ala Le - #u Leu Ser His Gly Val 235          - #       240          - #       245 - - GAG GGC GCC ATC TAT GGT GTG GAT GGG AAA CT - #G CTC CAG CTC CAA GAG 880 Glu Gly Ala Ile Tyr Gly Val Asp Gly Lys Le - #u Leu Gln Leu Gln Glu 250              - #   255              - #   260 - - GTT TTT CAG CTC TTT GAC AAC GCC AAC TGC CC - #A AGC CTA CAG AAC AAA 928 Val Phe Gln Leu Phe Asp Asn Ala Asn Cys Pr - #o Ser Leu Gln Asn Lys 265                 2 - #70                 2 - #75                 2 - #80 - - CCA AAA ATG TTC TTC ATC CAG GCC TGC CGT GG - #A GGT GCT ATT GGA TCC      976 Pro Lys Met Phe Phe Ile Gln Ala Cys Arg Gl - #y Gly Ala Ile Gly Ser 285  - #               290  - #               295 - - CTT GGG CAC CTC CTT CTG TTC ACT GCT GCC AC - #C GCC TCT CTT GCT CTA 1024 Leu Gly His Leu Leu Leu Phe Thr Ala Ala Th - #r Ala Ser Leu Ala Leu 300      - #           305      - #           310 - - TGAGACTGAT CGTGGGGTTG ACCAACAAGA TGGAAAGAAC CACGCAGGAT CC - #CCTGGGTG   1084 - - CGAGGAGAGT GATGCCGGTA AAGAAAAGTT GCCGAAGATG AGACTGCCCA CG - #CGCTCAGA   1144 - - CATGATATGC GGCTATGCCT GCCTCAAAGG GACTGCCGCC ATGCGGAACA CC - #AAACGAGG   1204 - - TTCCTGGTAC ATCGAGGCTC TTGCTCAAGT GTTTTCTGAG CGGGCTTGTG AT - #ATGCACGT   1264 - - GGCCGACATG CTGGTTAAGG TGAACGCACT TATCAAGGAT CGGGAAGGTT AT - #GCTCCTGG   1324 - - CACAGAATTC CACCGGTGCA AGGAGATGTC TGAATACTGC AGCACTCTGT GC - #CGCCACCT   1384 - - CTACCTGTTC CCAGGACACC CTCCCACATG ATGTCACCTC CCCATCATCC AC - #GCCAAGTG   1444 - - GAAGCCACTG GACCACAGGA GGTGTGATAG AGCCTTTGAT CTTCAGGATG CA - #CGGTTTCT   1504 - - GTTCTGCCCC CTCAGGGATG TGGGAATCTC CCAGACTTGT TTCCTGTGCC CA - #TCATCTCT   1564 - - GCCTTTGAGT GTGGGACTCC AGGCCAGCTC CTTTTCTGTG AAGCCCTTTG CC - #TGTAGAGC   1624 - - CAGCCTTGGT TGGACCTATT GCCAGGAATG TTTCAGCTGC AGTTGAAGAG CC - #TGACAAGT   1684 - - GAAGTTGTAA ACACAGTGTG GTTATGGGGA GAGGGCATAT AAATTCCCCA TA - #TTTGTGTT   1744 - - CAGTTCCAGC TTTTGTAGAT GGCACTTTAG TGATTGCTTT TATTACATTA GT - #TAAGATGT   1804 - - CTTGAGAGAC CATCTCCTAT CTTTTATTTC ATTCATATCC TCCGCCCTTT TT - #GTCCTAGA   1864 - - GTGAGAGTTT GGAAGGTGTC CAAATTTAAT GTAGACATTA TCTTTTGGCT CT - #GAAGAAGC   1924 - - AAACATGACT AGAGACGCAC CTTGCTGCAG TGTCCAGAAG CGGCCTGTGC GT - #TCCCTTCA   1984 - - GTACTGCAGC GCCACCCAGT GGAAGGACAC TCTTGGCTCG TTTGGGCTCA AG - #GCACCGCA   2044 - - GCCTGTCAGC CAACATTGCC TTGCATTTGT ACCTTATTGA TCTTTGCCCA TG - #GAAGTCTC   2104 - - AAAGATCTTT CGTTGGTTGT TTCTCTGAGC TTTGTTACTG AAATGAGCCT CG - #TGGGGAGC   2164 - - ATC                  - #                  - #                  - # 2167 - -  - - (2) INFORMATION FOR SEQ ID NO:53: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 312 amino - #acids (B) TYPE: amino acid (D) TOPOLOGY: linear - -     (ii) MOLECULE TYPE: protein - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:53: - - Met His Pro His His Gln Glu Thr Leu Lys Ly - #s Asn Arg Val Val Leu 1               5 - #                 10 - #                 15 - - Ala Lys Gln Leu Leu Leu Ser Glu Leu Leu Gl - #u His Leu Leu Glu Lys 20     - #             25     - #             30 - - Asp Ile Ile Thr Leu Glu Met Arg Glu Leu Il - #e Gln Ala Lys Val Gly 35         - #         40         - #         45 - - Ser Phe Ser Gln Asn Val Glu Leu Leu Asn Le - #u Leu Pro Lys Arg Gly 50             - #     55             - #     60 - - Pro Gln Ala Phe Asp Ala Phe Cys Glu Ala Le - #u Arg Glu Thr Lys Gln 65                 - # 70                 - # 75                 - # 80 - - Gly His Leu Glu Asp Met Leu Leu Thr Thr Le - #u Ser Gly Leu Gln His 85 - #                 90 - #                 95 - - Val Leu Pro Pro Leu Ser Cys Asp Tyr Asp Le - #u Ser Leu Pro Phe Pro 100      - #           105      - #           110 - - Val Cys Glu Ser Cys Pro Leu Tyr Lys Lys Le - #u Arg Leu Ser Thr Asp 115          - #       120          - #       125 - - Thr Val Glu His Ser Leu Asp Asn Lys Asp Gl - #y Pro Val Cys Leu Gln 130              - #   135              - #   140 - - Val Lys Pro Cys Thr Pro Glu Phe Tyr Gln Th - #r His Phe Gln Leu Ala 145                 1 - #50                 1 - #55                 1 - #60 - - Tyr Arg Leu Gln Ser Arg Pro Arg Gly Leu Al - #a Leu Val Leu Ser Asn 165  - #               170  - #               175 - - Val His Phe Thr Gly Glu Lys Glu Leu Glu Ph - #e Arg Ser Gly Gly Asp 180      - #           185      - #           190 - - Val Asp His Ser Thr Leu Val Thr Leu Phe Ly - #s Leu Leu Gly Tyr Asp 195          - #       200          - #       205 - - Val His Val Leu Cys Asp Gln Thr Ala Gln Gl - #u Met Gln Glu Lys Leu 210              - #   215              - #   220 - - Gln Asn Phe Ala Gln Leu Pro Ala His Arg Va - #l Thr Asp Ser Cys Ile 225                 2 - #30                 2 - #35                 2 - #40 - - Val Ala Leu Leu Ser His Gly Val Glu Gly Al - #a Ile Tyr Gly Val Asp 245  - #               250  - #               255 - - Gly Lys Leu Leu Gln Leu Gln Glu Val Phe Gl - #n Leu Phe Asp Asn Ala 260      - #           265      - #           270 - - Asn Cys Pro Ser Leu Gln Asn Lys Pro Lys Me - #t Phe Phe Ile Gln Ala 275          - #       280          - #       285 - - Cys Arg Gly Gly Ala Ile Gly Ser Leu Gly Hi - #s Leu Leu Leu Phe Thr 290              - #   295              - #   300 - - Ala Ala Thr Ala Ser Leu Ala Leu 305                 3 - #10 - -  - - (2) INFORMATION FOR SEQ ID NO:54: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1402 base - #pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both - -     (ii) MOLECULE TYPE: cDNA - -     (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 45..1301 - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:54: - - CTTTTTTTTT TTTTTTTTTT TATGTCCTGG AGTCCTGCAC AGCC ATG G - #CG GCC AGG      56 - #                  - #             Met Ala Ala - #Arg - #                  - #               1 - - AGG ACA CAT GAA AGA GAT CCA ATC TAC AAG AT - #C AAA GGT TTG GCC AAG      104 Arg Thr His Glu Arg Asp Pro Ile Tyr Lys Il - #e Lys Gly Leu Ala Lys 5                - #  10                - #  15                - #  20 - - GAC ATG CTG GAT GGG GTT TTT GAT GAC CTG GT - #G GAG AAG AAT GTT TTA 152 Asp Met Leu Asp Gly Val Phe Asp Asp Leu Va - #l Glu Lys Asn Val Leu 25 - #                 30 - #                 35 - - AAT GGA GAT GAG TTA CTC AAA ATA GGG GAA AG - #T GCG AGT TTC ATC CTG 200 Asn Gly Asp Glu Leu Leu Lys Ile Gly Glu Se - #r Ala Ser Phe Ile Leu 40     - #             45     - #             50 - - AAC AAG GCT GAG AAT CTG GTT GAG AAC TTC TT - #A GAG AAA ACA GAC ATG 248 Asn Lys Ala Glu Asn Leu Val Glu Asn Phe Le - #u Glu Lys Thr Asp Met 55         - #         60         - #         65 - - GCA GGA AAA ATA TTT GCT GGC CAC ATT GCC AA - #T TCC CAG GAA CAG CTG 296 Ala Gly Lys Ile Phe Ala Gly His Ile Ala As - #n Ser Gln Glu Gln Leu 70             - #     75             - #     80 - - AGT TTA CAA TTT TCT AAT GAT GAG GAT GAT GG - #A CCT CAG AAG ATA TGT 344 Ser Leu Gln Phe Ser Asn Asp Glu Asp Asp Gl - #y Pro Gln Lys Ile Cys 85                 - # 90                 - # 95                 - #100 - - ACA CCT TCT TCT CCA TCA GAA TCC AAG AGA AA - #A GTA GAG GAT GAT GAA 392 Thr Pro Ser Ser Pro Ser Glu Ser Lys Arg Ly - #s Val Glu Asp Asp Glu 105  - #               110  - #               115 - - ATG GAG GTA AAT GCT GGA TTG GCC CAT GAA TC - #A CAT CTA ATG CTG ACA 440 Met Glu Val Asn Ala Gly Leu Ala His Glu Se - #r His Leu Met Leu Thr 120      - #           125      - #           130 - - GCT CCT CAT GGA CTC CAG AGC TCA GAA GTC CA - #A GAT ACA CTG AAG CTT 488 Ala Pro His Gly Leu Gln Ser Ser Glu Val Gl - #n Asp Thr Leu Lys Leu 135          - #       140          - #       145 - - TGT CCA CGT GAT CAG TTT TGT AAG ATA AAG AC - #A GAA AGG GCA AAA GAG 536 Cys Pro Arg Asp Gln Phe Cys Lys Ile Lys Th - #r Glu Arg Ala Lys Glu 150              - #   155              - #   160 - - ATA TAT CCA GTG ATG GAG AAG GAG GGA CGA AC - #A CGT CTG GCT CTC ATC 584 Ile Tyr Pro Val Met Glu Lys Glu Gly Arg Th - #r Arg Leu Ala Leu Ile 165                 1 - #70                 1 - #75                 1 - #80 - - ATC TGC AAC AAA AAG TTT GAC TAC CTT TTT GA - #T AGA GAT AAT GCT GAT      632 Ile Cys Asn Lys Lys Phe Asp Tyr Leu Phe As - #p Arg Asp Asn Ala Asp 185  - #               190  - #               195 - - ACT GAC ATT TTG AAC ATG CAA GAA CTA CTT GA - #A AAT CTT GGA TAC TCT 680 Thr Asp Ile Leu Asn Met Gln Glu Leu Leu Gl - #u Asn Leu Gly Tyr Ser 200      - #           205      - #           210 - - GTG GTG TTA AAA GAA AAC CTT ACA GCT CAG GA - #A ATG GAG ACA GAG TTA 728 Val Val Leu Lys Glu Asn Leu Thr Ala Gln Gl - #u Met Glu Thr Glu Leu 215          - #       220          - #       225 - - ATG CAG TTT GCT GGC CGT CCA GAG CAC CAG TC - #C TCA GAC AGC ACA TTC 776 Met Gln Phe Ala Gly Arg Pro Glu His Gln Se - #r Ser Asp Ser Thr Phe 230              - #   235              - #   240 - - CTG GTG TTT ATG TCC CAT GGC ATC CTG GAA GG - #A ATC TGT GGG GTG AAG 824 Leu Val Phe Met Ser His Gly Ile Leu Glu Gl - #y Ile Cys Gly Val Lys 245                 2 - #50                 2 - #55                 2 - #60 - - CAC CGA AAC AAA AAG CCA GAT GTT CTT CAT GA - #T GAC ACT ATC TTC AAA      872 His Arg Asn Lys Lys Pro Asp Val Leu His As - #p Asp Thr Ile Phe Lys 265  - #               270  - #               275 - - ATT TTC AAC AAC TCT AAC TGT CGG AGT CTG AG - #A AAC AAA CCC AAG ATT 920 Ile Phe Asn Asn Ser Asn Cys Arg Ser Leu Ar - #g Asn Lys Pro Lys Ile 280      - #           285      - #           290 - - CTC ATC ATG CAG GCC TGC AGA GGC AGA TAT AA - #T GGA ACT ATT TGG GTA 968 Leu Ile Met Gln Ala Cys Arg Gly Arg Tyr As - #n Gly Thr Ile Trp Val 295          - #       300          - #       305 - - TCC ACA AAC AAA GGG ATA GCC ACT GCT GAT AC - #A GAT GAG GAA CGT GTG 1016 Ser Thr Asn Lys Gly Ile Ala Thr Ala Asp Th - #r Asp Glu Glu Arg Val 310              - #   315              - #   320 - - TTG AGC TGT AAA TGG AAT AAT AGT ATA ACA AA - #G GCC CAT GTG GAG ACA 1064 Leu Ser Cys Lys Trp Asn Asn Ser Ile Thr Ly - #s Ala His Val Glu Thr 325                 3 - #30                 3 - #35                 3 - #40 - - GAT TTC ATT GCT TTC AAA TCT TCT ACC CCA CA - #T AAT ATT TCT TGG AAG     1112 Asp Phe Ile Ala Phe Lys Ser Ser Thr Pro Hi - #s Asn Ile Ser Trp Lys 345  - #               350  - #               355 - - GTA GGC AAG ACT GGT TCC CTC TTC ATT TCC AA - #A CTC ATT GAC TGC TTC 1160 Val Gly Lys Thr Gly Ser Leu Phe Ile Ser Ly - #s Leu Ile Asp Cys Phe 360      - #           365      - #           370 - - AAA AAG TAC TGT TGG TGT TAT CAT TTG GAG GA - #A ATT TTT CGA AAG GTT 1208 Lys Lys Tyr Cys Trp Cys Tyr His Leu Glu Gl - #u Ile Phe Arg Lys Val 375          - #       380          - #       385 - - CAA CAC TCA TTT GAG GTC CCA GGT GAA CTG AC - #C CAG ATG CCC ACT ATT 1256 Gln His Ser Phe Glu Val Pro Gly Glu Leu Th - #r Gln Met Pro Thr Ile 390              - #   395              - #   400 - - GAG AGA GTA TCC ATG ACA CGC TAT TTC TAC CT - #T TTT CCC GGG AAT 1301 Glu Arg Val Ser Met Thr Arg Tyr Phe Tyr Le - #u Phe Pro Gly Asn 405                 4 - #10                 4 - #15 - - TAGCACAGGC AACTCTCATG CAGTTCACAG TCAAGTATTG CTGTAGCTGA GA - #AGAAAAGA   1361 - - AAATTCCAAG ATCCCAGGAT TTTTAAATGT GTAAAACTTT T    - # - # 1402 - -  - - (2) INFORMATION FOR SEQ ID NO:55: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 419 amino - #acids (B) TYPE: amino acid (D) TOPOLOGY: linear - -     (ii) MOLECULE TYPE: protein - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:55: - - Met Ala Ala Arg Arg Thr His Glu Arg Asp Pr - #o Ile Tyr Lys Ile Lys 1               5 - #                 10 - #                 15 - - Gly Leu Ala Lys Asp Met Leu Asp Gly Val Ph - #e Asp Asp Leu Val Glu 20     - #             25     - #             30 - - Lys Asn Val Leu Asn Gly Asp Glu Leu Leu Ly - #s Ile Gly Glu Ser Ala 35         - #         40         - #         45 - - Ser Phe Ile Leu Asn Lys Ala Glu Asn Leu Va - #l Glu Asn Phe Leu Glu 50             - #     55             - #     60 - - Lys Thr Asp Met Ala Gly Lys Ile Phe Ala Gl - #y His Ile Ala Asn Ser 65                 - # 70                 - # 75                 - # 80 - - Gln Glu Gln Leu Ser Leu Gln Phe Ser Asn As - #p Glu Asp Asp Gly Pro 85 - #                 90 - #                 95 - - Gln Lys Ile Cys Thr Pro Ser Ser Pro Ser Gl - #u Ser Lys Arg Lys Val 100      - #           105      - #           110 - - Glu Asp Asp Glu Met Glu Val Asn Ala Gly Le - #u Ala His Glu Ser His 115          - #       120          - #       125 - - Leu Met Leu Thr Ala Pro His Gly Leu Gln Se - #r Ser Glu Val Gln Asp 130              - #   135              - #   140 - - Thr Leu Lys Leu Cys Pro Arg Asp Gln Phe Cy - #s Lys Ile Lys Thr Glu 145                 1 - #50                 1 - #55                 1 - #60 - - Arg Ala Lys Glu Ile Tyr Pro Val Met Glu Ly - #s Glu Gly Arg Thr Arg 165  - #               170  - #               175 - - Leu Ala Leu Ile Ile Cys Asn Lys Lys Phe As - #p Tyr Leu Phe Asp Arg 180      - #           185      - #           190 - - Asp Asn Ala Asp Thr Asp Ile Leu Asn Met Gl - #n Glu Leu Leu Glu Asn 195          - #       200          - #       205 - - Leu Gly Tyr Ser Val Val Leu Lys Glu Asn Le - #u Thr Ala Gln Glu Met 210              - #   215              - #   220 - - Glu Thr Glu Leu Met Gln Phe Ala Gly Arg Pr - #o Glu His Gln Ser Ser 225                 2 - #30                 2 - #35                 2 - #40 - - Asp Ser Thr Phe Leu Val Phe Met Ser His Gl - #y Ile Leu Glu Gly Ile 245  - #               250  - #               255 - - Cys Gly Val Lys His Arg Asn Lys Lys Pro As - #p Val Leu His Asp Asp 260      - #           265      - #           270 - - Thr Ile Phe Lys Ile Phe Asn Asn Ser Asn Cy - #s Arg Ser Leu Arg Asn 275          - #       280          - #       285 - - Lys Pro Lys Ile Leu Ile Met Gln Ala Cys Ar - #g Gly Arg Tyr Asn Gly 290              - #   295              - #   300 - - Thr Ile Trp Val Ser Thr Asn Lys Gly Ile Al - #a Thr Ala Asp Thr Asp 305                 3 - #10                 3 - #15                 3 - #20 - - Glu Glu Arg Val Leu Ser Cys Lys Trp Asn As - #n Ser Ile Thr Lys Ala 325  - #               330  - #               335 - - His Val Glu Thr Asp Phe Ile Ala Phe Lys Se - #r Ser Thr Pro His Asn 340      - #           345      - #           350 - - Ile Ser Trp Lys Val Gly Lys Thr Gly Ser Le - #u Phe Ile Ser Lys Leu 355          - #       360          - #       365 - - Ile Asp Cys Phe Lys Lys Tyr Cys Trp Cys Ty - #r His Leu Glu Glu Ile 370              - #   375              - #   380 - - Phe Arg Lys Val Gln His Ser Phe Glu Val Pr - #o Gly Glu Leu Thr Gln 385                 3 - #90                 3 - #95                 4 - #00 - - Met Pro Thr Ile Glu Arg Val Ser Met Thr Ar - #g Tyr Phe Tyr Leu Phe 405  - #               410  - #               415 - - Pro Gly Asn - -  - - (2) INFORMATION FOR SEQ ID NO:56: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 418 amino - #acids (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown - -     (ii) MOLECULE TYPE: peptide - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:56: - - Met Ala Ala Arg Arg Thr His Glu Arg Asp Pr - #o Ile Tyr Lys Ile Lys 1               5   - #                10  - #                15 - - Gly Leu Ala Lys Asp Met Leu Asp Gly Val Ph - #e Asp Asp Leu Val Glu 20      - #            25      - #            30 - - Lys Asn Val Leu Asn Gly Asp Glu Leu Leu Ly - #s Ile Gly Glu Ser Ala 35          - #        40          - #        45 - - Ser Phe Ile Leu Asn Lys Ala Glu Asn Leu Va - #l Glu Asn Phe Leu Glu 50              - #    55              - #    60 - - Lys Thr Asp Met Ala Gly Lys Ile Phe Ala Gl - #y His Ile Ala Asn Ser 65                  - #70                  - #75                  - #80 - - Gln Glu Gln Leu Ser Leu Gln Phe Ser Asn As - #p Glu Asp Asp Gly Pro 85  - #                90  - #                95 - - Gln Lys Ile Cys Thr Pro Ser Ser Pro Ser Gl - #u Ser Lys Arg Lys Val 100      - #           105      - #           110 - - Glu Asp Asp Glu Met Glu Val Asn Ala Gly Le - #u Ala His Glu Ser His 115          - #       120          - #       125 - - Leu Met Leu Thr Ala Pro His Gly Leu Gln Se - #r Ser Glu Val Gln Asp 130              - #   135              - #   140 - - Thr Leu Lys Leu Cys Pro Arg Asp Gln Phe Cy - #s Lys Ile Lys Thr Glu 145                 1 - #50                 1 - #55                 1 - #60 - - Arg Ala Lys Glu Ile Tyr Pro Val Met Glu Ly - #s Glu Gly Arg Thr Arg 165  - #               170  - #               175 - - Leu Ala Leu Ile Ile Cys Asn Lys Lys Phe As - #p Tyr Leu Phe Asp Arg 180      - #           185      - #           190 - - Asp Asn Ala Asp Thr Asp Ile Leu Asn Met Gl - #n Glu Leu Leu Glu Asn 195          - #       200          - #       205 - - Leu Gly Tyr Ser Val Val Leu Lys Glu Asn Le - #u Thr Ala Gln Glu Met 210              - #   215              - #   220 - - Glu Thr Glu Leu Met Gln Phe Ala Gly Arg Pr - #o Glu His Gln Ser Ser 225                 2 - #30                 2 - #35                 2 - #40 - - Asp Ser Thr Pro Gly Val Tyr Val Pro Trp Hi - #s Pro Gly Arg Asn Leu 245  - #               250  - #               255 - - Trp Gly Glu Ala Pro Lys Gln Lys Pro Asp Va - #l Leu His Asp Asp Thr 260      - #           265      - #           270 - - Ile Phe Lys Ile Phe Asn Asn Ser Asn Cys Ar - #g Ser Leu Arg Asn Lys 275          - #       280          - #       285 - - Pro Lys Ile Leu Ile Met Gln Ala Cys Arg Gl - #y Arg Tyr Asn Gly Thr 290              - #   295              - #   300 - - Ile Trp Val Ser Thr Asn Lys Gly Ile Ala Th - #r Ala Asp Thr Asp Glu 305                 3 - #10                 3 - #15                 3 - #20 - - Glu Arg Val Leu Ser Cys Lys Trp Asn Asn Se - #r Ile Thr Lys Ala His 325  - #               330  - #               335 - - Val Glu Thr Asp Phe Ile Ala Phe Lys Ser Se - #r Thr Pro His Asn Ile 340      - #           345      - #           350 - - Ser Trp Lys Val Gly Lys Thr Gly Ser Leu Ph - #e Ile Ser Lys Leu Ile 355          - #       360          - #       365 - - Asp Cys Phe Lys Lys Tyr Cys Trp Cys Tyr Hi - #s Leu Glu Glu Ile Phe 370              - #   375              - #   380 - - Arg Lys Val Gln His Ser Phe Glu Val Pro Gl - #y Glu Leu Thr Gln Met 385                 3 - #90                 3 - #95                 4 - #00 - - Pro Thr Ile Glu Arg Val Ser Met Thr Arg Ty - #r Phe Tyr Leu Phe Pro 405  - #               410  - #               415 - - Gly Asn - -  - - (2) INFORMATION FOR SEQ ID NO:57: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base - #pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:57: - - ATGCTAACTG TCCAAGTCTA            - #                  - # - # 20 - -  - - (2) INFORMATION FOR SEQ ID NO:58: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 19 base - #pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:58: - - TCCAACAGCA GGAATAGCA             - #                  - # - # 19 - -  - - (2) INFORMATION FOR SEQ ID NO:59: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 29 base - #pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:59: - - TGATCGCCAT CGGGGAAATC GAGGTAGAA         - #                  - # 29 - -  - - (2) INFORMATION FOR SEQ ID NO:60: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 29 base - #pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:60: - - ATCATATCAT CCAGGCATCG TGCAGAGGG         - #                  - # 29 - -  - - (2) INFORMATION FOR SEQ ID NO:61: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 30 base - #pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:61: - - GTTGCACTGC TTTCACGATC TCCCGTCTCT         - #                  - # 30 - -  - - (2) INFORMATION FOR SEQ ID NO:62: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 30 base - #pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:62: - - TCATCGACTT TTAGATGACT AGAGAACATC         - #                  - # 30 - -  - - (2) INFORMATION FOR SEQ ID NO:63: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 base - #pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:63: - - GTTTAATTAC CCAAGTTTGA G           - #                  - # - #21 - -  - - (2) INFORMATION FOR SEQ ID NO:64: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 19 base - #pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:64: - - CCGGTGACAT TGGACACTC             - #                  - # - # 19 - -  - - (2) INFORMATION FOR SEQ ID NO:65: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 15 base - #pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:65: - - ACTATTCAAC ACTTG              - #                  - # - #    15 - -  - - (2) INFORMATION FOR SEQ ID NO:66: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 5 amino - #acids (B) TYPE: amino acid (D) TOPOLOGY: both - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:66: - - Gln Ala Cys Arg Gly 1               5 - -  - - (2) INFORMATION FOR SEQ ID NO:67: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base - #pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:67: - - CAACCCTGTA ACTCTTGATT            - #                  - # - # 20 - -  - - (2) INFORMATION FOR SEQ ID NO:68: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 base - #pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:68: - - ACCTCTTTGG AGCTACCAGA A           - #                  - # - #21 - -  - - (2) INFORMATION FOR SEQ ID NO:69: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 28 base - #pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:69: - - CCAGATCTAT GCTAACTGTC CAAGTCTA         - #                  - # 28 - -  - - (2) INFORMATION FOR SEQ ID NO:70: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 28 base - #pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:70: - - AAGAGCTCCT CCAACAGCAG GAATAGCA         - #                  - # 28 - -  - - (2) INFORMATION FOR SEQ ID NO:71: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base - #pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:71: - - AGAAGCACTT GTCTCTGCTC            - #                  - # - # 20 - -  - - (2) INFORMATION FOR SEQ ID NO:72: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base - #pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:72: - - TTGGCACCTG ATGGCAATAC            - #                  - # - # 20 - -  - - (2) INFORMATION FOR SEQ ID NO:73: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 base - #pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:73: - - GATATCCGCA CAAGGAGCTG A           - #                  - # - #21 - -  - - (2) INFORMATION FOR SEQ ID NO:74: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base - #pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:74: - - CTATAGGTGG GAGGGTGTCC            - #                  - # - # 20 - -  - - (2) INFORMATION FOR SEQ ID NO:75: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 23 base - #pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:75: - - GATATCCAGA GGGAGGGAAC GAT           - #                  - # 23 - -  - - (2) INFORMATION FOR SEQ ID NO:76: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 23 base - #pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:76: - - GATATCAGAG CAAGAGAGGC GGT           - #                  - # 23 - -  - - (2) INFORMATION FOR SEQ ID NO:77: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 base - #pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:77: - - GATATCGTGG GAGGGTGTCC T           - #                  - # - #21 - -  - - (2) INFORMATION FOR SEQ ID NO:78: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 base - #pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:78: - - ATCCAGGCCT CTAGAGGAGA T           - #                  - # - #21 - -  - - (2) INFORMATION FOR SEQ ID NO:79: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 base - #pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:79: - - ATCTCCTCTA GAGGCCTGGA T           - #                  - # - #21 - -  - - (2) INFORMATION FOR SEQ ID NO:80: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 base - #pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:80: - - TGCGGCTATA CGTGCCTCAA A           - #                  - # - #21 - -  - - (2) INFORMATION FOR SEQ ID NO:81: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 base - #pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:81: - - TTTGAGGCAC GTATAGCCGC A           - #                  - # - #21 - -  - - (2) INFORMATION FOR SEQ ID NO:82: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH:  24 base - # pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:82: - - ATTCCGCACA AGGAGCTGAT GGCC          - #                  - # 24 - -  - - (2) INFORMATION FOR SEQ ID NO:83: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 19 base - #pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:83: - - GCTGGTCGAC ACCTCTATC             - #                  - # - # 19 - -  - - (2) INFORMATION FOR SEQ ID NO:84: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 23 base - #pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:84: - - CAAGCTTTTG ATGCCTTCTG TGA           - #                  - # 23 - -  - - (2) INFORMATION FOR SEQ ID NO:85: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base - #pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:85: - - CTCCAACAGC AGGAATAGCA            - #                  - # - # 20 - -  - - (2) INFORMATION FOR SEQ ID NO:86: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 35 base - #pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:86: - - GCGATCTTTC GATCGCGATC TTTCTGTCGG AAGGC       - #                  - #       35 - -  - - (2) INFORMATION FOR SEQ ID NO:87: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 38 base - #pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:87: - - CAGATCGCCT TGTAGATAGA AAGAACATCT TTGATCGG      - # - #     38 - -  - - (2) INFORMATION FOR SEQ ID NO:88: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base - #pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:88: - - ATGCTAACTG TCCAAGTCTA            - #                  - # - # 20 - -  - - (2) INFORMATION FOR SEQ ID NO:89: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base - #pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:89: - - GTCTCATCTT CATCAACTCC            - #                  - # - # 20 - -  - - (2) INFORMATION FOR SEQ ID NO:90: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 22 base - #pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:90: - - GTTACCTGCA CACCGAGTCA CG           - #                  - # 22 - -  - - (2) INFORMATION FOR SEQ ID NO:91: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 30 base - #pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:91: - - GCGTGGTTCT TCTTTCCATC TTGTTGGTCA         - #                  - # 30 - -  - - (2) INFORMATION FOR SEQ ID NO:92: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 27 base - #pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:92: - - ACCTTAATAT GCAAGACTCT CAAGGAG          - #                  - # 27 - -  - - (2) INFORMATION FOR SEQ ID NO:93: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 27 base - #pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:93: - - GCGGCTTGAC TTGTCCATTA TTGGATA          - #                  - # 27 - -  - - (2) INFORMATION FOR SEQ ID NO:94: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base - #pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:94: - - GACCTGACAG ACTACCTCAT            - #                  - # - # 20 - -  - - (2) INFORMATION FOR SEQ ID NO:95: - -      (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base - #pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:95: - - AGACAGCACT GTGTTGGCAT            - #                  - # - # 20 __________________________________________________________________________

## Claims

1. An isolated DNA molecule comprising a cDNA sequence selected from the group consisting of the cDNA sequence shown in FIGS. 10A-10B (SEQ ID No:50) and 10C-10E (SEQ ID No:52).

2. An expression vector having the DNA of claim 1.

3. A host cell transformed with the vector of claim 2.

4. The DNA molecule of claim 1 wherein said sequence is that shown in FIGS. 10A-10B (SEQ ID No:50).

5. The DNA molecule of claim 1 wherein said sequence is that shown in FIGS. 10C-10E (SEQ ID No:52).

6. An expression vector having the DNA of claim 4.

7. An expression vector having the DNA of claim 5.

8. A host cell transformed with the vector of claim 6.

9. A host cell transformed with the vector of claim 7.

10. An isolated DNA molecule encoding the amino acid sequence shown in FIGS. 10A-10B (SEQ ID No:51).

11. An isolated DNA molecule encoding the amino acid sequence shown in FIGS. 10C-10E (SEQ ID No:53).

12. An expression vector having the DNA of claim 10.

13. An expression vector having the DNA of claim 11.

14. A host cell transformed with the vector of claim 12.

15. A host cell transformed with the vector of claim 13.